olle-ringden
OLLE RINGDEN, MD, PHD
Professor of Transplantation Immunology

Karolinska University
Stockholm, Sweden
Phone: +46 8 585 82672
E-mail: Olle.Ringden@ki.se

Education

 

Profile

 

Research Interest

Allogeneic hematopoietic stem cell transplantation, mesenchymal stromal cells, and graft-versus-host disease

 

Professional Activities

1963-1970 Medical School at Karolinska Institutet (KI), Stockholm
1970 MD, KI
1971 Registered doctor in Sweden
1976 Dissertation. “Activation of human lymphocyte subpopulations”. KI
1978 Docent in Clinical Immunology, KI
1978-1979 US Public Health Service International Post-doc Research Fellow, The Fred Hutchinson Cancer Research Center, Seattle, USA
1982 Certified by the Swedish Board in General Surgery
1986 Certified by the Swedish Board in Clinical Immunology
1980-1985 Research Docent, KI
1986-1987 Acting Professor in Transplantation Immunology, KI
1989 Professor in Transplantation Biology, University of Gothenburg
1989- Professor in Transplantation Immunology, KI
1993-1999 Senior Physician, Transplantation Surgery, Huddinge University Hospital
1999-2003 Director, Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital
2003-2011 Medical Director, Centre for Allogeneic Stem Cell Transplantation
2011- Distinguished Professor, Division of Therapeutic Immunology, Karolinska Institutet

 

First in world, clinical achievements

1985 Cure of Gaucher’s disease by hematopoietic stem cell transplantation (HSCT), IgA deficiency transferred by HSCT, use of Foscarnet for CMV.
1987 Cure of Langerhans’ cells histiocytosis by HSCT.
1995 Peripheral blood stem cells from unrelated donors in HSCT.
1997 Cure of adult metachromatic leukodystrophy.
2000 HSCT and liver transplantation for primary liver cancer, home care in HSCT.
2001 A graft-versus-colon-cancer effect in HSCT.
2002 Successful use of mesenchymal stem cells (MSCs) for life-threatening acute GVHD.
2003 Demonstrates that G-CSF induces acute GVHD. Intrahepatic donor lymphocyte infusion for liver metastases.
2004 MSC for acute lung injury/ARDS.
2005 Intrauterine MSCs for osteogenesis imperfect.
2006 MSCs for chronic GVHD.
2007 MSCs for hemorrhagic cystitis, pneumomediastinum and colon perforation.
2011 MSCs for major gastrointestinal hemorrhage.
2013 Placenta-derived decidual stromal cells (DSCs) for treatment of acute GVHD, chronic GVHD, hemorrhagic cystitis
2014 DSCs for cure of ARDS and paralysis due to polyneuropathies

 

Editorial Boards:

  • Bone Marrow Transplantation,
  • Transplantation,
  • Pediatric Transplantation,
  • Biology of Blood and Marrow Transplantation,
  • Journal of Transplantation,
  • World Journal of Transplantation.

 

Society Appointments

Founder and secretary of the Nordic Bone Marrow Transplantation Group 1983-1999, Chair 2007 – ; Secretary, Scandinavian Transplant Society 1983-1985; Councillor of the Advisory Committee of the International Bone Marrow Transplantation Registry (IBMTR) 1989 - 2008; Member of the Executive Committee of the International Bone Marrow Transplantation Registry 1996 - 2008; Chair, Nominating Committee of the IBMTR 1996 –1999; Chairman, GVHD Working Party of the IBMTR 1996 - 2010; Chair, IBMTR, 2003-2004; European Chairman, Center for International Blood and Marrow Transplant Research 2004 – 06 ; Councillor Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation since 1990; General Secretary, Nordic Expert Committee for Transplantation 1986 – 1991; President, Correction of Genetic Diseases by Transplantation, COGENT Society 1996 – 1998

Honors and Awards

Honours, Fellowships and Awards

Swedish Cancer Foundation 1973, 1974, 1976; Swedish Society for Medical Science to promising young scientists 1975; The Sweden-America Foundation 1978; Fogarthy International 1978-1979; The Swedish Medical Research Council 1980; Roll of Honour, International Union Against Cancer 1996; The Mortimer Bortin Award for outstanding research in bone marrow transplantation 2001; Prize for Best Article published in Scandinavian Journal of Immunology 2004; US Tandem Meeting on BMT, Best Abstract Award 2006 (Ringdén et al); The Van Bekkum Award 2006 (Ringdén et al); The 1st Ulrika Broomé Award for best supervisor at Karolinska University Hospital 2006 , The Claes Högman Honorary Lecturer 2007 , Hematology Master Class, London 2007, Distinguished Professor Award, ranked among the top 10 at Karolinska Institutet 2010. Olle Ringdén Laboratory, honored by Karolinska Institutet 2012; Maharshi Sushruta Award for Transplantation Biology, Ahmedabad, India 2013. Sheikh Hamdan Bin Rashid Al Maktoum Award for Excellence in Medical Science, Dubai 2014

Publications

  1. Collste H, Bergström J, Björkén C, Groth CG, Hultman E, Lundgren G, Ringdén O, Sahlin K. Metaboliter i cortex hos preserverade njurar. Sv. Kirurgisk Förening Förhandlingar 30: 163-164, 1973.
  2. Tillegård A, Lundgren G, Ringdén O, Werner B. Femoralispares - kirurgisk komplikation till njurtransplantation. Sv. Kirurgisk Förening Förhandlingar 30: 166-167, 1973.
  3. Ringdén O, Groth CG, Lundgren G, Magnusson G, Möller E. HL-A och Mixed Lymphocyte Cultures (MLC) vid njurtransplantation med levande anhörig donator. Svensk Kirurgi 31: 128-129, 1974.
  4. Lundgren G, Groth CG, Magnusson G, Möller E, Ringdén O, Tillegård A. Resultat vid njurtransplantation av nekronjurar med dålig HL-A kompatibilitet. Svensk Kirurgi 31: 126-127, 1974.
  5. Groth CG, Arner P, Hårdstedt C, Lewander R, Lundgren G, Ringdén O, Östman J. Pankreastransplantation vid diabetes mellitus. Rapport av två fall. Svensk Kirurgi 31: 85-86, 1974.
  6. Ringdén O, Möller E. Anti-ß2-mikroglobulin - en stimulator av humana B-lymfocyter. Svensk Kirurgi 31: 40-41, 1974.
  7. Ringdén O, Möller E. B-cell mitogenic effects of rabbit anti-human ß2 microglobulin for human lymphocytes. Scand. J. Immunol. 4: 171-179, 1975. Times cited: 61.
  8. Scandiatransplant Report. HL-A matching and kidney graft survival. Lancet 1: 240-242, 1975.
  9. Groth CG, Björkén C, Lundgren G, Ringdén O, Tillegård A. Preservation of human kidneys beyond 24 hours with the Gambro system. Opus. Medico Technica Lundensia 14: 102-107, 1975.
  10. Lundgren G, Berg B, Groth CG, Magnusson G, Möller E, Ringdén O. Shall poorly HL-A matched cadaveric kidneys be transplanted or discarged? Scand. J. Urol. Nephrol. Suppl. 29: 11-13, 1975.
  11. Ringdén O, Groth CG, Lundgren G, Möller E. Prognostic value of HLA typing and mixed lymphocyte culture tests in kidney transplantations from living related donors. Scand. J. Urol. Nephrol. Suppl. 29: 15-18, 1975.
  12. Berg B, Groth CG, Magnusson G, Lundgren G, Ringdén O. Gastrointestinal complications in 250 renal transplant recipients. Scand. J. Urol. Nephrol. Suppl. 29: 19-20, 1975.
  13. Krzymanski M, Quadracci LJ, Ringdén O, Lundgren G. Lymphocyte subpopulations in uremics and in transplanted patients. Scand. J. Urol. Nephrol. Suppl. 29: 37-40, 1975.
  14. Lundgren G, Arner P, Groth CG, Hårdstedt C, Lewander R, Ringdén O, Östman J. Pancreatic transplantation for diabetes mellitus. Discussion of indications and surgical technique with reference to three cases. Scand. J. Urol. Nephrol. Suppl. 29: 63-65, 1975.
  15. Groth CG, Björkén C, Lundgren G,. Ringdén O. A technique for rapid harvesting of cadaveric renal and pancreatic grafts after circulatory arrest. Scand. J. Urol. Nephrol. Suppl. 29: 67-69, 1975.
  16. Berg B, Groth CG, Magnusson G, Lundgren G, Ringdén O. Allvarliga gastrointestinala komplikationer hos njurtransplanterade. Svensk Kirurgi 32: 55-56, 1975.
  17. Lundgren G, Collste H, Franksson C, Groth CG, Magnusson G, Ringdén O. Maligna tumörer hos njurtransplanterade patienter. Svensk Kirurgi 32: 95-97, 1975.
  18. Ringdén O, Björkén C, Collste H, Groth CG, Lundgren G. En ny metod för tillvaratagande av njur- och pankreastransplantat från nyss avlidna. Svensk Kirurgi 32: 99-100, 1975.
  19. Ringdén O, Fagrell B, Friman L, Lundgren G. Subcutaneous arteriovenous fistulas for dialysis with special emphasis on vascular insufficiency. Scand. J. Urol. Nephrol. 10: 73-79, 1976.Timed cited: 7.
  20. Franksson C, Lundgren G, Magnusson G, Ringdén O. Drainage of thoracic duct lymph in renal transplant patients. Transplantation 21: 133-140, 1976. Times cited: 36.
  21. Quadracci LJ, Ringdén O. Water-treated stimulatory cells in the unidirectional mixed lymphocyte culture. Transplantation 21: 171-173, 1976.
  22. Möller E, Persson U, Rask L, Ringdén O. Anti-b2 microglobulin - A selective PBA for human and mouse B lymphoytes. In: The role of products of the histocompatibility gene complex in immune responses. Katz, D.H, Benacerraf, B. (eds). Academic Press, pp. 579-592, 1976.
  23. Lundgren G, Collste L, Groth CG, Krzymansky M, Magnusson G, Ringdén O, Quadracci LJ, Svehag SE. Experience with antilymphocyte globulin in 144 renal transplant recipients. Postgrad. Med. 52 (Suppl. 5): 67-71, 1976. Times cited: 6.
  24. Ringdén O, Möller E, Lundgren G, Groth CG. Role of MLC compatibility in intrafamilial kidney transplantation. Transplantation 22: 9-17, 1976. Times cited: 32.
  25. Björkén C, Lundgren G, Ringdén O, Groth CG. A technique for rapid harvesting of cadaveric renal and pancreatic grafts after circulatory arrest. Br. J. Surg. 63: 517-519, 1976.Times cited: 19.
  26. Ringdén O, Möller E. Use of mitogens for the functional characterization of human lymphocyte subpopulations -With special reference to activation of human B lymphocytes by antibodies to ß2 microglobulin. Scand. J. Immunol. 5 (Suppl. 5): 125-134, 1976.
  27. Quadracci LJ, Ringdén O, Krzymanski M. The effect of uremia and transplantation on lymphocyte subpopulations. Kidney Int. 10: 179-184, 1976. Times cited: 84.
  28. Ringdén O. Activation of human lymphocyte subpopulations by rabbit anti-human ß2 microglobulin and by lipopolysaccharide. Scand. J. Immunol. 5: 891-900, 1976. Times cited: 39.
  29. Ringdén O. Activation of human lymphocyte subpopulations. Role of HLA-D in renal transplantation and effects of anti-ß2 microglobulin on human B lymphocytes. Thesis. Karolinska Institutet, 1976.
  30. Ringdén O, Johansson BG. Mitogenic properties of Fab and F(ab’)2 fragments of rabbit anti-human b2 microglobulin for human lymphocytes. Scand. J. Immunol. 6: 281-289, 1977.Times cited: 10.
  31. Lundgren G, Ringdén O. Transplantation immunology. In: Annual Review of Allergy 1977-1978.Frazier C.A. (ed.). Medical Examination publishing Co. Inc. Flushing, NY, pp. 504-521, 1976.
  32. Ringdén O, Persson U, Möller E. Triggering of lymphocytes by antibodies against ß2 microglobulin (Also published in Immunology of receptors. B. Cinander (ed.)Dekkar Inc. NY & Basel, p. 391). Immunol. Commun. 5: 553-567, 1976.
  33. Berg B, Collste H, Groth CG, Magnusson G, Lundgren G, Ringdén O. Allvarliga gastrointestinala komplikationer hos 290 njurtransplanterade patienter. Läkartidningen 74: 2206-2208, 1977.
  34. Ringdén O, Johansson BG, Quadracci LJ, Möller E. Activation of human B cells by anti-b2 microglobulin. Transplant. Proc. 9: 1223-1227, 1977.Times cited: 5.
  35. Groth CG, Berg B, Collste H, Lundgren G, Magnusson G, Ringdén O, Quadracci LJ. Anti-humanlymfocyt globulin Behring vid klinisk njurtransplantation: Har medlet någon effekt? Svensk Kirurgi 33: 78-79, 1976.
  36. Berg B, Ringdén O. Betydelsen av HLA-A, -B och HLA-D kompatibilitet för transplantatöverlevnaden vid transplantation med njurar från besläktad och obesläktad givare. Svensk Kirurgi 33: 79-81, 1976.
  37. Berg B, Collste H, Lundgren G, Magnusson G, Möller E, Ringdén O, Groth CG. The significance of HLA-A and B matching for cadaver kidney survival in Stockholm 1970-1976. Scand. J. Urol. Nephrol. Suppl. 42: 32-35, 1977.
  38. Groth CG, Berg B, Collste H, Lundgren G, Magnusson G, Ringdén O, Pieper R. A controlled trial of antihuman lymphocyte globulin (Behring) in cadaveric renal transplantation: Improvement in graft and patient survival at one year using a high-dose regimen. Scand. J. Urol. Nephrol. Suppl. 42: 83-85, 1977.
  39. Ringdén O, Quadracci LJ, Groth CG. The effects of anti-lymphocyte globulin on lymphocyte subpopulations in recipients of kidney allografts. Scand. J. Urol. Nephrol. Suppl. 42: 86-89, 1977.
  40. Ringdén O, Berg B. Correlation between magnitude of MLC and kidney graft survival in intrafamilial transplantation. Tissue Antigens 10: 364-372, 1977. Times cited: 38.
  41. Ringdén O, Rynnel-Dagöö B, Waterfield EM, Möller E, Möller G. Polyclonal antibody secretion in human lymphocytes induced by killed staphylococcal bacteria and by lipopolysaccharide. Scand. J. Immunol. 6: 1159-1169, 1977. Times cited: 109
  42. Ringdén O, Friman L, Lundgren G, Magnusson G. Living related kidney donors: Complications and long-term renal function. Transplantation 25: 221-223, 1978. Times cited: 41.
  43. Ringdén O, Rynnel-Dagöö B. Activation of human B and T lymphocytes by protein A of Staphylococcus aureus. Europ. J. Immunol. 8: 47-52, 1978. Times cited: 99.
  44. Franksson C, Lundgren G, Magnusson G, Ringdén O. Thoracic duct drainage in renal transplantation in man. Excerpta Medica. Transplantation and Clinical Immunology IX, pp. 179-187, 1977.
  45. Ringdén O, Möller E, Sanderson AR. Primate HLA antibodies are specifically mitogenic for human lymphocytes and act synergistically with b2 m antibodies. Scand. J. Immunol. 7: 337-343, 1978.Times cited: 4.
  46. Groth CG, Berg B, Collste H, Lundgren G, Magnusson G, Ringdén O. Effekten av antihumanlymfocytglobulin Behring vid njurtransplantation. Svensk Kirurgi 34: 58, 1977.
  47. Magnusson G, Berg B, Collste H, Groth CG, Lundgren G, Ringdén O.  Selektiv rejektion av ena transplantatet hos patienter med två fungerande njurtransplantat från olika givare. Svensk Kirurgi 34: 61-62, 1977.
  48. Rynnel-Dagöö B, Ringdén O, Alfredsson H, Möller E. The use of bacterias for the functional characterization of human lymphocyte subpopulations in various lymphoid organs. Scand. J. Immunol. 8: 369-375, 1978. Times cited: 27
  49. Kunori T, Ringdén O, Möller E. Optimal conditions for polyclonal antibody secretion and DNA synthesis in human blood and spleen lymphocytes by lipopolysaccharide. Scand. J. Immunol. 8: 451-458, 1978. Times cited: 49.
  50. Rynnel-Dagöö B, Kunori T, Ringdén O, Möller E. Induction of antibody synthesis in human lymphocytes from different organs by different PBA substances: In: Antibody Production in man: In vitro synthesis and clinical implications. Fauci. A.S., Ballieux, R.E. (eds). Academic Press, New York,  pp. 35-47, 1979.
  51. Ringdén O, Rynnel-Dagöö B, Kunori T, Freijd A, Möller E. Antibody production and DNA synthesis of human lymphocyte subpopulations induced by PPD tuberculin. Clin. Exp. Immunol. 6: 528-535, 1979.Times cited: 17.
  52. Källenius G, Möller E, Ringdén O, Strandvik B. The first infant to survive a generalized BCG infection. Acta Pediatrica Scandinavia 71: 161-165, 1982. Times cited: 7.
  53. Groth CG, Gahrton G, Lundgren G, Möller E, Pihlstedt P, Ringdén O, Sundelin P. Successful treatment with prednisolone of graft-versus-host disease in an allogeneic bone marrow transplant recipient. Scand. J. Hematol. 22: 333-338, 1979.Times cited: 14.
  54. Kunori T, Fehrman I, Ringdén O, Möller E. In vitro characterization of immunological responsiveness of uremic patients. Nephron 26: 234-239, 1980. Times cited: 82.
  55. Ringdén O, Rynnel-Dagöö B, Kunori T, Smith CE, Hammarström L, Feijd A, Möller E. Induction of antibody synthesis in human B lymphocytes by different polyclonal B cell activators: Evaluation by direct and indirect PFC assay. Immunol. Rev. 45: 195-218, 1979. Times cited: 63.
  56. Lundgren G, Berg B, Bieberfeldt P, Groth CG, Kunori T, Ringdén O. Analysis of the immunological effect of lymph drainage in organ transplant recipients. Scand. J. Urol. Nephrol. Suppl. 54: 111-115, 1980.
  57. Kunori T, Ringdén O. Polyclonal antibody secretion induced in human mixed lymphocyte cultures. Scand. J. Immunol. 10: 487-491, 1979. Times cited: 20.
  58. Ringdén O. Activation of T and B cells by rabbit anti-human b2  microglobulin. Scand. J. Immunol. 11: 121-130, 1980.Times cited: 10.
  59. Kunori T, Ringdén O. Antibody secretion and DNA synthesis induced by Lipopolysaccharide in enriched human lymphocyte subpopulations. Scand. J. Immunol. 11: 137-145, 1980.Times cited: 3.
  60. Ringdén O, Witherspoon R, Storb R, Ekelund E, Thomas ED. B cell function in human marrow transplant recipients assessed by direct and indirect hemolysis-in-gel assays. J. Immunol. 123: 2729-2734, 1979. Times cited: 57.
  61. Ringdén O, Witherspoon R, Storb R, Ekelund E, Thomas ED. Increased in vitro B cell IgG secretion during acute graft-versus-host disease and infection. Observations in 50 human marrow transplant recipients. Blood 55: 179-186, 1980. Times cited: 46.
  62. Ringdén O. Benmärgstransplantation i Seattle. Förbättrade behandling vid aplastisk anemi och akut leukemi. Läkartidningen 50: 4588-4592, 1979.
  63. Berg B, Groth CG, Klintmalm G, Lundgren G, Möller E, Ringdén O. Betydelse av HLA-A, -B och -DR typning för resultat efter njurtransplantaton i Stockholm. Svensk Kirurgi 32:2: 141-142, 1979.
  64. Lundgren G, Hårdstedt C, Ringdén O, Groth CG. Var står vi inom transplantationskirurgin? MAF-nytt 3-4: 7-13, 1980.
  65. Kunori T, Ringdén O. Polyclonal antibody secretion induced in human mixed lymphocyte cultures. II. No direct activation of B cells. Tissue Antigens 15: 483-491, 1980.Times cited: 8.
  66. Fehrman I, Ringdén O, Bergström J. MLC blocking factors in uremic sera. Clin. Nephrol. 14: 183-189, 1980. Times cited: 20.
  67. Fehrman I, Ringdén O, Möller E, Lundgren G, Groth CG. Is cell-mediated immunity in the uremic patient affected by blood transfusions? Transplant. Proc. 13: 164-166, 1981.Times cited: 16.
  68. Ringdén O, Witherspoon RP, Storb R, Thomas ED. The use of hemolysis-in-gel assays to study polyclonal antibody secretion in bone marrow transplant recipients. Blut 42: 221-226, 1981.Times cited: 3.
  69. Ringdén O. Benmärgstransplantation vid osteopetros. Läkartidningen 77: 3467-3468, 1980.
  70. Fehrman I, Ringdén O.Lymphocytes from multitransfused uremic patients have poor MLC reactivity. Tissue Antigens 17: 386-395, 1981. Times cited: 27
  71. European group for bone marrow transplantation. European results of bone marrow transplantation for severe aplastic anemia. Blut 41:3: 154-157, 1980.
  72. Zwaan FE for the EBMT leukemia working party. Bone marrow transplantation for acute leukemia in remission - European results. Blut 41:3: 208-213, 1980.
  73. Ringdén O, Groth CG. Cyclosporin A - Ett nytt immunsuppressivt medel. Läkartidningen 78: 2739-2740, 1981.
  74. Groth CG, Berg B, Collste H, Lundgren G, Magnusson G, Ringdén O.Further experience with antihuman lymphocyte globulin (Behring): No effect on cadaveric renal graft survival. Scand. J. Urol. Nephrol. 15: 295-297, 1981.Times cited: 5.
  75. Ringdén O. Benmärgstransplantation. Informationsbladet, Immunbrist¬patienternas förening, IBF 2: 3-7, 1981.
  76. Ringdén O, Blom B, Collste H, Gahrton G, Groth CG, Grimfors G, Heimdahl A, Lundgren G, Lönnqvist B, Möller E, Pihlstedt P. Bone marrow transplantation for aplastic anemia and acute leukemia at Huddinge Hospital. Scand. J. Urol. Nephrol. Suppl. 64: 238-245, 1981.
  77. Ringdén O, Bergstrand A, Collste H, Grimfors G, Lundgren G, Groth CG. Immunosuppression by Cyclosporin A in human renal transplant recipients. Scand. J. Urol. Nephrol. Suppl. 64: 220-229, 1981.
  78. Berg B, Groth CG, Lundgren G, Magnusson G, Möller E, Ringdén O. The influence of HLA-D matching on the outcome of intrafamilial kidney transplantation with special emphasis on the predictive value of the relative response in MLC. Scand. J. Urol. Nephrol. Suppl. 64: 46-51, 1981.
  79. Groth CG, Lundgren G, Ringdén O, Berg B, Grimfors G, Bieber CP. Use of Rabbit Anti-human Thymocyte Globulin in cadaver kidney transplantation. Preliminary experiences. Scand. J. Urol. Nephrol. Suppl. 64: 200-204, 1981.
  80. Öst L, Collste H, Lundgren G, Magnusson G, Ringdén O, Groth CG. Reduced steroid doses in cadaveric renal transplantation. Scand. J. Urol. Nephrol. Suppl. 64: 195-199, 1981.
  81. Ringdén O, Båryd I, Gahrton G, Groth CG, Johansson B, Lundgren G, Lönnqvist B, Möller E, Sundelin P. Early treatment and prophylaxis of graft-versus-host disease using prednisolone. Excerpta Medica.Bone marrow transplantation in Europe Vol II,  pp. 171-177, 1981.
  82. Berg B, Ringdén O. Correlation between relative responses in mixed lymphocyte culture, HLA-D and -DR typing and graft survival in renal transplantation. Transplantation 33: 291-297, 1982. Times cited: 24.
  83. Groth CG, Collste H, Lundgren G, Ringdén O, Wilczek H, Thulin L, Gunnarsson R, Östman J. Surgical techniques for pancreatic transplantation. A critical appraisal of methods used and suggested new modification. Horm. Metabol. Res. Suppl. 13: 37-41, 1982.Times cited: 5.
  84. Ringdén O, Lönnqvist B, Lundgren G, Gahrton G, Groth CG, Möller E, Båryd I, Johansson B, Pihlstedt P, Gullbring B. Experience with a cooperative bone marrow transplantation program in Stockholm. Transplantation 33: 500-504, 1982. Times cited: 84.
  85. Fehrman I, Ringdén O. Reduced immunological responsiveness in multitransfused anemic nonuremic patients. Transplant. Proc. 14: 341-343, 1982.Times cited: 17.
  86. Ringdén O, Collste H, Klintmalm G, Lundgren G, Magnusson G, Wilczek H, Groth CG. Cyclosporin A in high-risk renal transplant recipients and in recipients with azathioprine intolerance. Transplant. Proc. 14: 100-102, 1982.Times cited: 10.
  87. Fehrman I, Groth CG, Lundgren G, Magnusson G, Ringdén O, Möller E. Effect of blood transfusions on immune response and kidney graft survival. Transplant. Proc. 14: 156-159, 1982. Times cited: 6.
  88. Fehrman I, Ringdén O, Möller E. Blood transfusion as pretreatment for kidney transplantation. Immunization rate and effect on cellular immune response in vitro. Transplantation 35: 339-343, 1983. Times cited: 32.
  89. Berg B, Groth CG, Gunnarsson R, Lundgren G, Möller E, Ringdén O. The influence of HLA-DR match on cadaveric renal graft survival. Experience from Stockholm. Scand. J. Urol. Nephrol. Suppl. 64: 38-45, 1981.
  90. Klintmalm BGB, Starzl TE, Groth CG, Iwatsuki S, Ringdén O, Lundgren G, Magnusson G, Collste H. Cyclosporin A, ett nytt immunsuppressivum vid hjärt-, lever- och njurtransplantation. Svensk Kirurgi 39: 225, 1981.
  91. Ringdén O, Persson U, Johansson G, Gahrton G, Groth CG, Klintmalm G, Lundgren G, Lönnqvist B, Möller E. Correlation between increase in serum-IgE levels and clinical signs of acute graft-versus-host disease (GVHD). Exp. Hematol. 10 (Suppl. 10): 94-95, 1982.Times cited: 3.
  92. Heimdahl, A, Lönnqvist B, Gahrton G, Groth CG, Lundgren G, Nord CE, Ringdén O. Selective decontamination of the oral and gastrointestinal microflora in patients treated with BMT. Exp. Hematol. 10 (Suppl. 10): 11, 1982.
  93. Wahren B, Gahrton G, Groth CG, Lundgren G, Lönnqvist B, Möller E, Ringdén O.  Studies of transfer and persistence of viral antibody producing cells in bone marrow transplantation. Exp. Hematol. 10 (Suppl. 10): 5, 1982.
  94. Ringdén O, Persson U, Johansson SGO, Wilczek H, Gahrton G, Groth CG, Lundgren G, Lönnqvist B, Möller E. Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. Blood 61: 1190-1195, 1983. Times cited: 55.
  95. Groth CG, Collste H, Lundgren G, Wilczek, H, Klintmalm G, Ringdén O, Gunnarsson R, Östman J. Successful outcome of segmental human pancreatic transplantation with enteric exocrine diversion after modifications in technique. Lancet 2: 522-524, 1982. Times cited: 124
  96. Ringdén O, Båryd I, Johansson B, Bolme P, Gahrton B, Groth CG, Klintmalm G, Lundgren G, Lönnqvist B. Increased mortality in bone marrow transplant recipients accidentally receiving an increased dose rate of total body irradiation. Exp. Hematol. 11: 131-133, 1983.
  97. Berg B, Groth CG, Lundgren G, Möller E, Ringdén O, Wilczek H. Five-years experience with DR matching in cadaveric kidney transplantation. Transplant. Proc. 15: 1132-1135, 1983. Times cited: 16.
  98. Ringdén O, Persson U, Johansson SGO, Gahrton G, Groth CG, Lundgren G, Lönnqvist B. Early diagnosis and treatment of acute human graft-versus-host disease. Transplant. Proc. 15: 1490-1494, 1983. Times cited: 21.
  99. Klintmalm G, Bergstrand A, Ringdén O, Wasserman J, Collste H, Lundgren G, Wilczek H, Groth CG. Graft biopsy for the differentiation between nephrotoxicity and rejection in Cyclosporin-A-treated renal transplant recipients. Transplant. Proc. 15: 493-496, 1983 Times cited: 54
  100. Johansson B, Lundgren G, Möller E, Ringdén O. Benmärgstransplantation vid leukemi. Läkartidningen 79: 3273, 1982.
  101. Ringdén O, Persson U, Johansson SGO. Are increased IgE levels a signal of an acute graft-versus-host reaction? Immunol. Rev. 71: 57-75, 1983. Times cited: 32.
  102. Heimdahl A, Gahrton G, Groth CG, Lundgren G, Lönnqvist B, Ringdén O, Nord CE. Selective decontamination of alimentary tract microbial flora in patients treated with bone marrow transplantation. Scand. J. Infect. Dis. 16: 51-60, 1984. Times cited: 24.
  103. Groth CG, Berg B, Collste H, Fehrman I, Klintmalm G, Lundgren G, Magnusson G, Ringdén O, Wilczek H, Öst L. Njurtransplantation. In: Transplantationskirurgi idag. Svenska Läkare-sällskapets Handl. Hygiea 91 Häfte 4: 7-23, 1982.
  104. Ringdén O. Benmärgstransplantation. In: Transplantationskirurgi idag. Svenska Läkare-sällskapets Handl. Hygiea 91 Häfte 4: 30-36, 1982.
  105. Ringdén O. Bättre prognos, utökade indikationer, nya metoder vid benmärgstransplantation. Läkartidningen 80: 426-427, 1983.
  106. Ringdén O. Erfarenheter av 55 benmärgstransplantationer. Informationsbladet Immunbrist-föreningen, IBF 1: 4-9, 1983.
  107. Ringdén O, Båryd I, Johansson B, Gahrton G, Groth CG, Lundgren G, Lönnqvist B. Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation. Acta Radiol. Oncol. 22: 423-428, 1983. Times cited: 47.
  108. Lönnqvist B, Heimdahl A, Gahrton G, Groth CG, Lundgren G, Nord CE, Ringdén O.  Prevention of sepsis in bone marrow transplant recipients. In: Second International Symposium on Infections in the Immunocompromised Host. C.S.F. Easmon, H. Gaya (eds.). Academic Press, London, pp. 268-271, 1983.
  109. Ringdén O. Bone marrow transplantation (BMT) in Scandinavia. Scandiatransplant rapport : p. 36-38, 1982.
  110. Tydén G, Ringdén O, Lundgren G. Treatment of mismatch bone-marrow transplantation syndrome. Lancet 1: 1278, 1983.
  111. Ringdén O, Öst L, Klintmalm G, Tillegård A, Fehrman I, Wilczek H, Groth CG. Improved outcome in renal transplant recipients above 55 years of age treated with Cyclosporine A and low doses of steroids. Transplant. Proc. 15: 2507-2512, 1983. Times cited: 31.
  112. Klintmalm G, Ringdén O, Groth CG. Clinical and laboratory signs in nephrotoxicity and rejection in Cyclosporine treated renal allograft recipients. Transplant. Proc. 15: 2815-2820, 1983. Times cited: 46.
  113. Fehrman I, Ringdén O. Increased incidence of sensitization among patients with polycystic kidney disease following pre-transplant blood transfusions. Nephron 40: 41-47, 1985.
  114. Smith CIE, Aarli JA, Biberfeld P, Bolme P, Christensson B, Gahrton G, Hammarström L, Lefvert AK, Lönnqvist B, Matell G, Pirskanen R, Ringdén O, Svanborg E. Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. N. Engl. J. Med. 25: 1565-1568, 1983. Times cited: 106.
  115. Wahren B, Gahrton G, Linde A, Ljungman P, Lönnqvist B, Ringdén O, Sundqvist VA. Transfer and persistance of viral antibody-producing cells in bone marrow transplantation.J. Infect. Dis. 150: 358-365, 1984. Times cited: 57.
  116. Klintmalm G, Lönnqvist B, Öberg B, Gahrton G, Lernestedt JO, Lundgren G, Ringdén O, Robèrt KH, Wahren B, Groth CG. Intravenous foscarnet for the treatment of severe cytomegalovirus infections in allograft recipients. Scand. J. Infect. Dis. 17: 157-163, 1985. Times cited: 92.
  117. Ringdén O. Benmärgstransplantationer i Seattle och Stockholm. Forskning och Praktik 16: 109-112, 1984.
  118. Svennerholm L, Månsson JE, Nilsson O, Tibblin E, Eriksson A, Groth CG, Lundgren G, Ringdén O. Bone marrow transplantation in the Norrbottnian form of Gaucher disease. Symposium on Molecular Basis of Lysosomal Storage Disorders, NINCD, Bethesda. R.O. Brady, J.A. Barranger (eds). Academic Press, San Diego, Calif.,  pp. 441-459, 1984.
  119. Klintmalm G, Säwe J, von Bahr C, Ringdén O, Lundgren G, Wilczek H, Tydén G, Groth CG. Optimal cyclosporine plasma levels decline with time of therapy. Transplant. Proc. 16: 1208-1211, 1984.Times cited: 11.
  120. Ljungman P, Gahrton G, Ringdén O, Wahren B. Donor and recipient origin of herpesvirus-reactive lymphocytes after bone marrow transplantation. Arch. Virol. 83: 117-122, 1985. Times cited: 8.
  121. Ringdén O, Nilsson B, Bolme P, Gahrton G, Lundgren G, Lönnqvist B, Möller E, Myrenfors P, Paulin T.  Factors associated with severe acute graft-versus-host disease (GVHD). Exp. Hematol. 12 (Suppl. 15): 49-50, 1984.
  122. Lönnqvist B, Paulin T, Ringdén O, Gahrton G, Wahren B. High frequency of chronic graft-versus-host disease and late immune dysfunction in marrow transplant recipients after cytomegalovirus infection. Exp. Hematol. 12 (Suppl. 15): 55-56, 1984.
  123. Lundgren G, Eriksson A, Groth CG, Gahrton G, Lönnqvist B, Myrenfors P, Nilsson O, Ringdén O, Sundelin P, Svennerholm L. Bone marrow transplantation in juvenile Gaucher’s disease. Exp. Hematol. 12 (Suppl. 15): 99-100, 1984.
  124. Groth CG, Ringdén O. Transplantation in relation to the treatment of inherited disease. Transplantation 38: 319-327, 1984. Times cited: 63.
  125. Lönnqvist B, Ringdén O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 38: 465-468, 1984. Times cited: 131.
  126. Wahren B, Linde A, SundqvistVA, Ljungman P, Lönnqvist B, Ringdén O. IgG-subclass-specific CMV reactivity in bone marrow transplant recipients. Transplantation 38: 479-483, 1984. Times cited: 22.
  127. Paulin T, Ringdén O, Lönnqvist B. Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation 39: 377-384, 1985. Times cited: 56.
  128. Ringdén O, Myrenfors P, Klintmalm G, Tydén G, Öst L. Nephrotoxicity by Co-trimoxazole and cyclosporin in transplanted patients. Lancet 1: 1016-1017, 1984. Times cited: 42.
  129. Danielsson K, Gahrton G, Heimdahl A, Liliemark J, Paul C, Ringdén O. Hur behandlas akut leukemi och aplastisk anemi. Tandläkartidningen 76: 1063-1070, 1984.
  130. Ringdén O, Heimdahl A, Lönnqvist B, MalmborgAS, Wilczek H. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of Acyclovir. Lancet 1: 744, 1984. Times cited: 56.
  131. Gahrton G, Wahren B, Lönnqvist B, Ringdén O, Lundgren G, Ljungman P, Smith CIE, Hammarström L. Donor cell involvement in hazards following allogeneic bone marrow transplantation. In: Leukemics and Lymphomas. Recent Progress in Diagnosis and Treatment. Ambrosiane, Milano, pp. 317-325, 1985.
  132. Wilczek H, Ringdén O, Tydén G. Cyclosporine-associated central nervous system toxicity after renal transplantation. Transplantation 39: 110, 1985. Times cited: 56.
  133. Klintmalm G, Säwe J, Ringdén O, von Bahr C, Magnusson A. Cyclosporin plasma levels in renal transplant patients - association with renal toxicity and allograft rejection. Transplantation 39: 132-137, 1985. Times cited: 111.
  134. Öst L, Klintmalm G, Ringdén O. Mutual interaction between prednisolone and cyclosporin in renal transplant patients. Transplant. Proc. 17: 1252-1255, 1984. Times cited: 37.
  135. Ringdén O, Lönnqvist B, Paulin T, Nilsson B, Ljungman P, Lundgren G, Wahren B, Öst L. Factors associated with chronic graft-versus-host disease and cytomegalovirus infection in bone marrow transplant recipients. Transplant. Proc. 17: 475-479, 1985. Times cited: 6.
  136. Fehrman I, Ringdén O, Öst L, Groth CG. The long-term effect of pretransplant blood transfusions on cadaveric kidney graft and patient survival rates. Transplant. Proc. 17: 1080-1082, 1985.
  137. Bohman SO, Klintmalm G, Ringdén O, Sundelin B, Wilczek H. Interstitial fibrosis in human kidney grafts after 12 to 46 months of cyclosporine therapy. Transplant. Proc. 17: 1168-1171, 1985. Times cited: 26.
  138. Carlsson B, Böhme J, Lundgren G, Möller E, Peterson PA, Rask L, Ringdén O, Wallin J. HLA class II genes studied with genomic hybridization in kidney and bone marrow transplantation donor-recipient pairs. Transplant. Proc. 17: 952-954, 1985.Times cited: 3.
  139. Groth CG, Lundgren G, Eriksson A, Nilsson O, Ringdén O, Sundelin P, Svennerholm L. Biochemical recovery in juvenile Gaucher’s disease after bone marrow transplantation. Transplant. Proc. 17: 453-454, 1985.Times cited: 4.
  140. Hammarström L, Lönnqvist B, Ringdén O, Smith CIE, Wiebe T. Transfer of IgA deficiency to a bone-marrow-grafted patient with aplastic anemia. Lancet 1: 778-781, 1985. Times cited: 32.
  141. Ringdén O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 40: 39-44, 1985. Times cited: 133
  142. Ringdén O. Induction of immunoglobulin secretion by protein A from staphylococcus aureus in human blood and bone marrow B cells. Scand. J. Immunol. 22: 17-26, 1985.Times cited: 17.
  143. Ringdén O, Paulin T, Pihlstedt P, Lönnqvist B, Wahren B. Cytomegalovirus antibody screening of blood donors for immunocompromised seronegative patients. Lancet 2: 1044, 1984.Timed cited: 7.
  144. Ringdén O, Paulin T, Lönnqvist B, Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease. Exp. Hematol. 13: 1062-1067, 1985. Times cited: 89.
  145. Gahrton G, Ringdén O, Lönnqvist B. Allogeneic bone marrow transplantation in leukemia. Argomenti di Oncologia 6: 113-129 (Italian), 1985.
  146. Wahren B, Öberg B, Wiklund M, Lönnqvist B, Ljungman P, Ringdén O, Lernestedt JO, Gahrton G. Foscarnet as a drug against cytomegalovirus. In: Herpes Viruses and Virus Chemotherapy. Pharmacological and Clinical approaches.R. Kono, A. Nakajima (eds.). Excerpta Medica, Amsterdam-New York-Oxford, pp. 67-71, 1985.
  147. Ljungman P, Lönnqvist B, Wahren B, Ringdén O, Gahrton G. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients. A one-year follow-up. Transplantation 40: 515-520, 1985. Times cited: 32.
  148. Ringdén O.Preliminär rapport av en benmärgstransplantation utförd på en immunbristpatient. Informationsbladet Immunbristföreningen, IBF 3: 3-4, 1985.
  149. Heimdahl A, Johnson G, Danielsson KH, Lönnqvist B, Sundelin P, Ringdén O. Oral condition of patients with leukemia and severe aplastic anemia - follow up 1 year after bone marrow transplantation. Oral Surgery 60: 498-504, 1985. Times cited: 44.
  150. Lönnqvist B, Ljungman P, Bolme P, Gahrton G, Ringdén O, Wahren B. Frequency of reactivation of varicella-zoster virus (VZV) infection with and without symptoms after bone marrow transplantation. Exp. Hematol. 13 (Suppl. 17): 72, 1985.
  151. Ljungman P, Gahrton G, Lönnqvist B, Ringdén O, Wahren B. Lymphocyte reactivity after cytomegalovirus infection may predict development of chronic graft versus host disease. Exp. Hematol. 13 (Suppl. 17): 133, 1985.
  152. Paulin T, Ringdén O, Lönnqvist B, Wahren B, Nilsson B, Gahrton G. Factors associated with infections after bone-marrow transplantation. Exp. Hematol. 13 (Suppl. 17): 110, 1985.
  153. Myrenfors P, Ringdén O, Persson U, Larsson P, Sundberg B, Johansson G. T lymphocyte reconstitution following bone marrow transplantation. Exp. Hematol. 13 (Suppl. 17): 79, 1985.Times cited: 3.
  154. Gahrton G, Ringdén O, Bolme P, Ljungman P, Lundgren G, Lönnqvist B, Paulin T, Öst L. Autolog transplantation av benmärg allternativ där donator saknas. Läkartidningen 82: 2597-2599, 1985.
  155. Lundgren G, Wilczek H, Lönnqvist B, Lindholm A, Wahren B, Ringdén O. Acyclovir prophylaxis in bone marrow transplant recipients. Scand. J. Infect. Dis. (Suppl) 47: 137-144, 1985.
  156. Lönnqvist B, Ringdén O, Ljungman P, Wahren B, Gahrton G. Reduced risk of recurrent leukemia in bone marrow transplant recipients after cytomegalovirus infection. Br. J. Haematol. 63: 671-679, 1986.Times cited: 23.
  157. Öst L, Lindholm A, Lundgren G, Magnusson G, Ringdén O, Tydén G, Groth CG, Franksson C. 20 års erfarenhet av njurtransplantation. Svensk Kirurgi 43:2: 91-92, 1985.
  158. Ringdén O, Bolme P, Lönnqvist B, Gahrton G, Lindholm A, Lundgren G, Öst L, Groth CG. Benmärgstransplantaion på Huddinge sjukhus. Svensk Kirurgi 43:2: 93-94, 1985.
  159. Lundgren G, Tydén G, Ringdén O, Groth CG. Transplantations¬kirurgins framtid. Svensk Kirurgi 43:2: 95, 1985.
  160. Paulin T, Ringdén O, Lönnqvist B, Wahren B, Nilsson B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors. Scand. J. Infect. Disease 18: 199-209, 1986. Times cited: 39
  161. Ringdén O, Bolme P, Båryd I, Gahrton G, Groth CG, Johansson B, Lantz B, Ljungman P, Lundgren G, Lönnqvist B, Möller E, Pihlstedt P. Benmärgstransplantation på Huddinge sjukhus. Alltmer framgångsrik terapi vid maligna sjukdomar. Indikationerna utökas successivt. Läkartidningen 82: 2239-2242, 1985.
  162. Ringdén O, Wilczek H, Lönnqvist B, Gahrton G, Wahren B, Lernestedt JO. Foscarnet for cytomegalovirus infections. Lancet 1: 1503-1504, 1985. Times cited: 56.
  163. Sundqvist KG, Paulin T, Ringdén O, Lönnqvist B, Heimdahl A. Analysis of immunological changes in the skin and oral mucosa after bone marrow transplantation (BMT). Transplant. Proc. 18: 113-114, 1986.Times cited: 4.
  164. Ringdén O, Bolme P, Borgström B, Gahrton G, Groth CG, Lindholm A, Lindquist R, Ljungman P, Lundgren G, Lönnqvist B, Möller E, Robèrt KH, Öst L. The Stockholm experience with allogeneic bone marrow transplantation. Transplant. Proc. 18: 119-122, 1986.Times cited: 9.
  165. Paulin T, Ringdén O, Lönnqvist B. Late infections after bone marrow transplantation. An analysis of risk factors. Transplant. Proc. 18: 123-125, 1986.Times cited: 4.
  166. Lundgren G, Wilczek H, Lönnqvist B, Lindholm A, Wahren B, Ringdén O. Combined intravenous and oral prophylaxis with acyclovir in bone marrow transplant recipients. Transplant. Proc. 18: 126-129, 1986.Times cited: 5.
  167. Ringdén O, Lönnqvist B, Paulin T, Ahlmén J, Bolme P, Wahren B, Wilczek H, Lernestedt JO. Treatment of life-threatening cytomegalovirus infections with i.v. foscarnet in immuno-compromised patients. In: Recent Advances in Chemotherapy. J. Ishigami (ed). Proc. 14th Int. Congr. of Chemotherapy. Univ. Tokyo Press,  pp. 2123-2124, 1985.
  168. Wahren B, Ljungman P, Paulin T, Ringdén O. Enhancing and suppressive effects of cytomegalovirus on human lymphocyte responses in vitro. J. Virol. 58: 909-913, 1986. Times cited: 21.
  169. Ringdén O, Lönnqvist B, Paulin T, Ahlmén J, Klintmalm G, Wahren B, Lernestedt JO. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J. Antimicrobial Chemother. 17: 373-387, 1986. Times cited: 126.
  170. Bäckman L, Ringdén O, Björkhem I, Lindbäck B. Increased serum b2 microglobulin during rejection, cyclosporin- induced nephrotoxicity, and cytomegalovirus infection in renal transplant recipients. Transplantation 42: 368-371, 1986. Times cited: 38.
  171. Gahrton G, Ringdén O, Lönnqvist B, Lindquist R, Ljungman P. Bone marrow transplantation in three patients with multiple myeloma. Acta Med. Scand. 219: 523-527, 1986. Times cited: 31.
  172. Gahrton G, Ringdén O, Lönnqvist B. Bone marrow transplantation in multiple myeloma. Acta Med. Scand. 219: 433-434, 1986. Times cited: 6.
  173. Persson U, Myrenfors P, Ringdén O, Sundberg B, Larsson P, Johansson SGO. T lymphocoyte subpopulations in bone-marrow-transplanted patients in relation to graft-versus-host disease and cytomegalovirus-induced infecton. Transplantation 43: 663-668, 1987.Times cited: 10.
  174. Ljungman P, Lönnqvist B, Gahrton G, Ringdén O, Wahren B. Cytomegalovirus specific lymphocyte proliferation and in vitro cytomegalovirus IgG synthesis for diagnosis of cytomegalovirus infections after bone marrow transplantation. Blood 68: 108-112, 1986.Times cited: 10.
  175. Öst L, Lönnqvist B, Eriksson L, Ljungman P, Ringdén O. Hemorrhagic cystitis - a manifestation of graft versus host disease? Bone Marrow Transplantation 2: 19-25, 1987. Times cited: 61
  176. Ljungman P, Lönnqvist B, Gahrton G, Ringdén O, Sundqvist VA, Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J. Infect. Dis. 153: 840-847, 1986. Times cited: 135.
  177. Ringdén O, Bäckman L, Lönnqvist B, Heimdahl A, Lindholm A, Bolme P, Gahrton G. A randomized trial comparing the use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematologic malignancies. Bone Marrow Transplantation 1: 41-51, 1986. Times cited: 144
  178. Ringdén O, Paulin T, SundqvistVA, Wahren B, Pihlstedt P. Induction of immunoglobulin secretion and DNA synthesis in human lymphocytes in vitro by cytomegalovirus preparations. Scand. J. Immunol. 24: 273-281, 1986.Times cited: 11.
  179. Paulin T, Ringdén O, Nilsson B, Lönnqvist B, Gahrton G. Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation 43: 393-398, 1987. Times cited: 46
  180. Bäckman L, Ringdén O,Björkhem I. Monitoring of serum neopterin levels in renal transplant recipients: Increased values during impaired renal function and cytomegalovirus infection. Nephron 46: 319-322, 1987. Times cited: 18.
  181. Åkesson-Johansson A, Lernestedt JO, Ringdén O, Lönnqvist B, Wahren B. Sensitivity of cyto-megalo¬virus to intravenous foscarnet treatment. Bone Marrow Transplantation 1: 215-220, 1986.Times cited: 12.
  182. Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lönnqvist B, Ringdén O, Wahren B.Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte prolifera¬tion responses to herpes virus antigen in vitro. Bone Marrow Transplantation 1: 185-192, 1986. Times cited: 69.
  183. Ringdén O, Groth CG, Erikson A, Bäckman L, Granqvist S, Månsson IE, Svennerholm L. Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease. Transplantation 46: 66-69, 1988. Times cited: 80.
  184. Ringdén O, Lönnqvist B, Gahrton G, Bolme P, Tollemar J, Wahren B, Lernestedt JO. Comparison of two dose regimens using Foscarnet for severe cytomegalovirus infections in 20 bone marrow transplant recipients. Bone Marrow Transplantation 1 (Suppl. 1): 41-42, 1986.
  185. Lundgren G, Wilczek H, Lönnqvist B, Ljungman P, Wahren B, Ringdén O. Six months prophylaxis with acyclovir in bone marrow transplant recipients. Bone Marrow Transplantation 1 (Suppl. 1): 54-55, 1986.
  186. Lindholm A, Zucker W, Ringdén O, Lönnqvist B. Long term cyclosporine treatment in bone marrow transplant recipients. Bone Marrow Transplantation 1 (Suppl. 1): 85, 1986.
  187. Paulin T, Ringdén O. A multifactor analysis of immunological long-term reconstitution after marrow transplantation. Bone Marrow Transplantation 1 (Suppl. 1): 155-156, 1986.
  188. Gahrton G, Ringdén O, Lönnqvist B, Lindquist R, Ljungman P. Bone marrow transplantation in three patients with multiple myeloma. Bone Marrow Transplantation 1 (Suppl. 1): 182, 1986.
  189. Ringdén O. Benmärgstransplantation. Informationsskrift från Barncancer¬fonden. Utgåva 1. Tre Punkter AB, Göteborg,, 1986.
  190. Ringdén O, Lönnqvist B, Paulin T, Ljungman P, Wahren B, Lernestedt JO. A pilot trial using Foscarnet for cytomegalovirus infections in marrow transplant recipients. In: Progress in bone marrow transplantation. (eds. RP Gale & R Champlin).  Alan R.Liss Inc. NY,  pp. 589-593, 1987.
  191. Lindholm A, Ringdén O, Lönnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation 43: 680-684, 1987. Times cited: 26.
  192. Ringdén O, Åhström L, Lönnqvist B, Båryd I, Svedmyr E, Gahrton G.  Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis. N. Engl. J. Med. 316: 733-735, 1987. Times cited: 49.
  193. Ringdén O. Cyclosporin in allogeneic bone marrow transplantation. Transplantation 42: 445-452, 1986. Times cited: 47.
  194. Ringdén O, Zwaan FE, Hermans J, Gratwohl A. for the Leukemia Working party of the European Group for Bone Marrow Transplantation: European experience of bone marrow transplantation for leukemia. Transplant. Proc. 19: 2600-2604, 1987. Times cited: 60
  195. Groth CG, Fehrman I, Ringdén O, Lundgren G. Related donor kidney transplantation is the best form of treatment for uremia. Transplant. Proc. 19: 2278-2279, 1987.Timed cited: 7.
  196. Bäckman L, Brandt I, Ringdén O, Dallner G. Distribution of 3H-cyclosporin A in mice by autoradiography. Transplant. Proc. 19: 1236-1239, 1987.Times cited: 13.
  197. Paulin T, Ringdén O. Interaction between cytomegalovirus and staphylococcus aureus protein A in immunoglobulin secretion and DNA synthesis. Transplant. Proc. 19: 2133-2134, 1987.
  198. Ringdén O, Deeg HJ, Beschorner W, Slavin S. Effector cells of graft-versus-host disease, host resistance and the graft-versus-leukemia effect: Summary of a workshop on bone marrow transplantation. Transplant. Proc. 19: 2758-2761, 1987.Times cited: 15.
  199. Fehrman I, Ringdén O. Pre-transplant blood transfusions and selection for renal transplantation. Nephron 47: 308-309, 1987.
  200. Paulin T, Ringdén O, Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplantation 1: 317-328, 1987. Times cited: 55.
  201. Herzig RH, Bortin MM, Barrett AJ, Blume KG, Gluckman E, Horowitz MM, Jacobsen SJ, Marmont A, Masaoka T, Prentice HG, Ramsay NKC, Rimm AA, Ringdén O, Speck B, Zwaan FE, Gale RP. Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet 1: 786-788, 1987. Times cited: 93
  202. de Gast GC, Gratama JW, Ringdén O, Gluckman E. The multifactorial etiology of graft-versus-host disease. Immunology Today 8: 209-212, 1987. Times cited: 39.
  203. Ringdén O.  DNA synthesis in human blood mononuclear cells correlates with severity of acute graft-versus-host disease. Bone Marrow Transplant. 2: 259-269, 1987. Times cited: 6.
  204. Bacigalupo A, Hows J, Gordon-Smith EC, Gluckman E, Van Lint MT, Congiu M, James DCO, Barrett AJ, Gmur J, De Planque MM, Siimes MA, Toivanen A, Ringdén O, Marmont AM for the SAA Working Party of the EBMTG: Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party. Bone Marrow Transplant. 3: 531-535, 1988. Times cited: 66.
  205. Bäckman L, Appelkvist EL, Ringdén O, Dallner G. Glutathione transferase in the urine: A marker for post-transplant tubular lesions. Kidney International 33: 571-577, 1988. Times cited: 43.
  206. Gahrton G, Tura S, Flesch M, Gratwohl A, Gravett PJ, Lucarelli G, Michallet M, Reiffers J, Ringdén O, van Lint MT, Vernant JP, Zwaan F. Bone marrow transplantation in multiple myeloma. Report from the European Cooperative Group for Bone Marrow Transplantation (EBMT). Blood, 69: 1262-1264, 1987. Times cited: 62.
  207. Ringdén O, Pihlstedt P, Volin L, Nikoskelainen J, Lönnqvist B, Ruutu P, Ruutu T, Toivanen A, Wahren B. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant. 2: 299-305, 1987. Times cited: 61.
  208. Ringdén O, Sundberg B, Markling L, Tollemar J. Polyclonal antibody secretion during acute graft-versus-host disease. Scand. J. Immunol. 26: 469-476, 1987.Times cited: 3.
  209. Jacobsen N, Lönnqvist B, Ringdén O, Rajantie J, Siimes M, Volin L, Ruutu T, Nikoskelainen J, Toivanen A, Ryder L, Andersen HK, Keiding N, Gahrton G, for the Nordic BMT Group: Graft-versus-leukaemia activity associated with cytomegalovirus seropositive bone marrow donors but separated from graft-versus-host disease in allograft recipients with AML. Eur. J. Hematol. 38: 350-355, 1987.Times cited: 4.
  210. Ringdén O, Markling L, Sundberg B, Gahrton G, Lönnqvist B, Tollemar JJ. Blood lymphocyte DNA synthesis was increased during acute graft-versus-host disease (GVHD) especially in HLA mismatched recipients. Bone Marrow Transplant. 2 (Suppl 1): 286, 1987.
  211. Tollemar J, Ringdén O, Holmberg K, Lönnqvist B. Serological diagnosis of deep disseminating fungal infections in bone marrow transplantation recipients. Bone Marrow Transplant. 2 (Suppl. 1): 264, 1987.
  212. Lönnqvist B, Ringdén O, Gahrton G. No need to restrict marrow transplantation to patients under 40 years of age: An analysis in adult patients. Bone Marrow Transplant. 2 (Suppl. 1): 26, 1987.
  213. Gordon-Smith EC, Hows J, Bacigalupo A, Gluckman E, Van Lint MT, Congiu A, James DCO, Barrett AJ, De Planque MM, Siimes MA, Toivanen A, Ringdén O, Marmont AM, for the SAA Working party of the E.B.M.T.:  Bone marrow transplantation for severe aplastic anaemia (SAA) from donors other than HLA identical siblings. A report of the EBMT working party. Bone Marrow Transplant. 2 (Suppl. 1): 100, 1987.
  214. Bacigalupo A, Gordon-Smith EC, Van Lint MT, Congiu A, Gluckman E, Margiocco M, Ferrari G, De Planque MM, Ernst P, McCann S, Ragavashar A, Nissen C, Wursch A, Slavin S, Hinterberger W, Gmur J, Ringdén O, Toivanen A, Marmont AM, for the EBMT Working Party on Severe Aplastic Anaemia. Bone marrow transplantation (BMT) vs. immunosuppression (IS) in the management of severe aplastic anaemia (SAA). Bone Marrow Transplant. 2 (Suppl 1): 99, 1987.
  215. Jacobsen N, Badsberg JH, Lönnqvist B, Ringdén O, Rajantie J, Siimes MA, Volin L, Ruutu T, Nikoskelainen J, Toivanen A, Andersen HK, Keiding N, Gahrton G, for the Nordic Bone Marrow Transplantation Group: Graft-versus-leukaemia activity associated with CMV-seropositive bone marrow donors. Preliminary results of a multivariate analysis. Bone Marrow Transplant. 2 (Suppl. 1): 244, 1987.
  216. Dahllöf G, Barr M, Bolme P, Modéer T, Lönnqvist B, Ringdén O, Heimdahl A. Disturbances in the dental development after total body irradiation in bone marrow transplantation recipients. Oral Surg. Oral Med. Oral Pathol. 65: 41-44, 1988. Times cited: 66.
  217. Lefvert AK, Bolme P, Hammarström L, Lönnqvist B, Ringdén O, Slördahl S, Smith CIE. Bone marrow grafting selectively induces the production of acetylcholine receptor antibodies, immunoglobulins bearing related idiotypes and anti-idiotypic antibodies. Ann. NY. Acad. Sci 505: 825-827, 1987.Times cited: 11.
  218. Jacobsen N, Keiding N, Ryden L, Ringdén O, Lönnqvist B, Gahrton G, Rajantie J, Siimes M, Volin L, Ruutu T, Nikoskelainen J, Toivvanen A, Andersen HK. Graft-versus-leukaemia activity associated with cytomegalovirus antibody positive bone marrow donors in acute myeloid leukaemia. Lancet 1: 456-457, 1987.Times cited: 5.
  219. Vartdal F, Albrechtsen D, Ringdén O, Kvalheim G, Lea T, Bosnes V, Gaudernack G, Brinchmann J, Ugelstad J.  Immunomagnetic treatment of bone marrow allografts. Bone Marrow Transplant. 2 (Suppl 2): 94-98, 1987.Times cited: 9.
  220. Lantz B, Ringdén O, Rodriguez M.  Benmärgaferes vid AB0-oförenlig transplantation. Opuscula Medica 32: 19-20, 1987.
  221. Dahllöf G, Heimdahl A, Bolme P, Lönnqvist B, Ringdén O. Oral condition in children treated with bone marrow transplantation. Bone Marrow Transplant. 3: 43-51, 1988. Times cited: 37
  222. Ringdén O.  Scandiatransplant - past, present and future. Scandiatransplant Report 1986, Repro Print, Stockholm, 1987.
  223. Bäckman L, Ringdén O,Björkhem I. Monitoring of serum b2 microglobulin and neopterin levels in renal transplant recipients: Increased values during impaired renal function and cytomegalo¬virus infection. Transplant. Proc. 20: 410-412, 1988.Timed cited: 7.
  224. Bäckman L, Appelkvist EL, Ringdén O, Dallner G. Appearance of basic glutathione transferase in the urine during tubular complications in renal transplant recipients. Transplant. Proc. 20: 427-430, 1988.
  225. Ringdén O, Bolme P, Lönnqvist B, Tollemar J, Borgström B, Dahllöf G, Lundgren G, Winiarski J, Gahrton G, Groth CG. Allogeneic bone marrow transplantation in children at HuddingeHospital. Transplant. Proc. 20: 487-490, 1988.
  226. Tollemar J, Ringdén O, Sundberg B, Bolme P, Brattström C, Gahrton G, Johansen L, Lönnqvist B. Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate. Transplant Proc 20: 494-498, 1988.Times cited: 5.
  227. Ringdén O, Markling L, Sundberg B, Tollemar J. Spontaneous antibody secretion and DNA synthesis in blood lymphocytes increase during acute graft-versus-host disease. Transplant. Proc. 20: 503-505, 1988.
  228. Tollemar J, Ringdén O, Holmberg K, Lönnqvist B. Serological surveillance for evidence of deep disseminating fungal infections in bone marrow transplantation recipients. Transplant. Proc. 20: 501-502, 1988.
  229. Ringdén O, Lönnqvist B, Sundberg B. Cytomegalovirus immune bone-marrow donors and interstitial pneumonitis. Lancet 2: 105-106, 1987.Times cited: 3.
  230. Dahllöf G, Modéer T, Bolme P, Ringdén O, Heimdahl A. Oral health in children treated with bone marrow transplantation. A one year follow up. J. Dent. Child. : 196-200, 1988.Times cited: 9.
  231. Ringdén O, Åhström L, Löwhagen T. Allogeneic bone marrow transplantation in a patient with chemotherapy- resistant progressive Langerhans cell histiocytosis. N. Engl. J. Med. 317: 773-774, 1987.
  232. Bäckman L, Ringdén O. The value of the relationship between true and calculated values of serum b2 microglobulin in renal transplant recipients. Transplantation 45: 841-842, 1988.
  233. Paulin T, Ringdén O, Wahren B. Cytomegalovirus infected adherent cells interact synergis-tically and antagonistically with staphylococcus aureus protein A in vitro. Scand. J. Immunol. 28: 177-184, 1988.
  234. Ringdén O, Bolme P, Lönnqvist B, Tollemar J, Dahllöf G, Gahrton G, Groth CG. Bone marrow transplantation in children. Clin. Transplantation 3: 12-18, 1989. Times cited: 28.
  235. Bäckman L, Ringdén O, Lundgren G, Groth CG. Renal cell carcinomas in renal allografts - A report of three cases. Clin. Transplantation 2: 146-149, 1988.
  236. Ringdén O, Sundberg B, Lönnqvist B, Tollemar J, Gahrton G, Nilsson B. Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. Bone Marrow Transplant. 3: 281-290, 1988. Times cited: 38.
  237. Bäckman L, Ringdén O, Dati F. Serum levels of a1 microglobulin in recipients of renal allografts. Transplant. Int. 2: 23-26, 1989.Times cited: 4.
  238. Ringdén O, Bolme P, Lönnqvist B, Gustafsson G, Kreuger A. Allogeneic bone marrow transplantation versus chemotherapy in children with acute leukemia in Sweden. Pedr. Hematol. Oncol. 6: 137-144, 1989.Times cited: 10.
  239. Tollemar J, Holmberg K, Ringdén O, Lönnqvist B. Surveillance tests for the diagnosis of invasive fungal infections in bone marrow transplant recipients. Scand. J. Infect. Dis. 21: 205-212, 1989. Times cited: 35.
  240. Bäckman L, Brandt I, Dallner G, Ringdén O. Tissue distribution of [3H]cyclosporine A in mice. Transplant. Proc. 20: 684-691, 1988.Times cited: 10.
  241. Bäckman L, Appelkvist E-L, Ringdén O, Dallner G. Effects of cyclosporine A on hepatic protein synthesis. Transplant. Proc. 20 (Suppl. 3): 853-858, 1988.Times cited: 8.
  242. Tollemar J, Ringdén O, Heimdahl A, Lönnqvist B, Sundberg B. Decreased incidence and severity of GVHD in HLA matched and mismatched marrow recipients combining cyclosporin and methotrexate. Transplant. Proc. 20 (Suppl. 3): 470-479, 1988. Times cited: 6.
  243. Jacobsen N, Badsberg JH, Lönnqvist B, Ringdén O, Volin L, Ruutu T, Rajantie J, Siimes MA, Nikoskelainen J, Toivanen A, Andersen HK, Keiding N, Gahrton G, for the Nordic Bone Marrow Transplantation Group. Predictive factors for chronic graft-versus-host disease and leukemic relapse after allogeneic bone marrow transplantation. In: Experimental Hematology Today-1987 SJ.Baum, GW Santos, F Takaku (eds). Springer-Verlag,  pp. 161-164, 1987.
  244. Ringdén O. Benmärgstransplantation vid Huddinge sjukhus. Informationsbladet Immunbrist-föreningen, IBF 1: 10-16, 1988.
  245. Tollemar J, Ringdén O, Ericzon B-G, Tydén G. Cyclosporin-associated central nervous system toxicity. N. Engl. J. Med. 318: 788-789, 1988. Times cited: 25.
  246. Gahrton G, Ringdén O, Robèrt K-H. Benmärgstransplantation - snabb utveckling mot nya indikationer. Läkartidningen 85: 689-695, 1988.
  247. Boström L, Ringdén O, Sundberg B, Linde A, Tollemar J, Nilsson B. Pretransplant herpes virus serology and acute graft-versus-host disease. Transplantation 46: 548-552, 1988. Times cited: 59.
  248. Ringdén O, Boström L, Paulin T. On herpes virus immunity, graft-versus-host disease, pneumonitis and relapse. In: Bone Marrow Transplantation: Current Controversies. UCLA Symposia, Vol. 91, Alan R. Liss. Inc., pp. 573-584, 1989.
  249. Ringdén O. CMV immunoglobulin for prevention of pneumonitis after BMT (Letter). Bone Marrow Transplant. 3: 235-236, 1988.
  250. Bäckman L, Ringdén O, Tollemar J, Lönnqvist B. An increased risk of relapse in cyclosporin-treated compared with methotrexate-treated patients: long-term follow-up of a randomized trial. Bone Marrow Transplant. 3: 463-471, 1988.Times cited: 16.
  251. Boström L, Ringdén O, Sundberg B, Linde A, Tollemar J, Lönnqvist B, Nilsson B,  for the Bone Marrow Transplantation Team at Huddinge Hospital. The role of herpes virus serology for the development of acute and chronic graft-versus-host disease. Bone Marrow Transplant. 3 (Suppl. 1): 305, 1988.
  252. Dahllöf G, Forsberg C-M, Modéer T, Heimdahl A, Bolme P, Ringdén O. Dental and craniofacial abnormalities in children treated with bone marrow transplantation. Bone Marrow Transplant. 3 (Suppl. 1): 269, 1988.
  253. Ljungman P, Fridell E, Bolme P, Gahrton G, Linde A, Lönnqvist B, Ringdén O, Wahren B. Vaccination of marrow transplant patients with attenuated measles, mumps and rubella vaccine. Bone Marrow Transplant. 3 (Suppl. 1): 265, 1988.
  254. Paulin T, Ringdén O, Sundberg B, Lönnqvist B, Tollemar J. Symptomatic cytomegalovirus infection after bone marrow transplantation. Importance of high marrow cell dose. Bone Marrow Transplant. 3 (Suppl. 1): 251-252, 1988.
  255. Tollemar J, Ringdén O, Barkholt L, Bolme P, Dahllöf G, Gahrton G, Heimdahl A, Lindquist R, Ljungman P, Lönnqvist B, Möller E, Paulin T, Sundberg B. Reduction of acute graft-versus-host disease with methotrexate combined with cyclosporin. Bone Marrow Transplant. 3 (Suppl. 1): 227, 1988.Times cited: 4.
  256. Ringdén O,  for the Advisory Committee of the International Bone Marrow Transplant Registry. Graft-versus-leukaemia reactions in early leukaemia. Bone Marrow Transplant. 3 (Suppl. 1): 216, 1988.
  257. Horowitz MM, for the Writing Committee: Atkinson K, van Bekkum DW, Bortin MM, Gluckman E, Gale RP, Good RA, Jacobsen N, Kolb H-J, Rimm AA, Ringdén O, Rozman C, Zwaan FE. Risk factors for chronic graft-versus-host disease: a preliminary report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 3 (Suppl. 1): 215, 1988.
  258. Bolme P, Ringdén O, Gustafsson G, Kreuger A, Lönnqvist B, Tollemar J. BMT Group at HuddingeHospital. Bone marrow transplantation versus chemotherapy in children with leukaemia in Sweden. Bone Marrow Transplant. 3 (Suppl. 1): 192, 1988.
  259. Heimdahl A, Mattsson T, Dahllöf G, Lönnqvist B, Ringdén O.  The oral cavity as a portal of entry for early infections in patients treated with bone marrow transplantation. Oral Surg. Oral Med. Oral Pathol. 68: 711-716, 1989. Times cited: 90.
  260. Gahrton G, Ringdén O.Benmärgstransplantation. In: Lärobok i Hematologi, 1990.
  261. Dahllöf G, Forsberg C-M, Ringdén O, Bolme P, Borgström B, Näsman M, Heimdahl A, Modéer T. Facial growth and morphology in long-term survivors after bone marrow transplantation. Eur. J. Orthod. 11: 332-340, 1989. Times cited: 23.
  262. Ringdén O.  Bone marrow transplantation in Stockholm. Scandiatransplant Report 1987.Repro Print, Stockholm: 37-45, 1988.
  263. Ljungman P, Fridell E, Bolme P, Böttiger M, Gahrton G, Linde A, Lönnqvist B, Ringdén O, Wahren B. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J. Infect. Dis. 159: 610-615, 1989. Times cited: 104.
  264. Dahllöf G, Heimdahl A, Modéer T, Twetman S, Bolme P, Ringdén O.  Oral mucous membrane lesions in children treated with bone marrow transplantation. Scand. J. Dent. Res. 96: 268-277, 1989. Times cited: 19.
  265. Ringdén O, Horowitz MM, for the Advisory Committee of the International Bone Marrow Transplant Registry. Graft-versus-leukemia reactions in humans. Transplant. Proc. 21: 2989-2992, 1989. Times cited: 66.
  266. Abedi MR, Bäckman L, Persson U, Ringdén O. Serum IgE levels after bone marrow transplantation. Bone Marrow Transplant. 4: 255-260, 1989.Times cited: 8.
  267. Ringdén O, Aschan J, Westerberg L. Thalidomide for severe acute graft-versus-host disease (letter). Lancet 2: 568, 1988.Times cited: 10.
  268. Tollemar J, Ringdén O, Bäckman L, Janossy G, Lönnqvist B, Markling L, Philstedt P, Sundberg B. Results of four different protocols for prophylaxis against graft-versus-host disease. Transplant. Proc. 21: 3008-3010, 1989. Times cited: 6.
  269. Duraj F, Bäckman L, Dati F, Ringdén O.Serum a1 microglobulin levels as indicator of renal function in allograft recipients. Transplant. Proc. 21: 1871-1872, 1989.
  270. Bäckman L, Appelkvist EL, Ringdén O, Dallner G. Urinary levels of basic glutathione transferase as indicator of proximal tubular damage in renal transplant recipients. Transplant. Proc. 21: 1514-1516, 1989.Times cited: 14.
  271. Atkinson K, Horowitz MM, Van Bekkum DW, Gluckman E, Gale RP, Good RA, Jacobsen N, Kolb H-J, Parkman R, Rimm AA, Ringdén O, Rozman C, Zwaan FE, Bortin MM. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459-2464, 1990. Times cited: 257
  272. Paulin T, Ringdén O, Ljungman P, Nilsson B. Symptomatic cytomegalovirus infection after bone marrow transplantation. Clin. Transplant. 3: 279-285, 1989.Times cited: 8.
  273. Ringdén O. Viral infections and graft-versus-host disease. In: Hematology Vol. 12: Graft-versus-host disease. Immunology, Pathophysiology, and Treatment. SJ Burakoff, HJ Deeg, J Ferrara, K Atkinson (eds). Marcel Dekker,  pp. 467-486, 1990.
  274. Brattström C, Tollemar J, Ringdén O, Bergström K, Tydén G.  Isoamylase levels after total body irradiation in bone marrow transplant patients. Transplant. Int. 4:96-98, 1991.Times cited: 5.
  275. Smith CIE, Norberg R, Isenberg D, Staines NA, Gahrton G, Ringdén O, Hammarström L. Anti-DNA antibody synthesis after bone marrow transplantation: implications for IgG subclass restrictivity and pathogenicity of autoantibodies. Bone Marrow Transplant. 3: 583-588, 1988. Times cited: 6.
  276. Ringdén O.  Immunodeficiency associated with bone marrow transplanta¬tion. Current Opinion in Immunology 1: 497-501, 1989.
  277. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringdén O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 75:555-562, 1990. Times cited: 1913
  278. Boström L, Ringdén O, Sundberg B, Ljungman P, Linde A, Nilsson B. Pretransplant herpes virus serology and chronic graft-versus-host disease. Bone Marrow Transplantation 4: 547-552, 1989. Times cited: 20.
  279. Ljungman P, Lönnqvist B, Ringdén O, Skinhöj P, Gahrton G, for the Nordic Bone Marrow Transplant Group: A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in marrow transplant recipients. Bone Marrow Transplant. 4: 613-615, 1989. Times cited: 29
  280. Mattsson T, Heimdahl A, Dahllöf G, Ringdén O. Hur fungerar immunförsvaret och vilka brister medför ökad infektionsrisk? Tandläkartidningen 81: 208-217, 1989.
  281. Tollemar J, Ringdén O, Boström L, Nilsson B, Sundberg B. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 4: 635-641, 1989. Times cited: 110
  282. Bortin MM, Ringdén O, Horowitz MM, Rozman C, Weiner RS, Rimm AA. Temporal relationship between the major complications of bone marrow transplantation for leukemia. Bone Marrow Transplant. 4: 339-344, 1989. Times cited: 32.
  283. Dahllöf G, Näsman M, Borgström A, Modéer T, Forsberg C-M, Heimdahl A, Ringdén O.Effect of chemotherapy on dental maturity in children with hematological malignancies. Pediatr. Dent. 11: 303-306, 1989.
  284. Ringdén O.  Den aktuella tekniken vid allogen benmärgstransplantation. Rapport till Spri, 1988.
  285. Bortin MM, for the Writing Committee of the IBMTR: Factors influencing the risk of acute and chronic graft-versus-host disease in humans: a preliminary report from the IBMTR. Bone Marrow Transplant. 4 (Suppl. 1): 222-224, 1989.Times cited: 3.
  286. Bäckman L, Ringdén O.  The Neopterin/Creatinine Ratio cannot be used to diagnose rejection episodes in renal transplant recipients. Nephron (letter) 53: 287, 1989.
  287. Aschan J, Ringdén O, Ljungman P, Andersson J, Lewensohn-Fuchs I, Forsgren M. Influenza-B in transplant patients. Scand. J. Infect. Dis. 21: 349-350, 1989. Times cited: 47.
  288. Laurenzi MA, Persson MAA, Dalsgaard C-J, Ringdén O. Stimulation of human B lymphocyte differentiation by the neuropeptides substance P and neurokinin A. Scand. J. Immunol. 30: 695-701, 1989. Times cited: 39.
  289. Tollemar J, Ringdén O, Holmberg K. Candida albicans; mannan and protein activation of cells from various human lymphoid organs. Scand. J. Immunol. 30: 473-480, 1989.Times cited: 9.
  290. Boström L, Ringdén O, Gratama JW, Jacobsen N, Prentice G, Zwaan F, Nilsson B, for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation: A role of herpes virus serology for the development of acute graft versus host disease. Bone Marrow Transplant. 5: 321-326, 1990. Times cited: 51.
  291. Ringdén O, Lönnqvist B, Aschan J, Sundberg B. Foscarnet prophylaxis in marrow transplant recipients. Bone Marrow Transplant (letter) 4: 713, 1989.Times cited: 13.
  292. Aschan J, Ringdén O, Sundberg B, Markling L, Pihlstedt P, Båryd I, Lönnqvist B, Ljungman P, Gahrton G, Möller E, Shanwell A, Heimdahl A, Tollemar J, Groth C-G. Förbättrade resultat vid benmärgstransplantation hos äldre patienter. Läkartidningen 87: 752-754, 1990.
  293. Ringdén O.Bone Marrow Transplantation. In: Nobel Medicare Research Forum. Temo Tryck AB, Stockholm, 1989.
  294. Abedi MR, Ringdén O, Bäckman L, Persson U. Serum IgE levels after bone marrow transplantation. Bone Marrow Transplant. 4 (Suppl. 2): 35, 1989.
  295. Boström L, Ringdén O, Gratama JW, Jacobsen N, Zwaan F, Nilsson B, for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation: A European multicenter study of acute and chronic graft-versus-host disease. A role of herpes virus serology. Bone Marrow Transplant. 4 (Suppl. 2): 97, 1989.
  296. Ringdén O, Bäckman L, Tollemar J, Heimdahl A, Aschan J, Gahrton G, Ljungman P, Lönnqvist B, Sundberg B. Long-term follow-up of a randomized trial comparing graft-versus-host disease prophylaxis using cyclosporin or methotrexate in patients with haematological malignancies. Bone Marrow Transplant. 4 (Suppl. 2): 119, 1989.
  297. Ljungman P, Wilund-Hammarsten M, Lönnqvist B, Bolme P, Duraj V, Hammarström L, Paulin T, Ringdén O, Smith E, Gahrton G. Efficacy of tetanus vaccination in marrow transplant recipients. Bone Marrow Transplant. 4 (Suppl. 2): 32, 1989.
  298. Erikson A, Groth CG, Månsson J-E, Ringdén O, Svennerholm L. Clinical and biochemical outcome of bone marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Pediatr. Scand. 79: 680-685, 1990. Times cited: 39.
  299. Boström L, Ringdén O, Jacobsen N, Zwaan F, Nilsson B, for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation: A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors - acute graft-versus-host disease, and splenectomy. Transplantation 49: 1100-1105, 1990. Times cited: 47.
  300. Ash RC, Horowitz MM, Gale RP, Bach FH, Barrett JA, van Bekkum DW, Casper JT, Gluckman E, Gordon-Smith EC, Henslee PJ, Jacobsen N, Kersey JH, Kolb H-J, Lowenberg B, Masaoka T, McGlave PB, Rimm AA, Ringdén O, van Rood JJ, Sondel PM, Vowels MB, Zwaan FF, Bortin MM. Bone marrow transplantation from related donors other than HLA-identical siblings: Effect of T-cell depletion. Bone Marrow Transplant., 7:443-452,  1991. Times cited: 125.
  301. Lönnqvist B, Ringdén O. Migraine precipitated by red wine after bone marrow transplantation (letter). Lancet 335: 364, 1990.
  302. Jacobsen N, Badsberg JH, Lönnqvist B, Ringdén O, Volin L, Rajantie J, Nikoskelainen J, Keiding N, for the Nordic Bone Marrow Transplantation Group. Graft-versus-leukemia activity associated with CMV-seropositive donor, posstransplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. Bone Marrow Transplant. 5: 413-418, 1990. Times cited: 27.
  303. Abedi MR, Bäckman L, Boström B, Lidbäck B, Ringdén O.Serum erythropoietin levels after bone marrow transplantation. Transplant. Proc. 22: 205, 1990.Timed cited: 7.
  304. Aschan J, Ringdén O, Tollemar J, Ljungman P, Lönnqvist B, Pihlstedt P, Markling L, Sundberg B. Improved survival in marrow recipients above 30 years of age with better prevention of graft-versus-host disease. Transplant. Proc. 22: 195-197, 1990.Times cited: 3.
  305. Boström L, Ringdén O, Gratama JW, Jacobsen N, Zwaan F, Nilsson B, for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation. The impact of pretransplant herpes virus serology on acute and chronic graft-versus-host disease. Transplant Proc. 22: 206-207, 1990.Times cited: 14.
  306. Tollemar J, Ringdén O, Aschan J, Sundberg B. Which bone marrow transplant recipients are at risk to acquire life threatening fungal infections? Transplant. Proc. 22: 208-209, 1990.Times cited: 5.
  307. Ringdén O, Groth CG, Aschan J, Bolme P, Ljungman P, Lönnqvist B, Malm G, Månsson J-E, Shanwell A, Svennerholm L, Tollemar J. Bone marrow transplantation for metabolic disorders at HuddingeHospital. Transplant. Proc. 22: 198-202, 1990. Times cited: 37.
  308. Duraj FF, Bäckman L, Dati F, Ringdén O. Monitoring of low molecular weight serum proteins in cyclosporine A treated bone-marrow transplant recipients. Transplant. Proc. 22: 203-204, 1990.
  309. Mattsson T, Heimdahl A, Dahllöf G, Lönnqvist B, Ringdén O. Predisposing factors for development of oral lesions after allogenic bone marrow transplantation (BMT). Transplant. Proc. 22: 210, 1990.
  310. Ringdén O, Groth CG, Erikson A, Månsson J-E, Svennerholm L. Bone marrow transplantation in the Norrbottnian type of Gaucher disease. In: Correction of Certain Genetic Diseases by Transplantation. JR. Hobbs (ed). Proc. of the COGENT-meeting, London, July 29: pp.30-33, 1989.
  311. Ringdén O. Results in malignant disease in bone marrow transplantation. Transplantation and Immunology Letter 6: 10-12, 1990.
  312. Gahrton G, Tura S, Belanger C, Cavo M, Chapvis B, Ferrant A, Flesch M, Gore M, Gratwohl A, Gravett PJ, Harrouseau JL, Lindeberg A, Ljungman P, Löwenberg B, Lucarelli G, Michallet M, Reiffers J, Ringdén O, Van Lint MT,  Vernant JP,  Sallerfors B, Simonsson B, Toivanen A, Troussard X, Verdonck LF, Volin L, Zwaan FE, for the European Group for Bone Marrow Transplantation (EBMT): Allogeneic bone marrow transplantation in patients with multiple myeloma. Eur. J. Hematol. 43 (Suppl. 51): 182-185, 1989.Times cited: 9.
  313. Ringdén O. Tidig benmärgstransplantation rekommenderas vid metabola sjukdomar. Läkartidningen 86: 4219-4220, 1989.
  314. Abedi MR, Bäckman L, Boström L, Lindbäck B, Ringdén O. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant. 6: 121-126, 1990. Times cited: 33.
  315. Ljungman P, Wiklund-Hammarsten M, Duraj V, Hammarström L, Lönnqvist B, Paulin T, Ringdén O, Sullivan Pepe M, Gahrton G. Response to tetanus toxoid immunization after allogeneic marrow transplantation. J. Infect. Dis. 162: 496-500, 1990. Times cited: 89.
  316. Dahllöf G, Forsberg C-M, Näsman M, Mattsson T, Modéer T, Borgström B, Bolme P, Ringdén O. Craniofacial growth in bone marrow transplant recipients treated with growth hormone after total body irradiation. Scand. J. Dent. Res. 99: 44-47, 1991.Times cited: 13.
  317. Horowitz M, Przepiorka D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, Prentice HG, Rimm AA, Ringdén O, Bortin MM. Should bone marrow transplants be restricted to large centers. Blood 79:2771-2774, 1992. Times cited: 35.
  318. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28 (Suppl B): 83-91, 1991. Times cited: 195.
  319. Ringdén O, Groth CG. Benmärgstransplantation - framgångsrikt behandlingsalternativ vid Gauchers sjukdom. Läkartidningen 87: 105, 1990.
  320. Marmont AM, Horowitz MM, Gale RP, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, O’Reilly RJ, Prentice HG, Rimm AA, Ringdén O, Speck B, Weiner RS, Bortin MM. T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130, 1990. Times cited: 614
  321. Ringdén O.  Sicklecellsanemi ej längre någon obotlig sjukdom. Läkartidningen 87: 1855, 1990.
  322. Lönnqvist B, Aschan J, Ljungman P, Ringdén O. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease (letter). Br. J. Hematol.  74:547-548, 1990. Times cited: 26.
  323. Tollemar J, Ringdén O, Tydén G. Liposomal Amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin. Transplant. 4: 167-175, 1990. Times cited: 82.
  324. Abedi MR, Hammarström L, Ringdén O, Smith CIE. Development of IgA deficiency after bone marrow transplantation: The influence of acute and chronic graft-versus-host disease. Transplantation 50:415-421, 1990.Times cited: 10.
  325. Tollemar J, Ericzon BG, Barkholt L, Andersson J, Ringdén O, Groth CG. Risk factors for deep Candida infections in liver transplant recipients. Transplant. Proc. 22: 1826-1827, 1990. Times cited: 26.
  326. Gahrton G, Ljungman P, Tura S, Belanger C, Cavo M, Chapvis B, Ferrant A, Flesch M, Gore M, Gratwohl A, Gravett PJ, Harrouseau JL, Lindeberg A, Löwenberg B, Lucarelli G, Michallet M, Reiffers J, Ringdén O, Van Lint MT, Vernant JP.  et al. Allogeneic bone marrow transplantation in multiple myeloma. In: New Strategies in Bone Marrow Transplantation. Wiley-Liss Inc., pp. 395-404, 1991.Times cited: 3.
  327. Juliusson G, Hast R, Ljungman P, Björkholm M, Lönnqvist B, Sandstedt B, Båryd I, Ringdén O, Gahrton G. Simultaneously presenting aplastic anemia and Hodgkin’s disease successfully treated with allogeneic bone marrow transplantation. Eur. J. Haematol. 46:314-316, 1991.Times cited: 3.
  328. Tydén G, Brattström C, Ringdén O, Tollemar J. Pancreatic insufficiency after bone-marrow transplantation. Lancet (letter) 338: 1088-1089,  1991.
  329. Ringdén O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse ER, Viviani M, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother.  28 (Suppl. B) : 73-82, 1991. Times cited: 235
  330. Mattsson T, Heimdahl A, Dahllöf G, Nilsson B, Lönnqvist B, Ringdén O. Variables predicting oral mucosal lesions in allogenic bone marrow recipients. Head & Neck 13:224-229, 1991.Times cited: 19.
  331. Ringdén O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P, Lönnqvist B, Tollemar J, Janossy G, Sundberg B. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant. 7: 221-226, 1991. Times cited: 110
  332. Ljungman P, Duraj V, Magnius L, Aschan J, Lönnqvist B, Ringdén O, Gahrton G. Hepatitis C infection in allogeneic bone marrow transplant recipients. Clin. Transplant. 5:283-286, 1991.Times cited: 5.
  333. Ringdén O, Tollemar J. Clinical experience with liposomal amphotericin B (AmBisome) in deep fungal infections. In: Liposomal Amphotericin B in deep mycoses.VG Daniels (ed). Symposium Report, pp. 1-8, 1990.
  334. Shanwell A, Ringdén O, Wiechel B, Rumin S, Åkerblom O. A study of the effect of AB0 incompatible plasma in platelet concentrates transfused to bone marrow transplant recipients. Vox. Sang. 60: 23-27, 1991.Times cited: 20.
  335. Dahllöf G, Barr M, Heimdahl A, Mattsson T, Modéer T, Ringdén O. Infections and oral complications during the neutropenic phase in children and adults treated with bone marrow transplantation. J. Paediatr. Dent. 6: 109-114, 1990.
  336. Aschan J, Ringdén O, Sundberg B, Gahrton G, Ljungman P, Winiarski J. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant. 7:113-119, 1991. Times cited: 63
  337. Boström L, Ringdén O, Nilsson B, Jacobsen N, Zwaan F, for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Early leukaemia, seropositivity for several herpes viruses and chronic graft-versus-host disease are associated with decreased incidence of relapse after allogeneic bone marrow transplantation. Clin Transplant 5:351-358,  1991.Times cited: 4.
  338. Ljungman P, Aschan J, Bolme P, Lindqvist R, Lönnqvist B, Ringdén O, Winiarski J, Gahrton G.  Svår aplastisk anemi; behandling med benmärgstransplantation respektive anti-thymocytglobulin. Läkartidningen 88:2308-2311, 1991.
  339. Boström L, Ringdén O. No association between splenomegaly and acute graft-versus-host disease in humans after allogeneic bone marrow transplantation. Transplant. Proc.24:374-375, 1992.
  340. Pihlstedt P, Paulin T, Sundberg B, Nilsson B, Ringdén O. Blood transfusion in marrow graft recipients.  Ann. Hematol. 65:66-70, 1992. Times cited: 10.
  341. Boström L, Ringdén O, Forsgren M. Strong donor mononuclear cell reactivity for herpes simplex virus (HSV) antigen in HSV immune donors combined with recipient seropositivity for HSV, is associated with acute graft-versus-host disease. Scand. J. Immunol. 34:45-52, 1991.Timed cited: 7.
  342. Ringdén O. Bone marrow transplantation using related donors. In: The HLA system in clinical transplantation. B. Solheim, S. Ferrone, E. Möller (eds). Springer Verlag, Heidelberg, pp. 351-365, 1992.
  343. Ringdén O, Aschan J, Boström L, Dahllöf G, Tollemar J, Paulin T, Gahrton G, Groth CG, Klaesson S, Lindquist R, Ljungman P, Lönnqvist B, Persson U, Shanwell A, Winiarski J.  Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survival. In: Clinical Transplants 1990.P. Terasaki (ed). UCLA, Los Angeles, pp. 175-188, 1990.
  344. Tollemar J, Sundberg B, Markling L, Ringdén O. Immunological response in vitro by Candida after allogeneic bone marrow transplantation. Bone Marrow Transplant. 7 (Suppl. 2): 48, 1991.
  345. Tollemar J, Ringdén O, for the AmBisome users group. Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome®) Drug Invest. 4:232-238, 1992. Times cited: 20.
  346. Gratama JW, Lennette ET, Lönnqvist B, Oosterveer MAP, Klein G, Ringdén O,Ernberg I. Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients. J. Med. Virol. 37:39-47, 1992. Times cited: 29
  347. Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringdén O, Veum JA, Bortin MM. Identical twin bone marrow transplants for leukemia. Ann. Int. Med. 120:646-652, 1994. Times cited: 184.
  348. Ringdén O, Klaesson S, Sundberg B, Ljungman P, Lönnqvist B, Persson U. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin as compared to monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant.  9:19-25, 1992. Times cited: 35.
  349. Svennerholm L, Erikson A, Groth C-G, Ringdén O, Månsson JE. Norrbottnian type of Gaucher disease -Clinical, Biochemical and molecular biology aspects. Successful treatment with bone marrow transplantation. Dev. Neurosci, 13:345-351, 1991. Times cited: 13.
  350. Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllöf G, Ringdén O. Alterations in taste acuity associated with allogeneic bone marrow transplantation. J. Oral Pathol. Med. 21:33-37, 1992. Times cited: 31.
  351. Ringdén O. Benmärgstransplantation. Obesläktade givare bra, men risken ökad för transplantat-kontra-värdreaktion. Läkartidningen 40:3259-3260, 1991.
  352. Tollemar J, Ringdén O. Early recovery of lymphocyte response to Candida after bone marrow transplantation in colonized patients. Bone Marrow Transplant. 7: 285-291, 1991.
  353. Shanwell A, Larsson S, Aschan J, Ringdén O. A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipients.  Eur. J. Haematol. 49:77-81, 1992. Times cited: 23.
  354. Gahrton G, Tura S, Ljungman P, et al, for the EBMT Group. Allogeneic bone marrow transplantation in multiple myeloma using HLA-compatible sibling donors - an EBMT Registry Study. Bone Marrow Transplant. 7 (Suppl. 2): 32, 1991.
  355. Boström L, Ringdén O, Forsgren M. Strong donor mononuclear cell reactivity for herpes simplex virus (HSV) antigen in HSV immune donor/recipient pairs is associated with acute graft-versus-host disease. Transplant. Proc.24: 376-377, 1992.
  356. Ringdén O. Allogeneic bone marrow transplantation. The Huddinge  experience. Transplant. Proc. 24:371-373, 1992.
  357. Tollemar J, Sundberg B, Markling L, Ringdén O. Immune response to Candida before and up to 5 years after allogeneic bone marrow transplantation. Transplant. Proc. 24:378-379, 1992.
  358. Duraj FF, Bäckman L, Dati F, Ringdén O. Serum levels for alpha-1 microglobulin and beta-2 microglobulin in bone marrow transplant recipients treated with cyclosporin A. Transplant. Int. 4: 146-150, 1991.Timed cited: 8.
  359. Ringdén O. Correlation of pretransplant viral serology and complications of bone marrow transplantation. Ann. Hematol. 64:A143-A147, 1992.
  360. Gratama JW, Oosterveer MAP, Lepoutre J, Fibbe WE, Ringdén O, Vossen JMJJ, Willemze R,  Bolhuis RLH, van Rood JJ, Ernberg  I. Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists. Ann. Hematol. 64:A162-A165, 1992.Times cited:  8.
  361. Mattsson T, Heimdahl A, Dahllöf G, Lönnqvist B, Ringdén O. Oral and nutritional status in allogeneic marrow recipients treated with T-cell  depletion or cyclosporine combined with methotrexate to prevent  graft-versus-host disease. Oral Surg. Oral Med. Oral Pathol. 74: 34:40, 1992.
  362. Aschan J, Ringdén O, Ljungman P, Lönnqvist B, Ohlman S. Foscarnet for treatment of cyto-megalo¬virus infections in bone marrow transplant recipients. Scand. J. Infect. Dis. 24:143-150, 1992. Times cited: 36.
  363. Tibell A, Ringdén O, Sundberg B. Cyclosporine A in fat emulsion carrier: immunosuppressive effect in  vitro. Scand. J. Immunol. 35:231-236, 1992.Times cited: 3.
  364. Ringdén O, Kersey JH. Prevention and therapy of graft-versus-host disease. Bone Marrow Transplant. 10 (Suppl. 1): 22-24,1992.Times cited: 11.
  365. Mattsson T, Sundqvist KG, Heimdahl A, Dahllöf G, Ljungman P, Ringdén O. A comparative  immunological analysis of the oral mucosa in  chronic graft-versus-host disease and oral lichen planus. Arch. Oral  Biol.  37:539-547, 1992. Times cited: 38.
  366. 366.  Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, Jacobsen N, Phillips GL,   Rimm AA, Ringdén O, Rozman C, Sobocinski KA, Veum JA, Bortin MM. Bone marrow transplants may  cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80: 1090-1093, 1992.Times cited: 152.
  367. Boström L, Ringdén O. Monoclonal antibodies in prophylaxis and treatment of graft-vs-host disease after bone marrow transplantation. Book:Monoclonal Antibodies. Production, engineering and clinical application. (eds. M Ritter, H Ladyman) Postgraduate Medical Science, Cambridge, 1995, pp. 317-339.
  368. Tydén G, Brattström C, Ringdén O. Pancreatic insufficiency after bone marrow transplantation. Lancet 338: 1088-1089, 1991
  369. Johnsen HE, Boström L, Möller J, Jörgensen JA, Jensen L, Ringdén O, Jacobsen N. A study of donor alloreactivity which may predict acute graft-versus-host disease in HLA identical bone marrow transplantations for early leukaemia. Scand. J. Immunol. 35: 353-360, 1992.Times cited: 8.
  370. Wilton J, Jung K, Nyström B, Ringdén O, Flock JI. Outbreak of lethal coagulase-negative staphylococcal infection in a transplant unit: an epidemiologic study. Journal of Hospital Infection 19: 287-289, 1991.Times cited: 4.
  371. Krivit W, Shapiro E, Lockman L, Kennedy W, Dhuna A, Ringdén O, Henslee-Downey J, Yeager A, Wenger D,  Bayever E. Recommendations for treatment of metachromatic leuko-dystrophy by bone marrow transplantation based on a review of seven patients who have been engrafted for at least 1 year. In: Correction of Certain Genetic Diseases by Transplantation. J.R. Hobbs, P.G. Riches (eds). Publ. The COGENT Fund, London, pp. 57-72, 1991
  372. Prentice HG, Ringdén O, Meunier F, Tollemar J, McWhinney P, Kibbler CC, Huang D, for the AmBisome Users Group. Invasive pilzinfektionen bei neutropenischen und anderen immunsupprimierten patienten und die wirksamkeit einer behandlung mit liposomalem Amphotericin B (AmBisome). (Invasive fungal infection in neutropenic and other immunocompromised patients and the efficacy of treatment by  liposomal amphotericin B (AmBisome). Satelliten-Symposium des 17 International Congresses uber Chemotherapie, Juni 1991, Berlin, Deutschland. Insights, Band 1, nr 1. Febr 1992. Gardiner-Caldwell Communications Ltd., Macclesfield, Cheshire, pp. 9-17.
  373. Békássy AN, Ringdén O. Benmärgs- och organtransplantation kan ge bot vid ärftliga metaboliska sjukdomar.  Läkartidningen 89:2658-2660, 1992.
  374. Ringdén O, Tollemar J, Tydén G. Liposomal amphotericin B. Lancet 339: 374, 1992. Times cited:  11.
  375. Westgren M, Bui TH, Ek S, Egdberg N, Hagenfelt L, Markling L, Pschera H, Seiger Å, Ringdén O. Intrauterin transplantation med fetala stamceller botar sjuka foster. Läkartidningen 89: 1645-1651, 1992. 
  376. Boström L, Ringdén O. Viral infections. In: Clinical Bone Marrow Transplantation. Atkinson K (ed). Chapter 45, pp. 344-355, 1993. 
  377. Tollemar J, Ringdén O.Fungal infections. In: Clinical Bone Marrow Transplantation.Atkinson K (ed). Chapter 44, pp. 337-343, 1993.
  378. Ljungman P, Aschan J, Azinge JN, Brandt L, Ehrnst A, Hammarström V, Klaesson S, Linde A,  Lönnqvist B, Ringdén O, Wahren B, Gahrton G. Cytomegalovirus viremia and specific T-helper cell responses as  predictors of disease after allogeneic marrow transplantation. Br. J. Haematol. 83:118-124, 1993. Times cited: 63
  379. Ringdén O, Horowitz MM, Sondel P, Gale RP, Biggs JG, Champlin RE, Deeg HJ, Dicke K, Masaoka T,  Powles RL, Rimm AA, Rozman C, Sobocinski KA, Speck B, Zwaan FE, Bortin MM. Methotrexate, cyclosporine or  both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood  81:1094-1101, 1993. Times cited: 151.
  380. Aschan J, Ringdén O, Sundberg B, Klaesson S, Ljungman P, Lönnqvist B. Increased risk of relapse in  patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methtorexate combined with cyclosporin or  monotherapy for the prevention of graft-versus-host disease. Eur. J. Hematol. 50:269-274, 1993.Times cited: 24
  381. Heurlin N, Markling L, Barkholt L, Lönnqvist B, Andersson J, Ringdén O. Rapid detection of cytomegalovirus antigen on alveolar cells from transplant patients with cytomegalovirus pneumonia. Clin Transplantation 8:466-473, 1994.Times cited: 8.
  382. Shanwell A, Wikman A, Ringdén O. Pretransfusion incubation of apheresis platelets at 37°C improves posttransfusion recovery. Transfusion 32: 715-718, 1992. Times cited: 7.
  383. Ringdén O. Authors updated comments in Critical Papers in Bone Marrow Transplantation 1991. An Anthology. R. Powles, EC Gordon-Smith (Eds), pp. 53-58, 124-130, 1991.
  384. Ek S, Ringdén O, Markling L, Westgen M. Cryopreservation of fetal stem cells. Bone Marrow Transplant. 11 (Suppl. 1): 123, 1993.Times cited: 3.
  385. Ringdén O, Wennberg L, Ericzon BG, Kallman R, Åström M, Duraj F, Söderdahl G, Tydén G, Groth CG. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. Lancet  340:546-547, 1992. Times cited: 26.
  386. Tollemar J, Andersson S, Ringdén O, Tydén G. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses 35: 215-220, 1992. Times cited: 29.
  387. Dahllöf G, Krekmanova L, Kop S, Borgström B, Forsberg CM, Ringdén O. Craniomandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation. Acta Odontol. Scand. 52:99-105, 1994. Times cited: 20.
  388. Ringdén O, for the Advisory Committee of the International Bone Marrow Transplant Registry. Decreased transplant-related complications and improved leukemia-free survival in adults receiving methotrexate combined with cyclosporin compared to either agent alone for prevention of graft-versus-host disease. Transplant. Proc. 25:1241-1242, 1993.Times cited: 4.
  389. Tollemar J, Ringdén O, Andersson S, Sundberg B, Ljungman P, Sparrelid E, Tydén G. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections. A randomized trial in bone marrow transplant recipients. Transplant. Proc.25:1495-1497, 1993. Times cited: 47.
  390. Ringdén O. Management of graft-versus-host disease. Eur. J. Haematol. 51: 1-12, 1993. Times cited: 34.
  391. Kuse ER, Ringe B, Bunzendahl H, Ringdén O, Ksionski G, Wenner-Ziegler S,  Pichlmayr I, Pichlmayr R. Liposomales Amphotericin B (Ambisome): Erste Ergebnisse zur Behandlung lebensbedrohlicher, systemischer Mykosen.
  392. Gahrton G, Bolme P, Ljungman P, Persson U, Ringdén O. Benmärgs¬transplantation. EG-projekt med obesläktade donatorer räddar fler. Läkartidningen 90: 948-950, 1993.
  393. Ek S, Ringdén O, Markling L, Dahlberg N, Pschera H, Seiger Å, Sundström E, Westgren M. Effects of cryopreservation on subsets of fetal liver cells. Bone Marrow Transplant. 11: 395-398, 1993. Times cited: 21.
  394. Ringdén O. Clinical use of AmBisome with special emphasis on experience in children. Bone Marrow Transplant. 12 (Suppl. 4): 149-150, 1993.Timed cited: 7.
  395. Ringdén O, Fauser AA. Graft-versus-host disease - prophylaxis and treatment. Bone Marrow Transplant. 12 (Suppl. 4): 51-53, 1993.
  396. Tollemar J, Ringdén O. Double-blind randomized trials with AmBisome as prophylaxis in bone marrow and liver transplant patients. Bone Marrow Transplant. 12(Suppl.4):151-152, 1993.
  397. Klaesson, S., Ringdén, O., Markling, L. , Remberger, M & LundquistI.:  Immune modulatory effects of immunoglobulins on cellmediated immune responses in vitro. Scand. J. Immunol. 38:477-484, 1993. Times cited: 43.
  398. Tollemar J, Ringdén O, Andersson S, Sundberg B, Ljungman P, Tydén G. A randomized double-blind study of AmBisome (liposomal amphotericin B) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 12:577-582, 1993. Times cited: 129.
  399. Ringdén O, Tollemar J. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Mycoses 36: 187-192, 1993. Times cited: 18.
  400. Norhagen Engström G, Engström PE, Björkstrand B, Hammarström L, Smith E, Ringdén O.  Salivary immunoglobulins in recipients of transplanted allogeneic and autologous bone marrow. Bone Marrow Transplant. 14:229-234, 1994.Times cited: 13.
  401. Aschan J, Ringdén O.  Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.  Clin. Transplant. 8:258-270, 1994.Times cited: 13.
  402. Ringdén O, Remberger M, Aschan J, Ljungman P, Lönnqvist B, Markling L. Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients. Transplantation, 58:887-891, 1994. Times cited: 24.
  403. Ljungman P, Lawler M, Åsjö B, Bogdanovic G, Karlsson K, Malm C, McCann SR, Ringdén O, Gahrton G. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. British Journal of Haematology 88:403-405, 1994. Times cited: 35.
  404. Ljungman P, Aschan J, Boström L, Johansson B, Lönnqvist B, Ringdén O, Teodosiu O, Ehnst A. Early ganciclovir therapy of cytomegalovirus viremia diagnosed by polymerase chain reaction in allogeneic bone marrow transplant patients. In: Recent Advances in Chemotherapy. Einhorn, Nord, Norrby (eds). pp. 637-638, 1993
  405. Ringdén O, Horowitz M, Gale RP,  Biggs JC, Gajewski J, Rimm AA, Speck B, Veum-Stone JA, de Witte T, Bortin MM. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 270:57-60, 1993. Times cited: 118.
  406. Klaesson S, Ringdén O, Ljungman P, Lönnqvist B, Wennberg L. Reduced blood transfusions requirements after allogeneic bone marrow transplantation, - results of a randomised, double-blind study with high dose erythropoietin. Bone Marrow Transplant.13: 397-402, 1994. Times cited: 53.
  407. Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindeløv L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, Mellander L, Jacobsen N, for the Nordic Bone Marrow Transplantation Group: A randomized trial comparing busulphan vs. total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplant. Proc. 26:1831-1832, 1994.Timed cited: 8.
  408. Aschan J, Ringdén O, Andström E, Ljungman P, Remberger M. Prevention of graft-versus-host disease on an individual basis. Transplant Proc 26:1823-1824,  1994
  409. Remberger M, Ringdén O, Aschan J, Ljungman P, Lönnqvist B, Markling L. Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients. Transplant Proc 26(3):1829 -1830, 1994. Times cited: 3.
  410. Hassan M, Ljungman P, Bolme P, Ringdén O, Syruccková Z, Békàssy A, Stary J, Wallin I, Kållberg N. Busulphan bioavailability. Blood 84: 2144-2150, 1994. Times cited: 138.
  411. Ringdén O, Horowitz MM, Bortin MM. Outcome after allogeneic bone marrow transplant for leukemia in older adults (letter). JAMA 270(21):2560, 1993.
  412. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringdén O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D, Blanche S, Fischer A, on behalf of the European Group for Bone Marrow Transplantation: Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 345:1398-1402, 1995. Times cited: 164.
  413. Westgren M, Ek S, Bui TH, Hagenfeldt L, Markling L, Pschera H, Seiger Å, Sundström E, Ringdén O. Establishment of a tissue bank for fetal stem cell transplantation. Acta Obstet Gynecol Scand 73:385-388, 1994. Times cited: 33.
  414. Lönnqvist B, Aschan J, Ringdén O. Foscarnet as inpatient prophylaxis only is insufficient to prevent cytomegalovirus infection after marrow transplantation. J. Infect. Dis. 168:1073, 1993 (Letter).
  415. Boström L, Brytting M, Jazi-Mousavi M, Ringdén O, Ljungman P, Lönnqvist B, Wahren B, Sundqvist VA. PCR detection of CMV DNA in peripheral blood leucocytes and plasma from BMT recipients. Transplant. Proc. 26:1723-1724, 1994.
  416. Aschan J, Ringdén O, Andström E, Ljungman P, Lönnqvist B, Remberger M. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transplant. 14:79-87, 1994. Times cited: 35
  417. Brytting M, Mousavi-Jazi M, Boström L, Larsson M, Lundeberg J, Ljungman P, Ringdén O, Sundqvist VA. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients. Transplantation 60:961-965, 1995. Times cited: 31.
  418. Ek S, Ringdén O, Markling L, Westgren M. Immunological capacity of human fetal liver cells. Bone Marrow Transplant 19:9-14, 1994. Times cited: 21.
  419. Ehrnst A, Barkholt L, Lewensohn-Fuchs I, Ljungman P, Teodosiu O, Staland Å, Ringdén O, Tydén G, Johansson B. CMV PCR monitoring in leucocytes of transplant patients. Clin. Diagnostic Virol 3:139-153, 1995. Times cited: 36.
  420. Ringdén O. Liposomal amphotericin B as a therapeutic and prophylactic agent for invasive fungal infections. In: Systemic Fungal Infections in Immunocompromised Patients. Wikströms AB, Uppsala, pp. 18-21, 1994.
  421. Tollemar J, Höckerstedt K, Ericzon BG, Sundberg B, Ringdén O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: Results of two randomized double-blind studies. Transplantation Proceedings 26:1833, 1994. Times cited: 18.
  422. Ljungman P, Lewensohn-Fuchs I, Hammarström V, Aschan J, Brandt L, Bolme P, Lönnqvist B, Johansson N, Ringdén O, Gahrton G. Long-term immunity to measles, mumps and rubella after allogeneic bone marrow transplantation.  Blood 84: 657- 663, 1994. Times cited: 61.
  423. Ringdén O, Remberger M, Persson U, Ljungman P, Aschan J, Bolme P, Dahllöf G, Dalianis T, Gahrton G, Lönnqvist B, Olerup O, Shanwell A, Sparrelid E, Winiarski J, Öberg M, Möller E. Nya data från benmärgstransplantation. Obesläktad givare lika bra som besläktad. Läkar-tidningen 91: 26-27, 1994.
  424. Ringdén O, Tollemar J, Dahllöf G, Tydén G. High cure rate of invasive fungal infections in immunocompromised children using Ambisome. Transplant. Proc. 26: 175-177, 1994. Times cited: 19.
  425. Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindeløv L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, Mellander L, Jacobsen N, for the Nordic Bone Marrow Transplantation Group: A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia. A report from the Nordic Bone Marrow Transplantation Group. Blood 83:2723-2730, 1994. Times cited: 245
  426. Ringdén O, Groth CG, Erikson A, Grankvist S, Månsson JE, Sparrelid E. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 59(6):864-870, 1995. Times cited: 82.
  427. Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: Long-term results of a randomized, placebo-controlled trial. Transplant Proc 27: 1195-1198, 1995. Times cited: 29.
  428. Westgren M, Ringdén O. Fetal to fetal transplantation. Acta Obstet Gynecol Scand 73:371-372, 1994.Times cited: 4.
  429. Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 59:45-50, 1995. Times cited: 133.
  430. Hägglund H, Boström L, Ringdén O, Nilsson B, Remberger M. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients. Transplant Proc 26(3):1821-1822, 1994.Timed cited: 7.
  431. Remberger M, Ringdén O, Markling L. TNF-alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplantation 15:99-104, 1995. Times cited: 105
  432. Ek S, Westgren M, Pschera H, Seiger S, Sundström E, Bui TH. Ringdén O. Screening of fetal stem cells for infection and cytogenetic abnormalities. Fetal Diagnosis and Therapy 9:357-361, 1994.Timed cited: 7.
  433. Ringdén O, Remberger M, Persson U, Ljungman P, Aldener A, Andström E, Aschan J, Bolme P, Dahllöf G, Dalianis T, Gahrton G, Hägglund H, Lönnqvist B, Olerup O, Shanwell A, Sparrelid E, Winiarski J, Öberg M, Möller E. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplantation 15:619-625, 1995. Times cited: 160.
  434. Ringdén O, Andström E, Remberger M, Svahn B-M, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplantation 14(suppl 5):S10-S14, 1994. Times cited: 45.
  435. Ringdén O.  Allogen benmärgstransplantation på Huddinge sjukhus. Haema  4: 3- 4, 1994.
  436. Ljungman P, Hägglund H, Lönnqvist B, Sönnerborg A, Ringdén O. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver. Blood (letter) 84(4):1349-1353, 1994. Times cited: 14.
  437. Klaesson S, Ringdén O, Ljungman P, Aschan J, Hägglund H, Winiarski J. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 60:1225-1230, 1995. Times cited: 34.
  438. Saarinen U, Mellander L, Nysom K, Ringdén O, Schrøder H, Glomstein A, Gustafsson G. Allogeneic bone marrow transplantation in first remission for children with very high risk acute lymphoblastic leukemia: A retrospective case-control study in the Nordic Countries. Bone Marrow Transplantation 17:357-363, 1996. Times cited: 41
  439. Ringdén O.  Benmärgstransplantation. Chimerism och toleransutveckling. In: XV Congress of the Transplantation Society. Sandoz, pp 13-16, 1995.
  440. Dahllöf G, Bågesund M, Ringdén O. Impact of conditioning regimens on salivary function, caries-associated micro-organisms and dental caries in children treated with  bone marrow transplantation. A four-year longitudinal study. Bone Marrow Transplantation 20: 479-483, 1997. Times cited: 22.
  441. Ljungman P, Loré K, Aschan J, Klaesson S, Lewensohn-Fuchs I, Lönnqvist B, Ringdén O, Winiarski J, Ehrnst A. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplantation 17:583-587, 1996. Times cited: 84.
  442. Bolme P, Henter J-I, Winiarski J, Elinder G, Ljungman P, Lönnerholm G, Ringdén O. Allogeneic bone marrow transplantation for hemophagocytic lymphohistiocytosis in Sweden. Bone Marrow Transplantation 15:331-335, 1995. Times cited: 41
  443. Westgren M, Ek S, Remberger M, Ringdén O, Stangenberg M. Cytokines in fetal blood and amniotic fluid in Rh immunized pregnancies. Obstet Gynecol 86: 209-213, 1995. Times cited: 17.
  444. Ljungman P, Hassan M, Békássy AN, Ringdén O, Öberg G. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplant. Bone Marrow Transplantation 15:869-871, 1995. Times cited: 31.
  445. Ljungman P, Johansson N, Aschan J, Glaumann H, Lönnqvist B, Ringdén O, Sparrelid E, Sönnerborg A, Winiarski J, Gahrton G. Long-term effects of hepatitis C virus (HCV) infection in allogeneic bone marrow transplant recipients. Blood 86(4):1614-1618, 1995. Times cited: 55.
  446. Ringdén O, Andström E, Remberger M, Svahn B-M, Tollemar J. Allergic reactions and other rare side-effects of liposomal amphotericin. (letter). Lancet 344:1156-1157, 1994. Times cited: 35.
  447. Ringdén O, Groth CG, Erikson A, Granqvist S, Månsson J-E, Sparrelid E. Long-term results of bone marrow transplantation for Gaucher disease. In: Correction of Genetic Diseases by Transplantation III. Steward CG, Hobbs JR (eds). COGENT Press, London, U.K., 1995 pp. 57-63
  448. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff S (eds). Graft vs Host Disease, Second Edition. Marcel Dekker, Inc.,  New York, pp 525-559, 1996.
  449. Ringdén O, Lönnqvist B, Hägglund H, Ljungman P, Shanwell A, Lawlor E, Schmitz N. Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. (Letter) Bone Marrow Transplantation 16(6): 856-857, 1995. Times cited: 13.
  450. Henter J-I, Winiarski J, Ljungman P, Ringdén O, Öst Å. Bone marrow transplantation in two children with Congenital Amegakaryocytic Thrombocyto¬penia. Bone Marrow Transplantation 15: 799-801, 1995. Times cited: 20.
  451. Ek S, Markling L, Westgren M, Kjaeldgaard A, Ringdén O. Cytokine stimulation of human fetal hematopoietic cells. Fetal Diagnosis and Therapy 11:318-325, 1996.Times cited: 5.
  452. Ringdén O, Franksson C. Lymfsystemet. In: Franksson C, Hamberger B (eds). Kirurgi. Almqvist & Wiksell Förlag AB 1992, pp 763-791.
  453. Hägglund H, Boström L, Remberger M, Ljungman P, Nilsson B, Ringdén O. Risk factors for acute graft-versus-host-disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplantation 16:747-753, 1995. Times cited: 75.
  454. Ek S, Markling L, Ringdén O, Kjaeldgaard A, Westgren M. Colony formation of purified CD34+ hematopoietic cells, with and without cytokines, from fetal liver, bone marrow and cord blood. Fetal Diagnosis and Therapy  11:326-334, 1996.Times cited: 4.
  455. Heurlin N, Bergström S-E, Winiarski J, Ringdén O, Andersson J. Fungal pneumonia: the predominant lung infection causing death in children undergoing bone marrow transplantation. Acta Paediatr 85: 168-172, 1996.Times cited: 14.
  456. Ekelöf Andström E, Ringdén O,  Remberger M, Svahn B-M, Tollemar J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients - improvements gained. Mycoses 39: 185-193, 1996. Times cited: 30.
  457. Ruutu T, Ringdén O. Bone marrow transplantation. In: Atlas of Clinical Transplantation. Harjala A, Höckerstedt A (Eds.) Recall Med, p. 170-185, 1995
  458. Westgren LMR, Ringdén O, Eik-Nes S, Ek S, Anvret M, Brubakk A-M, Bui T-H,  Giambona A, Kiserud T, Kjaeldgaard A, Maggio A, Markling L, Seiger Å, Orlandi F. Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies. Transplantation 61:1176-1179, 1996. Times cited: 98.
  459. Remberger M, Ringdén O. Increased levels of soluble IL-2 receptor in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Transplantation 60:1293-1299, 1995. Times cited: 23.
  460. Ringdén O, Ekelöf Andström E, Remberger M, Svahn B-M, Tollemar J. No increase in cyclosporin neurotoxicity in transplant recipients treated with liposomal amphotericin B. (letter) Infection 24:269, 1996.
  461. Hägglund H, Ringdén O, Ljungman P, Lönnqvist B, Winiarski J, Ericzon BG, Tydén G. No beneficial effects, but severe side-effects by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplant Proc 27:3535, 1995.Times cited: 12.
  462. Aschan J, Ringdén O, Ljungman P, Hägglund H, Klaesson S, Dalianis T, Remberger M. Bone marrow transplantation for chronic myelogenous leukemia using unrelated donors: the experience at Huddinge Hospital. Transplantation Proceedings 27(6): 3531-3532, 1995
  463. Sparrelid E, Hägglund H, Remberger M, Ljungman P, Malmborg A-S, Winiarski J, Andersson J, Ringdén O. Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation. Transplant Proc 27:3530, 1995.Times cited: 8.
  464. Lönnqvist B, Ljungman P, Norrby M, Olerup O, Ringdén O, Winiarski J. Less acute GVHD in patients receiving totally matched transplants from unrelated donors. Transplantation Proceedings 27:3528-3529, 1995.
  465. Remberger M,  Ringdén O. Cytokines in veno-occlusive disease of the liver after bone marrow transplantation. Transplantation Proceedings 27(6):3533-3534, 1995. Times cited: 6.
  466. Klaesson S, Ringdén O, Markling L, Tammik L. Intravenous immunoglobulin: Immune modulatory effects in vitro and clinical effects in allogeneic bone marrow transplant recipients. Transplantation Proceedings 27(6):3536-3537, 1995.
  467. Ringdén O, Westgren M, Eik-Nes S, Ek S, Brubakk A-M, Bui TH, Giambona A, Jakil C, Kiserud T, Kjaeldgaard A, Maggio A, Markling L, Olerup O, B-M Svahn, F Orlandi. Intrauterine transplantations of foetal hematopoietic stem cells to four foetuses with haemoglobinopathies. In: Ontogeny of hematopoiesis. Aplastic anemia. (Eds. E. Gluckman, L. Coulombel). INSERM/John Libbey Eurotext Ltd. 1995, vol 235, pp. 163-168.
  468. Ringdén O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, Sierra J, Gorin NC. For the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Br J Haematol 93: 637-645, 1996. Times cited: 88.
  469. Tollemar J, Ringdén O. Lipid formulations of Amphotericin B. Less toxicity but at what economic cost? Drug Safety 13(4): 207-218, 1995. Times cited: 43.
  470. Winiarski J, Ringdén O, Remberger M, Dalianis T, Borgström B, Ljungman P. Bone marrow transplantation in children using unrelated donors at Huddinge Hospital. Acta Paediatrica 85: 327-35, 1996. Times cited: 22.
  471. Ferrara JLM, Krenger W, Cooke KR, Pan LY,  Blazar BR, Korngold R, Townsend RM, Levy RB, Baker M, Sykes M, Dey B, Yang Y-G, Chao NJ,  Deeg HJ, Petersdorf E, Ringdén O, Holler E, Heslop HE,  Niederwieser D, Murphy G, Crawford JM. Recent advances and furure directions. In: Ferrara JLM, Deeg HJ, Burakoff S (eds). Graft vs Host Disease, Second Edition. Marcel Dekker, Inc.,  New York, pp 775-810, 1996.
  472. Westgren M, Ek S, Bui TH, Jansson B, Kjaeldgaard A, Markling L, Nennesmo I , Seiger Å, Sarby B, Thornström S, Ringdén O. Tissue distribution of transplanted fetal liver cells in the human fetal recipient. Am J Obstet Gyn 176:49-53, 1997. Times cited: 17.
  473. Klaesson S, Tammik L, Markling L, Lundkvist I, Ringdén O. Inhibition of immunoglobulin production in vitro by IgG and F(ab´)2 fragments, but not by the Fc portion. Scandinavian Journal of Immunology 43: 574-582, 1996.Times cited: 14.
  474. Ringdén O. Benmärgstransplantation. Introduktion och framtidsvisioner. Nordisk Medicin 110: 302-304, 1995.
  475. Ringdén O, Potter MN, Oakhill A, Cornish J, Hägglund H, Lönnqvist B, Shanwell A, Winiarski J, and DH Pamphilon. Transplantation of peripheral blood progenitor cells from unrelated donors. Bone Marrow Transplantation 17(suppl 2):S62-S64, 1996Times cited: 3..
  476. Ringdén, O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. For the Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leukemia & Lymphoma 24:71-79, 1996. Times cited: 76.
  477. Hägglund H, Ringdén O, Ericzon B.G., Duraj F, Ljungman P, Lönnqvist B, Winiarski J, and Tydén G. Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 62:1076-1080, 1996. Times cited: 24.
  478. Ljungman P, Andersson J, Aschan J, Björkstrand B, Hägglund H, Lönnqvist B, Ringdén O, Winiarski J. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clinical Infectious Diseases 23:167-169, 1996.Times cited: 19.
  479. Lewensohn-Fuchs I, Ljungman P,  Kjerrström A, Ringdén O, Dalianis T. Loss of seroreactivity against human papillomavirus (HPV) in bone marrow transplant recipients. Bone Marrow Transplantation 18:333-337, 1996.Times cited: 4.
  480. Ljungman P, Hägglund H, Björkstrand B, Lönnqvist B, Ringdén O. Peroperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters: a randomized, controlled study. Support Care Cancer 5: 485-488, 1997. Times cited: 33.
  481. Gahrton G, Ringdén O.  Benmärgs- och stamcellstransplantation. In: Lärobok i Hematologi. Bokförlaget Natur och Kultur, Stockholm 1997, pp 440-448.
  482. Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harousseau JL, Fiere D, Bacigalupo A, Frassoni F and Gorin NC for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplantation 18: 921-929, 1996. Times cited: 89.
  483. Malm G, Ringdén O, Winiarski J, Gröndahl E, Uvebrant P, Eriksson U, Håkansson H, Skjeldahl O, Månsson J-E. Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplan¬ta¬tion 17:1003-1008, 1996. Times cited: 37.
  484. Aschan J, Lönnqvist B, Ringdén O, Kumlien G, Gahrton G. Graft-versus-myeloma effect (letter). Lancet 348: 346, 1996. Times cited: 55.
  485. Malm G, Ringdén O, Anvret M, von Döbeln U, Hagenfeldt L, Isberg B, Knuutila S,  Nennesmo I, Winiarski J, Marcus C. Treatment of adrenoleukodystrophy with bone marrow transplantation. Acta Paediatrica 86: 484-492, 1997. Times cited: 22.
  486. Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lönnqvist B, Ringdén O, Ruutu P, Volin L, Albrechtsen D, Sallerfors B, Ebeling F, Myllylä G for the Nordic BMT Group. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplantation 19: 233-236, 1997. Times cited: 30
  487. Orlandi F, Giambona A, Messana F, Marino M, Abate I, Calzolari R, Damiani F, Jakil C, Renda M, Dieli F, Buscemi F, Westgren M, Ringdén O, Maggio A. Evidence of induced non-tolerance in HLA-identical twins with hemoglobinopathy after in utero fetal transplantation. Bone Marrow Transplantation 18: 637-639, 1996. Times cited: 17.
  488. Jones DRE, Bui T-H, Anderson EM, Ek S, Liu DTY, Ringdén O, Westgren M. In utero haematopoietic stem cell transplantation: Current perspectives and future potential. Bone Marrow Transplantation 18: 831-837, 1996. Times cited: 32.
  489. Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Strong antileukemic effect of chronic graft-versus-host disease in allogeneic bone marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. Transplantation Proceedings, 29:733-734, 1997. Times cited: 21.
  490. Mattsson J, Ringdén O, Aschan J, Barkholt L, Dalianis T, Hägglund H, Ljungman P, Lönnqvist B, Tollemar J, Winiarski J, Remberger M. A low incidence of grades II to IV acute GVHD, but high mortality from infections using HLA-A, -B and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine and methotrexate. Transplantation Proceedings 29:735-736, 1997. Times cited: 9.
  491. Ringdén O, Labopin M, Gluckman E, Hows JM, Bradley BA, Fouillard L, Jacobsen N, Vernant JP, Boogaerts M, Witz F, Harousseau LJ, Gorin NC. For the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) study. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Bone Marrow Transplantation 19: 963-968, 1997. Times cited: 35.
  492. Dahllöf G, Bågesund M, Remberger M, Ringdén O. Risk factors for salivary dysfunction in children one year after bone marrow transplantation. Eur J Cancer, Oral Oncol 33: 327-331, 1997.Times cited: 18.
  493. Ringdén O, Lönnqvist B, Holst M. Twelve-year follow-up of the first allogeneic bone marrow transplantation for Langerhans’ cell histiocytosis. The Lancet 349: 476, 1997. Times cited: 7.
  494. Ringdén O. Bone marrow transplantation using unrelated donors for hematological malignancies. Medical Oncology 14: 11-22, 1997. Times cited: 20.
  495. Ljungman P, Lawler M, Lönnqvist B, Ringdén O, Shanwell A. Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by anti-lymphocyte globulin and donor lymphocyte infusions. Bone Marrow Transplanta¬tion 18:1179-1181, 1996
  496. Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M. Risk-factors in bone marrow transplant recipients with leukemia. Increased relapse risk in patients treated with ciprofloxacin for gut-decontamination. Clin Transplant 12: 84-92, 1998. Times cited: 22
  497. Hägglund H, Winiarski J, Ringdén O, Sparrelid, E, Ericzon B-G. Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing CMV viraemia and severe aplastic anaemia following orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Transplantation 64: 1207-1208, 1997.Times cited: 17.
  498. Ringdén O. Allogeneic bone marrow transplantation for hematological malignancies - controversies and recent advances. Acta Oncologica 36: 549-564, 1997. Times cited: 35.
  499. Boström L,  Ringdén O. Viral infections. In: Atkinson K (ed). Clinical Bone Marrow and Blood Stem Cell Transplantation. CambridgeUniversity Press, 1997.
  500. Ringdén O, Ekelöf Andström E, Remberger M, Dahllöf G, Svahn B-M, Tollemar J. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone marrow transplantation. Pediatric Transplantation 1: 124-129, 1997.
  501. Ljungman P, Hassan M, Békássy AN, Ringdén O, Öberg G. High busulfan concentrations are associated with increased transplant related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplantation 20: 909-913, 1997. Times cited: 80.
  502. Ringdén O, Franksson C. Lymfsystemet. In: Hamberger B, Haglund U (eds). Frankssons Kirurgi, 4th edition. Liber AB, Stockholm 1997, pp 763-791.
  503. Shanwell A, Kristiansson M, Remberger M, Ringdén O. Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion 37: 678-684, 1997. Times cited: 104.
  504. Malm G, Ringdén O, Winiarski J, Gröndahl E, Uvebrant P, Eriksson U, Håkansson H, Skjeldal O, Månsson J-E. Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. In: O. Ringdén, J.R. Hobbs, C.G. Steward (eds). Correction of Genetic Diseases by Transplantation 1997. London, COGENT 1997: 28-31.
  505. Solders G, Celsing G, Hagenfeldt L, Ljungman P, Isberg B, Ringdén O. Bone marrow transplantation for adult metachromatic leukodystrophy. In: O. Ringdén, J.R. Hobbs, C.G. Steward (eds). Correction of Genetic Diseases by Transplantation 1997. London, COGENT 1997: 32-33.
  506. Malm G, Ringdén O, von Döbeln U, Hagenfeldt L, Isberg B, Winiarski J, Marcus C. Treatment of adrenoleukodystrophy with bone marrow transplantation. In: O. Ringdén, J.R. Hobbs, C.G. Steward (eds). Correction of Genetic Diseases by Transplantation 1997. London, COGENT 1997: 49-51.
  507. Ringdén O, Groth CG, Winiarski J, Månsson J-E, Erikson A. Bone marrow trans¬plan¬tation for Gaucher disease. In: O. Ringdén, J.R. Hobbs, C.G. Steward (eds). Correction of Genetic Diseases by Transplantation 1997.London, COGENT 1997: 80-86.
  508. Westgren M, Ringdén O, Ek S, Lindton B, Bui T-H, Kjaeldgaard A, Maggio A, Markling L, Olerup O, Orlandi F. Experience with a programme for intrauterine transplantations using cryopreserved fetal hematopoietic stem cells. In: O. Ringdén, J.R. Hobbs, C.G. Steward (eds). Correction of Genetic Diseases by Transplantation 1997. London, COGENT 1997: 156-162.
  509. Remberger M, Ringdén O. Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. Eur J Haematol 59: 254-262, 1997. Times cited: 31.
  510. Ringdén O, Remberger M, Mattsson J, Aschan J, Hägglund H, Carlens S, Lönnqvist B, Sparrelid E, Ljungman P. Transplantation with unrelated bone marrow in leukemic patients above 40 years of age. Transplantation Proceedings 29: 3145-3146, 1997.
  511. Carlens S, Ringdén O, Remberger M, Mattsson J, Aschan J, Hägglund H, Ljungman P. Factors affecting risk of relapse and leukemia-free survival in HLA-identical sibling marrow transplant recipients with leukemia. Transplantation Proceedings 29: 3147-3149, 1997.
  512. Ringdén O, Remberger M, Mattsson J, Aschan J, Carlens S, Hägglund H,  Lönnqvist B, Sparrelid E, Ljungman P. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplantation 21: 43-49, 1998.Times cited: 19.
  513. Söderdahl G, Tammik C, Remberger M, Ringdén O. Cadaveric bone marrow and spleen cells for transplantation. Bone Marrow Transplantation 21: 79-84, 1998. Times cited: 13.
  514. Hägglund H, Ringdén O, Ågren B, Wennberg L, Remberger M, L Rundqvist, Svahn B-M, Aspelin P. Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplantation 21:331-335, 1998. Times cited: 39.
  515. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P,  Greinix H, Frickhofen N, Ringdén O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A. Allogeneic bone marrow transplantation vs. filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multi¬centre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 21:995-1003, 1998. Times cited: 210.
  516. Ringdén O, Remberger M, Carlens S, Hägglund H, Mattsson J, Aschan J, Lönnqvist B, Klaesson S, Winiarski J, Dalianis T, Olerup O, Sparrelid E, Svahn BM, Ljungman P. Low incidence of acute graft-versus-host disease, using unrelated HLA-A, -B and -DR compatible donors and conditioning including anti-T-cell antibodies. Transplantation 66:620-625, 1998.Times cited: 58.
  517. Ringdén O, Hägglund H, Runde V, Basu O, Kroschinsky F, Stockschläder M, Potter MN. Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Bone Marrow Transplantation 21(suppl 3): S81-S84, 1998. Times cited: 7.
  518. Hägglund H, Ringdén O, Remberger M, Lönnqvist B, Sparrelid E, Tammik L, Kumlien G. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Bone Marrow Transplantation 22: 131-136, 1998. Times cited: 31.
  519. Ringdén O, Runde V, Hägglund H, Basu O, Potter M. Transplantation of peripheral blood progenitor cells (PBPC) from unrelated donors (letter). Transplantation 66:142-143, 1998.
  520. Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, Mattsson J, Svahn B-M, Winiarski J, Ljungman P, Aschan J. Risk-factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis. Bone Marrow Transplantation 22:755-761, 1998. Times cited: 100.
  521. Ringdén O, Jønsson V, Hansen M, Tollemar J, Niels Jacobsen. Severe and common side-effects of amphotericin B lipid complex (Abelcet®) (letter). Bone Marrow Transplantation 22: 733-734, 1998.Times cited: 18.
  522. Winiarski J, Mattsson J, Gustafsson Å, Wester D, Borgström B, Ringdén O, Ljungman P, Dalianis T. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation. Pediatric Transplantation 2:150-156, 1998
  523. Eneroth E,  Remberger M, Vahlne A, Ringdén O. Increased concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia. Acta Obstetrica et Gynecologica Scandinavica 77:591-593, 1998. Times cited: 26.
  524. Remberger M, Ringdén O, Ljungman P, Hägglund H, Winiarski J, Lönnqvist B, Aschan J. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplantation 22:73-78, 1998. Times cited: 40.
  525. Solders G, Celsing G, Hagenfeldt L, Ljungman P, Isberg B, Ringdén O. Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy. Bone Marrow Transplantation 22:1119-1122, 1998.Times cited: 16.
  526. Ljungman P, Halasz R, Hägglund H, Sönnerborg A, Ringdén O. Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation. Bone Marrow Transplantation 22: 499-501, 1998.
  527. Sparrelid E, Ljungman P, Ekelöf Andström E, Aschan J, Ringdén O, Winiarski J, Wåhlin B, Andersson J. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplantation 19:905-908, 1997. Times cited: 79.
  528. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lönnqvist B, Mattsson J, Sparrelid E, Winiarski J, Ringdén O. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66:1330-1334, 1998. Times cited: 115.
  529. Söderdahl G, Tammik C, Remberger M, Sandberg J, Tufveson G, Tollemar J, Ringdén O. Immune markers and hematopoiesis of cadaveric bone marrow for transplantation. Transplantation Proceedings 29: 714-715, 1997.Times cited: 3.
  530. Ringdén O. Transplantationer. Bonniers Läkarbok, 1998.
  531. Ringdén O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindeløv L, Parkkali T, Lenhoff S, Sallerfors B, Mellander L, Ljungman P and Jacobsen N, for the Nordic Bone Marrow Transplantation Group. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia using busulfan compared to total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood 93:2196-2201, 1999. Times cited: 124.
  532. Tollemar J, Gross N, Dolgiras N, Jarstrand C, Ringdén O, Hammarström L. Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplantation 23: 283-290, 1999. Times cited: 29.
  533. Hägglund H, Remberger M, Klaesson S, Lönnqvist B, Ljungman P, Ringdén O. Norethisterone treatment, a major risk-factor for veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Blood 92: 4568-4572, 1998. Times cited: 53.
  534. Falci S, Holtz A, Akesson E, Azizi M, Ertzgaard P, Hultling C, Kjaeldgaard A, Levi R, Ringdén O, Westgren M, Lammertse D, Seiger A. Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: First clinical attempt. Journal of Neurotrauma 14:875-884, 1997. Times cited: 66.
  535. Sparrelid E, Hägglund H, Remberger M, Ringdén O, Lönnqvist B, Ljungman P, Andersson J. Bactaeremia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplantation 22: 795-800, 1998 Times cited: 60.
  536. Ringdén O, Labopin M, Frassoni F, Sanz GF, Demeocq F, Prentice G, Cahn J-Y, Barbui T, Meloni G, Schaefer UW, Reiffers J, Gorin NC, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic bone marrow transplantation or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplantation 24:389-396, 1999. Times cited: 29.
  537. Schroeder H, Gustafsson G, Saarinen-Pihkala UM,  Glomstein A, Jonmundsson G, Nysom K, Ringdén O,. Mellander L. Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries. Bone Marrow Transplantation 23: 555-560, 1999. Times cited: 28.
  538. Ringdén O, Remberger M, Runde V, Bornhäuser M, Blau WI, Basara N, Hölig K, Beelen DW, Hägglund H, Basu O, Ehninger G, Fauser AA. Peripheral blood stem cell (PBSC) transplantation from unrelated donors: A comparison with marrow transplantation. Blood 94(2):455-64, 1999. Times cited: 144.
  539. Hägglund H, Ringdén O, Öman S, Remberger M, Carlens S, Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplantation 24: 831-836, 1999. Times cited: 23.
  540. Chryssanthou E, Klingspor L, Tollemar J, Petrini B, Larsson L, Christensson B, Ringdén O. PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients. Mycoses 42:239-247, 1999. Times cited: 27.
  541. Remberger M, Svahn B-M, Hentschke P, Löfgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated  haematopoietic stem cell transplantation. Bone Marrow Transplantation 24: 823-830, 1999. Times cited: 101.
  542. Gustafsson Å, Levitsky V,  Zou J-Z, Frisan T, Dalianis T, Ljungman P, Ringdén O, Winiarski J, Ernberg I, Masucci MG. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95: 807-814, 2000. Times cited: 222
  543. Carlens S, Aschan J, Remberger M, Dilber MS, Ringdén O.  Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow Transplantation 24: 629-635, 1999. Times cited: 46
  544. Hentschke P, Hägglund H, Mattsson J, Carlens S, Lönnqvist B, Ljungman P, Aschan J, Fredrikson S, Ringdén O. Bilaterial subdural haematomas following dural puncture in three haematopoietic stem cell transplant recipients. Bone Marrow Transplantation 24: 1033-1035, 1999.Times cited: 8.
  545. Ringdén O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, Aschan J. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplantation 25: 993-996, 2000. Times cited: 43
  546. Barrett J, Ringdén O, Zhang M-J, Bashey A, Cahn J,  Cairo MS, Gale RP, Gratwohl A, Locatelli F, Martino R, Schultz K, Tiberghien PW, and the GVHD/GVL Working Committee of the International Bone Marrow Transplant Registry. Effect of nucleated marrow cell dose on relapse and survival in identical twin transplants for leukemia. Blood 95: 3323-3327, 2000. Times cited: 42.
  547. Gustafsson Å, Remberger M, Winiarski J, Ringdén O. Unrelated bone marrow transplantation in children: outcome and comparison with sibling donor grafting. Bone Marrow Transplantation 25: 1059-1065, 2000. Times cited: 42.
  548. Zetterquist H, Mattsson J, Uzunel M, Näsman-Björk I, Svenberg P, Tammik L, Bayat G, Winiarski J, Ringdén O. Mixed chimerism in the B-cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B-cell acute lymphoblastic leukemia. Bone Marrow Transplantation 25:843-851, 2000. Times cited: 53.
  549. Ringdén O, Remberger M, Runde V, Bornhäuser M, Blau IW, Basara N, Hölig K, Beelen DW, Hägglund H, Basu O, Ehninger G, Fauser AA. Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: A comparison with marrow transplantation. Bone Marrow Transplantation 25(suppl 2): S6-S8, 2000.Times cited: 11.
  550. Champlin RE,  Passweg JR, Zhang M-J,  Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn J-Y, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey J, Herzig RH, Klein JP, Marmont AM, O’Reilly RJO, Ringdén O, Slavin S, Sobocinski KA,  Speck B, Weiner RS, Horowitz MM. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings. Blood 95: 3996-4003, 2000. Times cited: 99.
  551. Ringdén O, Söderdahl G, Mattsson J, Uzunel M, Remberger M, Hentschke P, Hägglund H, Sparrelid E, Elmhorn-Rosenborg A, Duraj F, Zetterquist H, Ericzon B-G. Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation 69:2043-2048, 2000. Times cited: 21.
  552. Ringdén O, Labopin M, Gorin NC, Meloni G, Blaise D, Reiffers J, Carlson K, Fouillard L, Frassoni F, for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or matched allograft is performed. Bone Marrow Transplantation 25: 1053-1058, 2000. Times cited: 25.
  553. Champlin RE, Schmitz N, Chapius B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Gratwohl A, Hertenstein B, Klein JP, Loberiza FR, Montserrat E, Murphy SC, Ringdén O, Rowlings PA, van Hoef MEHM, Horowitz MM, on behalf of the IBMTR Histocompatibility & Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation. Blood stem cells versus bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95: 3702-3709, 2000. Times cited: 348
  554. Januszkiewicz A, Essén P, McNurlan MA, Garlick PJ, Ringdén O, Wernerman J. In vivo protein synthesis of circulating human T lymphocytes does not respond to a cortisol challenge within 24 hours. Acta Anaesthesiol Scand 44:202-209, 2000.Times cited: 8.
  555. Mattsson J, Uzunel M, Remberger M, Ljungman P, Kimby E, Ringdén O, Zetterquist H. Minimal residual disease is common after allogeneic stemcell transplantation in patients with B-cell chronic lymphocytic leukemia and may be controlled by graft-vs-host disease. Leukemia 14:247-254, 2000. Times cited: 47.
  556. Lindton B, Markling L, Ringdén O, Kjaeldgaard A, Gustafsson O, Westgren M. Mixed lymphocyte culture of human fetal liver cells. Fetal Diagnosis and Therapy 15:71-78, 2000. Times cited: 23.
  557. Näsman Björk I, Brissac C, Remberger M, Mattsson J, Klaesson S, Ringdén O, Stewart J, Lundkvist I. Long-term persistence of oligoclonal serum IgM repertoires in patients treated with allogeneic bone marrow transplantation (BMT). Clin Exp Immunol 119: 240-249, 2000.Times cited: 5.
  558. Lindton B, Tolfvenstam T, Norbeck O, Markling L, Ringdén O, Westgren M, Broliden K. Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro. Fetal Diagnosis and Therapy 16: 26-31, 2001.Times cited: 11.
  559. Ringdén O, Groth CG, Winiarski J, Månsson J-E, Erikson A. The Huddinge experience of bone marrow transplantation for Gaucher disease. COGENT V, in press 2000.
  560. Solders G, Celsing G, Ringdén O. Improved peripheral nerve conduction, EEG and verbal IQ after BMT for adult metachromatic leukodystrophy, a 6-year follow-up study. COGENT V, in press 2000.
  561. Hassan M, Ljungman P, Ringdén O, Hassan Z, Öberg G, Nilsson C, Békassy A, Bielenstein M, Abdel-Rehim M, Georén S, Astner L. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplantation 25: 915-924, 2000. Times cited: 72.
  562. Hammarström V, Pauksen K, Svensson H, Lönnqvist B, Simonsson B, Ringdén O, Ljungman P. Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients. Transplantation 69: 1582-1586, 2000.Times cited: 14.
  563. Ringdén O, Tollemar J. Side-effects of amphotericin B lipid complex (Abelcet) differ greatly in various reports (correspondence). Bone Marrow Transplantation 25: 341-343, 2000.
  564. Hassan Z, Ljungman P, Ringdén O, Winiarski J, Nilsson C, Aschan J, Rosegren Whitley H, Hassan M. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplantation 27:479-485, 2001. Times cited: 21.
  565. Svennilson J, Ringdén O. Is it time to reduce toxicity by non-myeloablative conditioning for allogeneic stem cell transplantation in children? Pediatric Transplantation 4: 247-251,  2000.
  566. Åkesson E, Markling L, Kjaeldgaard A, Falci S, Ringdén O. MHC antigen expression in human first trimester spinal cord with implications for clinical transplantation procedures. Journal of Neuroimmunology 111:210-214, 2000.Times cited: 4.
  567. Ljungman P, Wang F-Z, Clark D, Emery VC, Remberger M, Ringdén O, Linde A. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. British Journal of Haematology 111: 774-781, 2000. Times cited: 109
  568. Hassan M, Svensson J-O, Nilsson C, Hentschke P, AL-Shurbaji A, Aschan J, Ljungman P, Ringdén O. Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy. Therapeutic Drug Monitoring 22:383-385, 2000. Times cited: 6.
  569. Carlens S, Remberger M, Aschan J, Ringdén O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biology of Blood and Marrow Transplantation 7:31-38, 2001. Times cited: 39.
  570. Mattsson J, Uzunel M, Remberger M, Tammik L, Omazic B, Levitsky V, Zou J-Z, Hentschke P, Ringdén O. Poor immune reconstitution after four or five major HLA antigens mismatched T-cell depleted allogeneic and autologous stem cell transplantation. Clinical and Experimental Immunology 123:162-169, 2001. Times cited: 6.
  571. Ringdén O, Labopin M, Gorin NC, Schmitz N, Schaefer UW, Prentice HG, Bergmann L, Jouet JP, Mandelli F, Blaise D, Frassoni F, for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EMBT). Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? British Journal of Haematology 111:1130-1137, 2000. Times cited: 43.
  572. Bågesund M, Richter S, Ågren B, Ringdén O, Dahllöf G. Scintigraphic study of the major salivary glands in pediatric bone marrow transplant recipients. Bone Marrow Transplantation 26: 775-779, 2000. Times cited: 7.
  573. Svahn B-M, Bjurman B, Myrbäck KE, Aschan J, Ringdén O. Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? - A preliminary report. Bone Marrow Transplantation 26: 1057-1060, 2000.Timed cited: 11.
  574. Remberger M, Aschan J, Lönnqvist B, Carlens S, Gustafsson B, Hentschke P, Klaesson S, Mattsson J, Ljungman P, Ringdén O. An ethnic role for chronic, but not acute graft-versus-host disease after HLA-identical sibling stem cell transplantation. Eur J Haematol 66: 50-56, 2001.Times cited: 9.
  575. Tollemar J, Klingspor L, Ringdén O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clinical Microbiology and Infection 7 (suppl 2): 68-79, 2001. Times cited: 33.
  576. Mattsson J, Uzunel M, Remberger M, Ringdén O. T-cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 71: 433-439, 2001. Times cited: 66.
  577. Ringdén O, Svahn B-M, Remberger M. Retrospective study of Thymoglobulin® in conditioning prior to hematopoietic stem cell transplantation. (SangStat). In: Thymoglobulin, Clinical Monograph, 43-48, 2001.
  578. Saarinen-Pihkala UM, Gustafsson G, Ringdén O, Heilmann C, Glomstein A, Lönnerholm G, Abrahamsson J, Bekassy A, Schroeder H and Mellander L, for the Nordic Society of Pediatric Hematology and Oncology. No disadvantage in outcome of using matched unrelated donors as compared to matched sibling donors for bone marrow transplantation in children with ALL in second remission. J Clin Oncol 19: 3406-3414, 2001. Times cited: 60.
  579. Socié G, Clift RA, Blaise D, Devergie A, Ringdén O, Martin PJ, Remberger M, Deeg J, Ruutu T, Michallet M, Sullivan KM, Chevret S. Busulfan plus cyclophosphamide compared with total body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 98: 3569-3574, 2001. Times cited: 140.
  580. Barkholt L, Hentschke P, Zetterquist H, Mattsson J, Uzunel M, Wersäll P, Martola J, Albiin N, Aschan J, Wijkström H, Tillegård A, Öman S, Wernerson A, Niederwieser D, Thörne A, Ringdén O. An allogeneic anti-cancer effect after hematopoietic stem cell transplantation. Transplantation Proceedings 33: 1862-1864, 2001.
  581. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringdén O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clinical Transplanta¬tion 15: 147-153, 2001. Times cited: 60.
  582. Filipovich AH, Stone JV, Tomany SC, Ireland M, Kollman C, Pelz CJ, Casper JT, Cowan MJ, Edwards JR, Fasth A, Gale RP, Junker A, Kamani NR, Loechelt BJ, Pietryga DW, Ringdén O, Vowels M, Hegland J, Williams AV, Klein JP, Sobocinski KA, Rowlings PA, Horowitz MM. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: Collaborative study of the Interna¬tional Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97: 1598-1603, 2001. Times cited: 142.
  583. Ringdén O. Transplante de células precursoras de sangre periférica vs. Trasplante de médula ósea. Salud i Ciencia 9: 5-7, 2000.
  584. Remberger M, Mattsson J, Ringdén O. Polyclonal anti-T-cell globulin (ATG) as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatric Transplantation 5: 285-292, 2001.Times cited: 14.
  585. Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringdén O. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 98: 1982-1984, 2001. Times cited: 56.
  586. Remberger M, Ringdén O, Blau IW, Ottinger H, Kremens B, Kiehl MG, Aschan J, Beelen DW, Basara N, Kumlien G, Fauser AA, Runde V. No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98: 1739-1745, 2001. Times cited: 78.
  587. Ringdén O. Stamcellstransplantation vid metastaserad njurcancer. SBU Alert-rapport. Läkartidningen 98: 4991-4995, 2001.
  588. Barkholt L, Ringdén O. Hematopoietisk stamcellstransplantation. (bokkapitel). In: Johnson C, Tufveson G (eds.) Transplantation.  Studentlitteratur, Lund 2001, pp 273-297.
  589. Ringdén O. Ten years' experience with liposomal amphotericin B in transplant recipients at HuddingeUniversityHospital. AmBisome 2000 International Workshop. Journal of Antimicrobial Chemotherapy 49 (S1): 51-55, 2002.Times cited: 4.
  590. Januszkiewicz A, Essén P, McNurlan MA, Ringdén O, Garlick PJ, Wernerman J. A combined stress hormone infusion decreases in vivo protein synthesis in human T lymphocytes in healthy volunteers. Metabolism 50: 1308-1314, 2001.Times cited: 11.
  591. Zetterquist H, Hentschke P, Thörne A, Wernerson A, Mattsson J, Uzunel M, Martola J, Albiin N, Aschan J, Papadogiannakis N, Ringdén O. A graft-versus-colonic cancer effect after allogeneic stem-cell transplantation. Bone Marrow Transplantation 28; 1161-1166, 2001. Times cited: 26
  592. Ljungman P, Larsson K, Kumlien G, Aschan J, Barkholt L, Gustavsson-Jernberg Å, Lewensohn-Fuchs I, Ringdén O. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. ScandJ Infect Dis 34: 347-350, 2002. Times cited: 31
  593. Van Rood JJ, Loberiza FR, Zhang M-J, Oudshoorn M, Claas F, Cairo MS, Champlin RE, Gale RP, Ringdén O, Hows JM, Horowitz MM. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA haploidentical sibling. Blood 99: 1572-1577, 2002. Times cited: 142.
  594. Remberger M, Ringdén O. Survival after bone marrow transplantation. Lancet 359: 887-889, 2002.
  595. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringdén O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 15: 1976-1985, 2001. Times cited: 85.
  596. Mattsson J, Uzunel M, Brune M, Hentschke P, Barkholt L, Stierner U, Aschan J, Ringdén O. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 115: 935-944, 2001. Times cited: 53
  597. Westgren M, Ringdén O, Bartmann P, Bui T-H, Lindton B, Mattsson J, Uzunel M, Zetterquist H, Hansmann M. Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency. Am J Obstet Gynecol 187: 475-482, 2002. Times cited: 40.
  598. Lee SJ, Klein JP, Barrett AJ, Ringdén O, Antin JH, Cahn J-Y, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socié G, Verdonck LF, Weisdorf DJ, Horowitz MM. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 100: 406-414, 2002. Times cited: 232.
  599. Carlens S, Liu D, Ringdén O, Aschan J, Christensson B, Levitsky V, Dilber MS. Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T-cell expansion. Journal of Hematotherapy and Stem Cell Research 11: 669-674, 2002. Timed cited: 8.
  600. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, Parkkali T, Hägglund H, Ringdén O, for the Nordic Bone Marrow Transplantation Group. Ursodeoxy¬cholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 100: 1977-1983, 2002. Times cited: 106.
  601. Hentschke P, Remberger M, Mattsson J, Barkholt L, Aschan J, Ljungman P, Ringdén O. Clinical tolerance after allogeneic haematopoietic stem cell transplantation: A study of influencing factors. Transplantation 73: 930-936, 2002. Times cited: 8.
  602. Remberger M, Storer B, Ringdén O, Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplantation 29: 391-397, 2002. Times cited: 67.
  603. Januszkiewicz A, Loré K, Essén P, Andersson B, McNurlan MA, Garlick PJ, Ringdén O, Andersson J, Wernerman J. Response of in vivo protein synthesis in T lymphocytes and leukocytes to an endotoxin challenge in healthy volunteers. Clinical and Experimental Immunology 130:263-270, 2002.Times cited: 11.
  604. Ringdén O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, Koc H, Bunjes D, Gluckman E, Rocha V, Schattenberg A, Frassoni F, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. Journal of Clinical Oncology 20; 4655-4664, 2002. Times cited: 106.
  605. Svahn B-M, Remberger M, Myrbäck K-E, Holmberg K, Eriksson B, Hentschke P, Aschan J, Barkholt L, Ringdén O. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared to hospital care. Blood 100; 4317-4324, 2002. Times cited: 84.
  606. Remberger M, Mattsson J, Hentschke P, Aschan J, Barkholt L, Svennilson J, Ljungman P, Ringdén O. The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. Bone Marrow Transplantation 30: 761-768, 2002.Times cited: 15.
  607. Svennilson J, Remberger M, Ringdén O. Risk factors for moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation in children. Pediatric Transplantation 7: 130-136, 2003. Timed cited: 7.
  608. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, Mattsson J, Svennilson J, Ringdén O. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation 8: 674-682, 2002. Times cited: 52.
  609. Remberger M, Persson U, Hauzenberger D, Ringdén O. An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Br J Haematol 119; 751-759, 2002.Times cited: 13.
  610. Le Blanc K, Tammik C, Sundberg B, Haynesworth S, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility system. Scand J Immunol 57: 11-20, 2003. Times cited: 680
  611. Uzunel M, Mattsson J, Brune M, Johansson J-E, Aschan J, Ringdén O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 101: 469-472, 2003. Times cited: 30.
  612. Barkholt L, Hentschke P, Uzunel M, Mattsson J, Wersäll P, Pisa P, Martola J, Albiin N, Wernerson A, Söderberg M, Remberger M, Thörne A, Ringdén O. Non-myeloablative hematopoietic stem cell transplantation for metastatic solid tumors. Haematologica 87 (suppl. to n. 6):21-25, 2003
  613. Garderet L, Labopin M, Gorin NC, Polge E, Fouillard L, Ehninger GE, Ringdén O, Finke J, Tura S, Frassoni F. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplantation 31: 23-29, 2003. Times cited: 29.
  614. Lindton B, Markling L, Ringdén O, Westgren M. In vitro studies of haematopoietic colony-forming capacity of human fetal liver cells at exposure to cytotoxic and immunomodulatory drugs. Fetal Diagnosis & Therapy 17: 104-109, 2002.
  615. Ringdén O, Barrett J, Zhang MJ, Loberiza F, Bolwell BJ, Cairo MS, Gale RP, Hale G, Litzow MR, Martino R, Russell JA, Tiberghien P, Urbano-Ispizua A, Horowitz MM, and the GVHD/GVL Working Committees. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. British Journal of Haematology 121:874-885, 2003. Times cited: 42.
  616. Götherström C, Ringdén O, Westgren M, Tammik C, Le Blanc K. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplantation 32:265-272, 2003. Times cited: 88.
  617. Sandström M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, Ringdén O, Öberg G, Bekassy A, Hassan M. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplantation 28:657-664, 2001. Times cited: 37.
  618. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svenberg P, Ringdén O. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplantation 32:217-223, 2003. Times cited: 46.
  619. Seidel C, Ringdén O, Remberger M. Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation 76: 423-426, 2003.Times cited: 24.
  620. Nilsson C, Aschan J, Hentschke P, Ringdén O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 31: 429-435, 2003.Times cited: 24.
  621. Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringdén O, Eber S, Seger R, Ljungman P. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m2 as an optimal dose for conditioning. Bone Marrow Transplantation 30: 833-841, 2002.Times cited: 16.
  622. Rocha V, Labopin M, Gluckman E, Powles R, Arcese W, Bacigalupo A, Reiffers J, Iriondo A, Ringdén O, Ruutu T, Frassoni F, on behalf of the Acute Leukemia Working Party (ALWP) of the European Blood and Marrow Transplant (EBMT) Registry. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European Survey. J Clin Oncol 20: 4324-4330, 2002. Times cited: 39.
  623. Larsson K, Lönnqvist B, Ringdén O, Hedquist B, Ljungman P. CMV retinitis after allogeneic bone marrow transplantation: a report of five cases. Transpl Infect Dis 4: 75-79, 2002.
  624. Söderdahl G, Barkholt L, Hentschke P, Mattsson J, Uzunel M, Ericzon BG, Ringdén O. Liver transplantation followed by adjuvant nonmyeloablative hemato¬poietic stem cell transplantation for advanced primary liver cancer in humans. Transplantation 75:1061-1066, 2003.Times cited: 8.
  625. Gustafsson Jernberg Å, Remberger M, Ringdén O, Winiarski J. Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplantation 31: 175-181, 2003. Times cited: 26.
  626. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersäll P, Pisa P, Martola J, Albiin N, Wernerson A, Söderberg M, Remberger M, Thörne A, Ringdén O. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplantation 31:253-261, 2003. Times cited: 115.
  627. Ihendyane N, Sparrelid E, Wretlind B, Remberger M, Andersson J, Ljungman P, Ringdén O, Henriques Normark B, Allen U, Low DE, Norrby-Teglund A. Viridans streptococcal septicaemia in neutropenic patients: Role of pro-inflammatory cytokines. Bone Marrow Transplantation 33: 79-85, 2004. Times cited: 6.
  628. Schaffer M, Aldener-Cannavá A, Remberger M, Ringdén O, Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 62: 243-250, 2003. Times cited: 54.
  629. Gorin NC, Labopin M, Rocha V, Arcese W, Beksac M, Gluckman E, Ringdén O, Ruutu T, Reiffers J, Bandini G, Falda M, Zikos P, Willemze R, Frassoni F. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 102:3043-3051, 2003. Times cited: 33.
  630. Sjöö F, Aschan J, Barkholt L, Hassan Z, Ringdén O, Hassan M. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulphan during conditioning prior to allogeneic stem cell transplantation. Bone Marrow Transplantation 32:349-354, 2003.Times cited: 16.
  631. Ringdén O. Stamceller fungerar redan idag. Källa 54: Livets urcell. Fem forskares syn på stamcellsforskning. Vetenskapsrådet 2003, 52-64
  632. Le Blanc K, Ringdén O, Remberger M. A low body mass index is correlated to poor survival after allogeneic stem cell transplantation. Haematologica 88:1044-1052, 2003.Times cited: 24.
  633. Ringdén O, Le Blanc K, Hovatta O. Transplantation of embryonic stem cells – possibilities and challenges. Transplantation 76: 1011-1012, 2003. Times cited: 7.
  634. Ringdén O. Novel treatment for refractory acute myeloid leukemia. Pediatric Transplantation 7: 422-425, 2003.
  635. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR, Ringdén O, Wagner Jr JE. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.  Journal of Clinical Oncology 22: 4872-4880, 2004. Times cited: 128.
  636. Uzunel M, Jaksch M, Mattsson J, Ringdén O. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol 122: 788-794, 2003. Times cited: 31.
  637. Ringdén O, Labopin M, Gorin N-C, Le Blanc K, Rocha V, Gluckman E, Reiffers J, Arcese W, Vossen JM, Jouet JP, Cordonnier C, Frassoni F, for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukaemia increases the risk of graft-versus-host disease and death. Journal of Clinical Oncology 22: 416-423, 2004. Times cited: 112.
  638. Le Blanc K, Tammik C, Götherström C, Zetterberg E, Ringdén O. HLA-expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology 31: 890-896, 2003. Times cited: 628.
  639. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76: 1208-1213, 2003. Times cited: 312
  640. Götherström C, Ringdén O, Tammik C, Zetterberg E, Westgren M, Le Blanc K. Immunological properties of human fetal mesenchymal stem cells. American Journal of Obstetrics and Gynecology 190: 239-245, 2004. Times cited: 113.
  641. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet 363: 1439-1441, 2004. Times cited: 1205
  642. Ringdén O, Schaffer M, Le Blanc K, Persson U, Hauzenberger D, Abedi MR, Olerup O, Ljungman P, Remberger M. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B and –DRb1 genomically identical volunteers? Biology of Blood and Marrow Transplantation 10: 128-134, 2004. Times cited: 38.
  643. Liu D, Tammik C, Zou J-Z, Ernberg I, Masucci MG, Ringdén O, Levitsky V. Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients. Clinical Transplantation 18: 518-524, 2004.Times cited: 9.
  644. Nordlander A, Mattsson J, Ringdén O, Le Blanc K, Gustafsson B, Ljungman P, Svenberg P, Svennilson J, Remberger M. Graft-versus-host disease is associated with a lower relapse incidence after haematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation 10: 195-203, 2004. Times cited: 25.
  645. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, Stelljes M, Bornhäuser M, Martin H, Scheid C, Ganser A, Zander AR, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser AA, Ringdén O. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia – no difference in related compared to unrelated transplant in 1. CR. Journal of Clinical Oncology 22:2816-2825, 2004. Times cited: 121.
  646. Grinnemo K-H, Månsson A, Dellgren G, Klingberg D, Wardell E, Drvota V, Tammik L, Ringdén O, Sylvén C, Le Blanc K. Xenoreactivity and engraftment of human mesen¬¬chymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 127:1293-300, 2004. Times cited: 170.
  647. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringdén O. A comparison of non-myeloablative and reduced intensity conditioning for allogeneic stem cell transplantation. Transplantation 78:1014-1020, 2004. Times cited: 42
  648. Remberger M, Svahn B-M, Mattsson J, Ringdén O. A dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 78:122-127, 2004. Times cited: 76.
  649. Le Blanc K, Rasmusson I, Götherström C, Seidel C, Sundberg B, Sundin M, Rosendahl K, Tammik C, Ringdén O. Mesenchymal stem cells inhibit the expression of IL-2 receptor (CD25) and CD38 on phytohemagglutinin activated lymphocytes. Scand J Immunol 60:307-315, 2004. Times cited: 181.
  650. Malm G, Månsson J-E, Winiarski J, Mosskin M, Ringdén O. Five-year follow-up of two siblings with aspartylglucosaminuria (AGU) undergoing allogeneic stem cell transplantation (ASCT) from unrelated donors. Transplantation 78:415-419, 2004.Times cited: 5.
  651. Svenberg P, Remberger M, Svennilson J, Mattsson J, Le Blanc K, Gustafsson B, Aschan J, Barkholt L, Winiarski J, Ljungman P, Ringdén O. Allogeneic stem cell transplantation for non-malignant disorders using matched unrelated donors. Biology of Blood and Marrow Transplantation 10:877-882, 2004.Times cited: 10.
  652. Eapen M, Giralt S, Horowitz MM, Klein JP, Wagner JE, Zhang M-J, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, DeLima M. Second transplantation for acute and chronic graft leukaemia relapsing after first HLA-identical sibling transplantation. Bone Marrow Transplantation 34:721-727, 2004. Times cited: 97.
  653. Seiger Å, Holtz A, Åkesson E, Azizi M, Ertsgaard P, Hultling C, Kjaeldgaard A, Levi R, Ringdén O, Westgren M, Lammertse D, Falci S. Fetal spinal cord grafting in man. J Neurol Rehab 12: 198-199, 1998.
  654. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringdén O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 105:548-551, 2005. Times cited: 49.
  655. Ringdén O. Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation (letter). Journal of Clinical Oncology 22: 4430-4432, 2004.
  656. Ringdén O. Introduction to graft-versus-host disease. Biology of Blood and Marrow Transplantation 11: 17-20, 2005. Times cited: 6.
  657. Schmid C, Schleuning M, Aschan J, Ringdén O, Hahn J, Holler E, Hegenbarth U, Niederwieser D, Dugas M, Ledderose G, Kolb H-J. Low-dose ARAC, donor cells and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 18: 1430-1433, 2004. Times cited: 26.
  658. Gustafsson Jernberg Å, Remberger M, Ringdén O, Winiarski J. Risk factors in pediatric stem cell transplantation for leukemia. Pediatric Transplantation 8. 464-474, 2004. Timed cited: 8.
  659. Ljungman P, Aschan J, Barkholt L, Broliden PA, Gustafsson B, Lewensohn-Fuchs I, Löfgren C, Winiarski J, Ringdén O. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus-host disease. Bone Marrow Transplantation 34: 589-593, 2004.Times cited: 13.
  660. Ringdén O, Söderdahl G, Barkholt L, Ericzon BG. Solid organ and marrow transplants: A combined strategy for tolerance and anti-tumour activity. In: New Perspectives in Allogeneic Transplantation of Hematopoietic Cells. Bacigalupo A, Corradini P, eds. GITMO, Universita Milano, Instituto Nazionale per lo Studio e la Cura dei Tumori, pp. 129-134, 2004.
  661. Diedrich B, Remberger M, Shanwell A, Svahn B-M, Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic stem cell transplant recipients. Transfusion 45: 1064-1072, 2005. Times cited: 39.
  662. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Experimental Cell Research 305: 33-41, 2005. Times cited: 249.
  663. Barkholt L, Danielssom R, Calissendorff B, Svensson L, Malihi R, Remberger M, Uzunel M, Thörne A, Ringdén O. Indium-III-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. Transplantation 78: 697-703, 2004.Times cited: 9.
  664. Omazic B, Hentschke P, Näsman-Björk I, Mattsson J, Oxelius V, Ringdén O, Permert J, Lundkvist I. Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic hematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens. Scandinavian Journal of Immunology 61:72-81, 2005. Times cited: 7.
  665. Bekassy A, Ringdén O, Juliusson G, Winiarski J. Insamling av navelsträngsblod bör finansieras offentligt. Läkartidningen 102:64, 2005
  666. Oh H, Zhang M-J, Loberiza FR, Ringdén O, Akiyama H, Asai T, Miyawaki S, Okamoto S, Horowitz MM, Antin JH, Bashey A, Bird JM, Carabasi MH, Fay JW, Gale RP, Giller RH, Goldman JM, Hale GA, Harris RE, Henslee-Downey J, Kolb H-J, Litzow MR, McCarthy PL, Neudorf SM, Serna DS, Socié G, Tiberghien P, Barrett JA. Comparison of graft-vs-host disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 105: 1408-1416, 2005. Times cited: 74.
  667. Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 11: 321-334, 2005. Times cited: 223.
  668. Ringdén O, Le Blanc K, Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions and future applications. Experimental Hematology 33: 505-512, 2005.Times cited: 14.
  669. Malmberg K-J, Schaffer M, Ringdén O, Remberger M, Ljunggren HG. KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Molecular Immunology 42: 531-534, 2005. Times cited: 27.
  670. Schaffer M, Malmberg KJ, Ringdén O, Ljunggren HG, Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 78: 1081-1085, 2004. Times cited: 54.
  671. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, Corradini P, Ciceri F, Remberger M, Rosti G, Ringdén O, Bregni M, Niederwieser D, on behalf of the EBMT Solid Tumour Working Party. Prognostic factors for survival in patients with advanced renal cell cancer undergoing non-myeloablative allogeneic stem cell transplantation. Cancer 104: 2099-2103, 2005. Times cited: 22.
  672. Ringdén O. Anti-apoptotic effect of growth factors in leukaemia. (letter). Journal of Clinical Oncology 23: 649, 2005. Times cited: 1.
  673. Le Blanc K, Götherström C, Ringdén O, Hassan M, McMahon R, Horwitz E,  Anneren G, Axelsson O, Nunn J, Ewald U, Nordén-Lindeberg S, Jansson M, Dalton A, Åström E, Westgren M. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 79: 1607-1614, 2005. Times cited: 228.
  674. Ljungman P, Aschan J, Gustafsson B, Lewensohn-Fuchs I, Winiarski J, Ringdén O. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplantation 34: 1067-1069, 2004. Times cited: 9.
  675. Le Blanc K, Ringdén O. Immune escape and suppression by human mesenchymal stem cells. In: Ho AD, Hoffman R, Zanjani ED (eds). Stem Cell Transplantation – Biology, Processes, Therapy.Wiley-VCH Verlag GmbH, Weinheim, Germany. 2006, pp. 233-245.
  676. Le Blanc K, Ringdén O. Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation. Haematologica 90: 438, 2005.
  677. Hentschke P, Omazic B, Mattsson J, Näsman-Björk I, Lundkvist I, Gigliotti D, Barkholt L, Ringdén O, Remberger M. T-cell receptor V repertoire after myeloablative and reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Scandinavian Journal of Immunology 61:285-294, 2005.Times cited: 10.
  678. Cahn J-Y, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett JA, Horowitz MM, Socié G. Prospective evaluation of two acute graft-versus-host (GVHD) grading systems: A joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI) and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106: 1495-1500, 2005. Times cited: 66.
  679. Januszkiewicz A, Klaude M, Loré K, Andersson J, Ringdén O, Rooyackers O, Wernerman J. Determination of in vivo protein synthesis in human palatine tonsil. Clinical Science 108: 179-184, 2005. Times cited: 3.
  680. Conrad R, Remberger M, Cederlund, K, Hentschke P, Sundberg B, Ringdén O, Barkholt L. Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. Biology of Blood and Marrow Transplantation 12: 346-354, 2006. Times cited: 6.
  681. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Vivek R, Hallen K, Atkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukaemia after using myeloablative conditioning: Results from the Center for International Blood and Marrow Transplant Research. Journal of Clinical Oncology 23: 5788-5794, 2005. Times cited: 60.
  682. Uzunel M, Ringdén O. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant 33:47-52, 2004.Times cited: 13.
  683. Larsson K, Aschan J, Remberger M, Ringdén O, Winiarski J, Ljungman P. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalo¬virus. Transplantation 77: 526-531, 2004.Times cited: 17.
  684. Svahn BM, Bjurman B, Myrbäck KE, Aschan J, Ringdén O. Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? A pilot trial.  Presse Med 33:474-478, 2004.
  685. Forslöw U, Mattsson J, Ringdén O, Klominek J, Remberger M. Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation. Scand J Infectious Diseases 38:970-976, 2006. Times cited: 8.
  686. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringdén O, Niederwieser D, Apperley JF, for the Chronic Leukaemia Working Party of the EBMT. Outcomes of reduced-intensity transplantation for chronic myeloid leukaemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106: 2969-2976, 2005. Times cited: 105.
  687. Ringdén O, Remberger M, Svahn B-M, Barkholt L, Aschan J, Mattsson J, Le Blanc K, Gustafsson B, Hassan Z, Omazic B, Svenberg P, Solders G, von Döbeln U, Winiarski J, Ljungman P, Malm G. Allogeneic hematopoietic stem cell transplantation for inherited disorders: Experience in a single-center.  Transplantation 81:718-725, 2006. Times cited: 30.
  688. Seebach JD, Stussi G, Passweg JR, Loberiza Jr FR, Gajewski J, Keating A, Goerner M, Rowlings P, Thiberghien P, Elfenbein G, Gale RP, van Rood JJ, Reddy V, Gluckman E, Hale G, Bolwell B, Klumpp TR, Horowitz MM, Ringdén O, Barrett J. AB0 blood group barrier in allogeneic bone marrow transplantation revisited. Biology of Blood and Marrow Transplantation 11:1006-1013, 2005. Times cited: 47.
  689. Ringdén O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation, state of the art and new perspectives. Acta Pathologica Microbiologica et Immunologica Scandinavica 113:813-830, 2006. Times cited: 42.
  690. Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn B-M, Barkholt L, Ringden O, Winiarski J, Ljungman P, Dalianis T. The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to the intensity of the conditioning regimen. Haematologica 91:401-404, 2006.Times cited: 51.
  691. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Sundin M, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81: 1390-1397, 2006. Times cited: 593.
  692. Khoury HJ, Loberiza FR, Ringdén O, Barrett AJ, Bolwell BJ, Cahn J-Y, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, Horowitz MM. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 107:1712-1716, 2006. Times cited: 37.
  693. Svahn B-M, Alvin O, Ringdén O, Gardulf A, Remberger M. Costs of allogeneic hematopoietic stem-cell transplantation. Transplantation 82: 147-153, 2006.Times cited: 18.
  694. Svahn B-M, Ringdén O, Remberger M. Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades. Transplantation 81: 1600-1603, 2006.Times cited: 10.
  695. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, Barkholt L, Larsson K, Winiarski J, Yun Z, Ringdén O. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91:78-83, 2006. Times cited: 84.
  696. Svahn B-M, Ringdén O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 36:511-516, 2005.Times cited: 23.
  697. Barkholt L, Bregni M, Remberger M, Peccatori J, Pedrazzoli P, Zambelli A, Massenkiel G, Blaise D, Bay JO, Francois S, Martino R, Bengala C, Brune M, Lenhoff S, Porcellini A, Falda M, Demirer T, Niederwieser D, Ringdén O. European experience of allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma. Annals of Oncology 17: 1134-40, 2006. Times cited: 48.
  698. Sundin M, Örvell C, Rasmusson I, Sundberg B, Ringdén O, Le Blanc K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplantation 37:1051-1059, 2006. Times cited: 40.
  699. Ringdén O, Le Blanc K. Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T-cells (letter). Biology of Blood and Marrow Transplantation 12: 693-694, 2006.Times cited: 10.
  700. Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. Mesenchymal stem cells stimulate antibody secretion in human B-cells. Scand J Immunol 65: 336-343, 2007. Times cited: 120.
  701. Ringdén O, Svenberg P, Le Blanc K, Mattsson J, Remberger M. Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases (letter). Bone Marrow Transplantation 38: 321-322, 2006. Times cited: 2.
  702. Malm G, von Döbeln U, Naess K, Ringdén O. Lysosomala sjukdomar – forskning och framsteg ger hopp om bot och bättring. (Progress on lysosomal diseases yields hope for cure and improvement) Läkartidningen 105:3731-3735, 2008.
  703. Le Blanc K, Ringdén O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Current Opinion in Immunology 18: 586-591, 2006. Times cited: 127
  704. Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 91: 1059-1067, 2006. Times cited: 42.
  705. Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B, Barkholt L, Ringdén O. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 82: 913-919, 2006. Times cited: 34.
  706. Ringdén O. Immunotherapy by allogeneic stem cell transplantation. Advances in Cancer Research 97C: 25-60, 2007.Times cited: 17.
  707. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells. Journal of Internal Medicine 262: 509-525, 2007. Times cited: 308.
  708. Remberger M, Watz E, Ringdén O, Mattsson J, Shanwell A, Wikman A. Major AB0 blood group mismatch increases the risk for graft failure after unrelated donor haematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 13:675-682, 2007.Times cited: 24.
  709. Ringdén O, Remberger M, Svenberg P, Svahn B-M, Dahllöf G, Gustafsson B, Hassan Z, Omazic B, Uzunel M, Aschan J, Barkholt L, Winiarski J, Ljungman P, Mattsson J. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem-cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplantation 39: 383-388, 2007. Times cited: 9.
  710. Hsu K, Gooley T, Malkki M, Pinto C, Dupont B, Bignon J-D, Bornhauser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M, Ringdén O, van Rood J, Petersdorf E. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biology of Blood and Marrow Transplantation 2006;12;828-836. Times cited: 94.
  711. Bågesund M, Richter S, Ringdén O, Dahllöf G. Longitudinal scintigraphic study of parotic and submandibular gland function after total body irradiation in children and adolescents. International Journal of Paediatric Dentistry 17:34-40, 2007. Times cited: 4.
  712. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lönnies H, Nava S, Ringdén O. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733-1738, 2007. Times cited: 195.
  713. Sundin M, Ringdén O, Sundberg B, Nava S, Götherström C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell transplant patients. Haematologica 92: 1208-1215, 2007. Times cited: 112.
  714. Remberger M, Ringdén O. Similar outcome after unrelated allogeneic peripheral-blood stem cell transplantation compared with bone marrow in children and adolescents. Transplantation 84: 551-554, 2007.Times cited: 11.
  715. Barkholt L, Remberger M, Bodegård H, Ringdén O, Böttiger Y. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 40: 683-689, 2007.Times cited: 13.
  716. Ringdén O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gustafsson J, Henningsohn L, Le Blanc K. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 21:2271-2276, 2007. Times cited: 106.
  717. Hassan Z, Remberger M, Svenberg P, Elbander M, Omazic B, Mattsson J, Conrad R, Svahn B-M, Uzunel M, Ahlgren A, Sairafi D, Aschan J, Le Blanc K, Barkholt L, Ringdén O. Hemorrhagic cystitis: a single center retrospective survey. Clinical Transplantation 21: 659-667 2007.Times cited: 22.
  718. Le Blanc K, Samuelsson H, Lönnies L, Sundin M, Ringdén O. Generation of immunosuppressive mesenchymal stem cells (MSC) in allogeneic human serum. Transplantation 84: 1055-1059, 2007. Times cited: 30.
  719. Shaw BE, Gooley TA, Malkki M, Madrigal JA, Begovich AB, Horowitz MM, Gratwohl A, Ringden O, Marsh SG, Petersdorf EW. The importance of HLA-DPB1 in unrelated donor haematopoietic cell transplantation. Blood 110:4560-4566, 2007. Times cited: 67.
  720. Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplantation 40: 865-869, 2007. Times cited: 34.
  721. Januszkiewicz A, Klaude M, Loré K, Andersson J, Ringdén O, Rooyackers O, Wernerman J. Enhanced in vivo protein synthesis in circulating immune cells of ICU patients. J Clin Immunol 27: 589-597, 2007.
  722. Deneberg S, Lerner R, Ljungman P, Ringdén O, Hägglund H. Relapse of preB-ALL after rituximab treatment for chronic GVHD. Implications for its use? Medical Oncology 24:354-356, 2007.Times cited: 3.
  723. Björklund A, Aschan J, Labopin M, Remberger M, Ringdén O, Winiarski J, Ljungman P. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplantation 40: 1055-1062, 2007. Times cited: 43.
  724. Mellgren K, Nilsson C, Fasth A, Abrahamsson J, Winiarski J, Ringdén O, Hassan M. Safe administration of oral busulfan twice daily during conditioning for stem cell transplantation in a paediatric population – a comparative study between the standard 4-dose and a 2-dose regimen. Bone Marrow Transplantation 41:621-625, 2008. Times cited: 4.
  725. Edvinsson B, Lundquist J, Ljungman P, Ringden O, Evengård B. A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS 116:345-351, 2008. Times cited: 11.
  726. Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn BM, H Karlsson, Brune M, Mattsson J, Ringden O. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 41:785-790, 2008.Times cited: 14.
  727. Mattsson J, Ringden O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 14:165-170, 2008. Times cited: 45.
  728. Svahn B-M, Remberger M, Heijbel M, Martell E, Wikström M, Eriksson B, Milovsavljevic R, Mattsson J, Ringdén O. Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation. The role of oral nutrition. Transplantation 85:1000-7, 2008. Times cited: 11.
  729. Conrad R, Remberger M, Cederlund K, Ringdén O, Barkholt L. A comparison between non-myeloablative and reduced intensity conditioning regimens in allogeneic stem cell transplantation for solid tumors. Haematologica 93:265-72, 2008. Times cited: 4.
  730. Sundin M, Remberger M, Lönnies H, Sundberg B, Ringdén O, Le Blanc K. No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells.Cytotherapy 10:238-42, 2008. Times cited: 4.
  731. Remberger M, Mattsson J, Hauzenberger D, Schaffer M, Svahn BM, Ringdén O. Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. Eur J Hematol 80:419-28, 2008. Times cited: 13.
  732. Giraud G, Priftakis P, Bogdanovic G, Remberger M, Dubrulle M, Hau A, Gutniak R, Mattsson J, Svahn B-M, Barkholt L, Ringden O, Winiarski J, Ljungman P, Dalianis T. BK-viruria and hemorrhagic cystitis are more frequent in allogeneic hematopoietic stem cell transplant patients receiving full conditioning regimen and unrelated HLA mismatched grafts. Bone Marrow Transplant 41:737-42, 2008. Times cited: 31.
  733. Norlin A-C, Sairafi D, Mattsson J, Ljungman P, Ringdén O, Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplantation 41:267-273, 2008.Times cited: 15.
  734. Remberger M, Mattsson J, Hassan Z, Karlsson N, Le Blanc K, Omazic B, Okas M, Sairafi D, Ringdén O. Risk-factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors - a single centre study. Bone Marrow Transplantation 41:399-405,  2008. Times cited: 17.
  735. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O. Mesenchymal stem cells for treatment of severe refractory acute graft-versus-host disease. Lancet 371:1579-1586, 2008. Times cited: 1025.
  736. Karlsson H, Samarasinghe S, Ball L, Sundberg B, Lankester AC, Dazzi F, Uzunel M, Veys P, Le Blanc K, Ringdén O, Amrolia P. Mesenchymal stem cells exert differential effects on alloantigen- and virus-specific T-cell responses. Blood 112: 532-541, 2008.Times cited: 79.
  737. Levine JE, Barrett JA, Zhang M-J, Arora M, Pulsipher M, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringdén O, Horowitz M, Collins R Jr. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplantation 42:201-205, 2008.Times cited: 27.
  738. Ringdén O, Okas M, Uhlin M, Uzunel M, Remberger M, Mattsson J. Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor. Bone Marrow Transplantation 42:643-648, 2008.Times cited: 22.
  739. Malm G, Gustafsson B, Berglund G, Lindström M, Naess K, Borgström B, von Döbeln U, Ringdén O. Outcome in six children with mucopolysaccharoidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatrica 97:1108-1112, 2008.Times cited: 15.
  740. Baker KS, Filipovich AH, Gross TG, Grossman WJ, Hale GA, Hayashi RJ, Kamani NR, Kurian S, Kapoor N, Ringden O, Eapen M. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplantation 42:175-180, 2008. Times cited: 38.
  741. Le Blanc K, Fibbe W, Frassoni F, Locatelli F, Ringden O. Mesenchymal stem cells for acute graft-versus-host disease – Author’s reply. Lancet 372:715-716, 2008.
  742. Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, Wandt H, Schaefer-Eckart K, Dornbusch HJ, Meisner C, Engel C, Stenger N, Mayer T, Ringdén O, Einsele H. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplantation 43:553-561, 2009.Times cited: 50.
  743. Benden C, Dipchand AI, Lara A, Danziger-Isakov LA, Esquivel CO, Ringdén O, Wray J, Marks SD. Pediatric transplantation: Ten years on. (review). Pediatric Transplantation 13:272-277, 2009. Times cited: 4.
  744. Sairafi D, Uzunel M, Remberger M, Ringden O, Mattsson J. No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplantation 41:961-964, 2008.Times cited: 23.
  745. Remberger M, Mattsson J, Svahn B-M, Ringdén O. Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globuline increases the risk of relapse, which can be overcome by a high stem cell-dose. Bone Marrow Transplantation 42:769-771, 2008. Times cited: 5.
  746. Hassan Z, Dalianis T, Le Blanc K, Ringdén O. Hemorrhagic cystitis: Pathogenesis and management in clinical stem cell transplantation. In: Wingard JR, Gastineau D, Leather H, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians. Bethesda, MD, USA: AABB Press, 2009, pp. 457-465.
  747. Ringdén O, Pavletic S, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks D, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Scouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 113:3110-3118, 2009. Times cited: 79.
  748. Hauzenberger D, Schaffer M, Ringdén O, Hassan Z, Omazic B, Mattsson J, Remberger M. Outcome of hematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs. allele mismatched donors: a single center study. Tissue Antigens 72:549-558, 2008. Times cited: 8.
  749. Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale G, Horan J, Isola L, Maziarz R, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia: A CIBMTR Study. Journal of Clinical Oncology 26:5728-5734, 2008. Times cited: 68.
  750. Uhlin M, Okas M, Karlsson H, Gertow J, Henningsohn L, Ringdén O, Kärre K, Levitsky V, Mattsson J. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoietic stem-cell transplantation. Transplantation 87: 467-472, 2009. Times cited: 2.
  751. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Arora M, Spellman S, Uberti J, Ringden O, Anasetti C, Cutler C, Antin J, Bornhäuser M, Hale G, Verdonck L, Cairo M, Gupta V, Gale RP, Pavletic S, for the Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA. Prior Rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation (PBSCT). British Journal of Haematology 145:816-824, 2009. Times cited: 39.
  752. Ringdén O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Finke J, Schwerdtfeger R, Eder M, Bunjes D, Gorin NC, Mohty M, Rocha V, on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Reduced intensity conditioning compared to myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. Journal of Clinical Oncology 27:4570-4577, 2009. Times cited: 109.
  753. Aglietta M, Barkholt L, Carnevale Schianca F, Caravelli D, Omazic B, Minotto C, Leone F, Hentschke P, Bertoldero G, Capaldi A, Ciccone G, Niederwieser D, Ringdén O, Demirer T, on behalf of the EBMT Solid Tumor Working Party. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European Group for Blood and Marrow Transplantation Experience. Biology of Blood and Marrow Transplantation 15: 326-335, 2009.Timed cited: 6.
  754. Ringdén O, Karlsson H, Omazic B. Immune reconstitution after HLA mismatched haemopoietic stem-cell transplantation. Lancet Oncology 10:440-442, 2009.
  755. Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, MacMillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute GVHD and increased relapse in children with leukemia receiving unrelated donor bone marrow transplants. Biology of Blood and Marrow Transplantation 15:360-366, 2009. Times cited: 22.
  756. Samuelsson H, Ringdén O, Lönnies L, Le Blanc K. Optimising in vitro conditions for immunomodulation and expansion of mesenchymal stem cells. Cytotherapy 11:129-136, 2009. Times cited: 31.
  757. Diedrich B, Ringdén O, Watz E, Shanwell A. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic hematopoietic progenitor cell transplantat recipients. Vox Sanguinis 97:254-259, 2009.Times cited: 7.
  758. Remberger M, Sundberg B, Mattsson J, Ringdén O. Low serum levels ot total rabbit-IgG is associated to acute GVHD after unrelated donor hematopoietic stem cell transplantation, results from a prospective study. Biology of Blood and Marrow Transplantation 15:996-999,  2009.
  759. Sundin M, Barrett AJ, Ringdén O, Uzunel M, Lönnies L, Dackland Å, Christensson B, Le Blanc K.. HSCT recipients have specific tolerance to MSC but not to the MSC donor. Journal of Immunotherapy 32:755-764, 2009.Times cited: 29.
  760. Le Blanc K, Barrett AJ, Schaffer M, Hägglund H, Ljungman P, Ringdén O, Remberger M. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myeloid malignancies. Biology of Blood and Marrow Transplantation 15:1108-1115, 2009. Times cited: 32.
  761. Okas M, Gertow J, Uzunel M, Karlsson H, Kärre K, Ringden O, Mattsson J, Uhlin M. Clinical expansion of cord blood derived T cells for use as donor lymphocyte infusion after cord blood transplantation. Journal of Immunotherapy 33:96-105, 2010. Times cited: 14.
  762. Omar H, Hägglund H, Gustafsson-Jernberg Å, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transplant Infectious Disease 11:393-399, 2009. Times cited: 32.
  763. Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A, Burns L, Gupta V, Ho V, McCarthy P, Ringdén O, Schouten H,Seftel M, Rizzo D. The effect of smoking on transplant outcome for CML. Biology of Blood and Marrow Transplantation 15:1277-1287, 2009.Times cited: 9.
  764. Mattsson J, Nordlander A, Hauzenberger D, Holgersson J, Remberger M, Uhlin M, Ringden O. Cytotoxic crossmatch analysis before allogeneic stem cell transplantation is a poor diagnostic tool for prediction of rejection. Bone Marrow Transplantation 45:235-238, 2010. Times cited: 1.
  765. Svenberg P, Mattsson J, Ringdén O, Uzunel M. Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism. Bone Marrow Transplantation 44, 757-763, 2009.Times cited: 11.
  766. Ernst P, Bacigalupo A, Ringdén O, Ruutu T, Kolb HJ, Lawrinson S, Skacel T. A phase 3, randomized, placebo-controlled trial of Filgrastim in patients with haematological malignancies undergoing matched-related allogeneic bone marrow transplantation. Archives of Drug Information 1:89-96, 2008.
  767. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. British Journal of Haematology(invited) 147:614-633, 2009. Times cited: 72.
  768. Gilli K, Remberger M, Hjelmkvist H, Ringdén O, Mattsson J. Sequential organ failiure assessment  predicts the outcome of SCT recipients admitted to the intensive care unit. Bone Marrow Transplantation 45:682-688, 2010.Times cited: 2.
  769. Ringdén O.Mesenchymal Stromal Cells as First-Line Treatment of Graft Failure after Hematopoietic Stem Cell Transplantation. Stem Cells and Development 18:1243-1246, 2009.Times cited: 5.
  770. Olsson R, Remberger M, Hassan Z, Omazic B, Mattsson J, Ringdén O. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. European Journal of Haematology 84:323-331, 2010. Times cited: 4.
  771. Björklund A, Schaffer M, Fauriat C, Ringdén O, Remberger M, Hammarstedt C, Barrett AJ, Ljungman P, Ljunggren HG, Malmberg KJ. NK cells expression inhibitory KIR for non-self ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 115:2686-2694, 2010.Times cited: 32.
  772. Luger S, Ringdén O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis VA, Lill MC, McCarthy PL, Weisdorf DJ, Pulsipher MA. Similar outcomes using myeloablative versus reduced intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplantation 47:203-211, 2012. Times cited:  73.
  773. Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Björkström NK, Söderdahl G, Cederlund K, Kimby E, Aschan J, Ringden O, Ljunggren HG, Dilber S. Safety analysis of ex vivo-expanded NK and NK-like T-cells administered to cancer patients: a Phase I clinical study. Immunotherapy 1:753-764, 2009.Times cited: 27.
  774. Blennow O, Remberger M, Klingspor L, Omazic B, Fransson K, Ljungman P, Mattsson J, Ringdén O. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced intensity conditioning and hematopoietic stem cell transplantation, Bone Marrow Transplantation 45:1710-1718, 2010.Times cited: 22.
  775. Uberti JP, Agovi M-A, Tarima S, Haagenson M, Gandham S, Abella E, Anasetti C, Baker S, Bashey A, Bearman S, Bolwell B, Bornhäuser M, Chan KW, Copelan E, Davies S, Dudek A, Elkins S, Finke J, Hale G, Kernan N, Kollman C, McCarthy P, Ratanatharathorn V, Ringdén O, Wade J, Weisdorf D, Rizzo JD. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplantation 46:34-43, 2011. Times cited: 8.
  776. Hoogduijn MJ, Popp FC, Grohnert A, Crop MJ, van Rhijn M, Eggenhofer E, Renner P, Reinders ME, Rabelink TJ, van der Laan LJW, Genever PG, Perico N, Lange, Durrbach, Houtgraf JH, Christ B, Seifert M, Shagidulin M, Donckier V, Deans R, Ringden O, Remuzzi G, Bartholomew A, Schlitt HJ, Weimar W, Baan CC, Dahlke MH. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 90:124-126, 2010.Times cited: 33.
  777. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, Bertaina A, Vinti L, Lankester A, Maccario R, Ringden O, Le Blanc K, Egeler RM, Fibbe WE, Locatelli F. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplantation 46:200-207, 2011.Times cited: 50.
  778. Sairafi D, Remberger M, Uhlin M, Ljungman P, Ringdén O, Mattsson J. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biology of Blood and Marrow Transplantation 16:1728-1737,  2010. Times cited: 11.
  779. Ringdén O, Hassan Z, Karlsson H, Olsson R, Omazic B, Mattsson J, Remberger M. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation 90:1022-1029, 2010. Times cited: 12.
  780. Remberger M, Mattsson J, Olsson R, Ringdén O. Second allogeneic hematopoietic stem cell transplantation (HSCT): a treatment for graft failure. Clinical Transplantation 25:E68-E76, 2011. Times cited: 5.
  781. Shaw PJ, Kan F, Ahn KW, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA Heemskerk MBA, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH , Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders JE, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher MA. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related or matched unrelated donors. Blood 116:4007-4015, 2010. Times cited: 35.
  782. Valcárcel D, Sierra J, Wang T, Kan F, Gupta V, Hale GA, Marks D, McCarthy PL, Oudshoorn M, Petersdorf EW, Ringden O, Setterholm M, Spellman SR, Waller E, Gajewski JL, Marino SR, Senitzer D, Lee SJ. One antigen mismatched related vs. HLA-matched unrelated donor hematopoietic transplantation in adults with acute leukemia: CIBMTR results in the era of molecular typing. Biology of Blood and Marrow Transplantation 17:640-648, 2011.Times cited: 26.
  783. Ringden O andKeating A. Mesenchymal stem cells as treatment for chronic graft-versus-host disease. Bone Marrow Transplantation 46:163-164, 2011.Times cited: 5.
  784. Ringden O, Le Blanc K. Pooled MSCs for treatment of severe hemorrhage. Bone Marrow Transplantation  46:1158-1160, 2011. Times cited: 7.
  785. Ringdén O. Mesenchymal stem cells. Immunomodulatory effects and treatment of graft-versus-host disease and tissue toxicity. Editor: K. Tangjaitrong. Asian Pacific Bone Marrow Transplantation. Book chapter, p 1-6, 2010.
  786. Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M, Gajewski J, Hale GA, Horan J, Battiwalla M, Marino SR, Setterholm M, Ringden O, Hurley C, Flomenberg N, Anasetti C, Fernandez-Vina M, Lee SJ. HLA-C antigen mismatches are associated with worse outcomes in unrelated donor peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation 17(6):885-892, 2011. Times cited: 62.
  787. Garming Legert K, Remberger M, Ringden O, Heimdahl A, Dahllöf G. Salivary secretion in children after fractionated or single-dose total body irradiation.Bone Marrow Transplantation 47:404-410, 2012.
  788. Ringdén O, Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Practice & Research Clinical Haematology 24(1):65-72, 2011. Times cited: 35.
  789. Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP, Hale GA, Ilhan O, Passweg JR, Ringdén O, Sabloff M, Schrezenmeier H, Socié G, Marsh JCW. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-identical sibling donors. Haematologica 95;2119-2125, 2010. Times cited: 30.
  790. Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringden O. N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell mediated immunity in vitro. European Journal of Immunology 41:1143-1153, 2011. Times cited: 5.
  791. Carlsson G, Winiarski J, Ljungman P, Ringdén O, Mattsson J, Nordenskjöld M, Touw I, Henter JI, Palmblad J, Fadeel B, Hägglund H. Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer 56:444-451, 2011. Times cited: 13.
  792. Remberger M, Ackefors M, Berglund S, Blennow O, Dahllöf G, Dlugosz A, Garming-Legert K, Gertow J, Gustafsson B, Hassan M, Hassan Z, Hauzenberger D, Hägglund H, Karlsson H, Klingspor L, Kumlien G, Le Blanc K, Ljungman P, Machaczka M, Marschall H-U, Mattsson J, Olsson R, Omazic B, Sairafi D, Schaffer M, Svahn B-M, Svenberg P, Swartling L, Szakos A, Uhlin M, Uzunel M, Watz E, Wernerson A, Wikman A, Wikström A-C, Winiarski J, Ringdén O. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single centre study. Biology of Blood and Marrow Transplantation 17:1688-1697, 2011. Times cited: 29.
  793. Svahn BM, Remberger M, Alvin O, Karlsson H, Ringdén O. Increased costs after allogeneic hematopoietic stem cell transplantation are associated with major complications and re-transplantation. Bone Marrow Transplantation 47:706-715, 2012.Times cited: 7.
  794. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lönnies L, Elgue G, Nilsson-Ekdahl K, Mougiakakos D, Lambris JD, Ringdén O, Le Blanc K, Nilsson B. Mesenchymal stromal cells engage complement and complement reactor bearing innate effector cells to modulate immune responses. PLoS One 2011;6(7):e21703. Times cited: 27.
  795. Garming-Legert K, Remberger M, Ringdén O, Hassan M, Dahllöf G. Long-term salivary function after conditioning with busulfan, fractionated or single dose TBI.Oral Diseases 17:670-676, 2011.Times cited: 3.
  796. Nordlander A, Uhlin M, Ringdén O, Kumlien G, Hauzenberger D, Mattsson J. Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. Transplantation Immunology 25:153-158, 2011.Times cited: 3.
  797. Farag SS, Maharry K, Zhang M-J, Pérez WS, George SL, Mrózek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ, on behalf of the Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients aged 60-70 years with acute myelogenous leukemia in first remission.Biology of Blood and Marrow Transplantation 17:1796-1803, 2011. Times cited: 33.
  798. Ringdén O, Remberger M, Dahllöf G, Garming-Legert K, Karlsson H, Svenberg P, Uhlin M, Uzunel M, Mattsson J. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. European  Journal of Haematology 87:503-509, 2011.Times cited: 13.
  799. Dahllöf G, Wondimu B, Barr-Agholme M, Garming-Legert K, Remberger M, Ringdén O.Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan. Oral Oncology 47(9):915-919, 2011.Times cited: 3.
  800. Ringdén O, Shresta S, da Silva GT, Zhang M-J, Dispenzieri A, Remberger M, Kamble R, Freytes CO, Gale RP, Gibson J, Gupta V, Holmberg L, Lazarus H, McCarthy P, Meehan K, Schouten H, Milone GA, Lonial S, Hari PN. Effects of acute and chronic graft-versus-host disease on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplantation 47:831-837, 2012.Times cited: 8.
  801. von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H, Ljungman P, Gustafsson B, Karlsson H, Le Blanc K, Ringdén O. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy.Biology of Blood and Marrow Transplantation18:557-564, 2012. Times cited: 56.
  802. Karlsson H, Erkers, T, Nava S, Ruhm S, Westgren M, Ringdén O. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clinical and Experimental Immunology 167:543-555, 2012. Times cited: 15.
  803. Uhlin M, Sairafi D, Berglund S, Thunberg S, Gertow J, Ringden O, Uzunel M, Remberger M, Mattsson J. Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord blood transplantation. Stem Cells and Development 21:1409-1417, 2012. Times cited: 8.
  804. Nahi H, Remberger M, Machaczka M, Ungerstedt J, Mattsson J, Ringdén O, Le Blanc K, Ljungman P, Hägglund H. Different impact of diagnostic intermediate and unfavourable cytogenetics on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. Medical Oncology 29:2348-2358, 2012.Times cited: 1.
  805. Fleischhauer K, Shaw B, Gooley R, Malkki M, Bardy P, Bignon JD, Dubios V, Horowitz MM, Madrigal JA, Morishima Y, Oudshoorn M, Ringdén O, Spellman S, Velardi A, Zino E, Petersdorf EW, on behalf of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Effect of T-cell-epitope matching at HLA-DPB1in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncology 13:366-374, 2012. Times cited: 64.
  806. Ringdén O, Labopin M, Gorin NC, Volin L, Torelli GF, Attal M, Jouet JP, Milpied N, Socié G, Cordonnier C, Michallet M, Iriondo A, Hermine O, Mohty M, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic haematopoietic-stem cell transplantation. British Journal of Haematology 157:220-229, 2012.
  807. Ringdén O.Mesenchymal stem cells for treatment and prevention of graft-versus-host disease and graft failure after hematopoietic stem cell transplantation and future challenges. In: Mesenchymal Stem Cell Therapy.Chase LG, Vemuri MC (Eds.)Springer Verlag, Humana Press, New York Heidelberg Dordrecht London2013, pp 173-206.ISBN 978-1-62703-199-8.
  808. Vesterbacka M, Ringdén O, Remberger M, Huggare J, Dahllöf G. Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation. Orthodontics & Craniofacial Research 15:21-29, 2012. Times cited: 2.
  809. Pérez-Simón JA, Afram G, Martino R, Piñana JL, Caballero-Velazguez T, Ringden O, Valcarcel D, Caballero D, Remberger M, de Paz Y, Sierra J, San Miguel J, Hägglund H. Evaluation of prognostic factors among patients with chronic graft-versus-host disease. Haematologica 97:1187-1195, 2012.Times cited: 3.
  810. Gahrton G, Ringdén O. StamcellstransplantationIn: Blodets sjukdomar. Gahrton G, Juliusson G, eds. Studentlitteratur AB, Lund, Sweden,pp. 153 – 161.  2012.
  811. Ringdén O, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Greinix H, Kyrcz-Krzemien S, Bunjes D, Brinch L, Niederwieser D, Arnold R, Mohty M, Rocha V, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukemia. Journal of Internal Medicine 272:472-483, 2012. Times cited: 5.
  812. von Bahr L, Batsis I, Moll G, Hägg M, Szakos A, Sundberg B, Uzunel M, Ringdén O, Le Blanc K. Analysis of tissues following mesenchymal stromal cell therapy in humans indicate limited long-term engraftment and no ectopic tissue formation. Stem Cells 30:1575-1578, 2012. Times cited: 74.
  813. Moll G, Duprez IR, von Bahr L, Andersen AMC, Sanchez J, Magnusson P, Elgue G, Funke L, Lönnies L, Sundberg B, Ringdén O,  Korsgren O, Nilsson B, Le Blanc K. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 30:1565-1574, 2012. Times cited: 42.
  814. Forslöw U, Blennow O, Le Blanc K, Ringden O, Gustafsson B, Mattsson J, Remberger M. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. European Journal of Haematology 89:220-227,  2012. Times cited: 19.
  815. Eapen M, Ahn KW, Orchard PJ, Cowan MJ, Davies SM, Fasth A, Hassebroek A, Ayas M, Bonfim C, O’Brien TA, Filipovich A, Gross TG, Horwitz M, Horwitz E, Kapoor N, Kurtzberg J, Majhail N, Ringden O, Szabolcs P, Veys P, Baker KS. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biology of Blood and Marrow Transplantation 18:1438-1445, 2012.Times cited: 8.
  816. Ringdén O, Sadeghi B. Is graft-versus-leukemia more effective using reduced-intensity conditioning compared to myeloablative conditioning? Biology of Blood and Marrow Transplantation 18:1615-1617, 2012.
  817. Ringdén O, Remberger M, Holmberg K, Edeskog L, Wikström M, Eriksson B, Finnbogadottir S, Fransson K, Milovsavljevic R, Omazic B, Svenberg P, Mattsson J, Svahn BM. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 19:314-20, 2013. Times cited: 4.
  818. Olsson R, Remberger M, Schaffer M,Berggren DM, Svahn BM, Mattsson J, Ringdén O. Graft failure in the modern era of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation48:537-543, 2013.Times cited: 6.
  819. Remberger M,  Ringdén O.Treatment of severe acute graft versus host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients.International Journal of Hematology, 96: 822-824, 2012.Times cited: 4.
  820. Berglund S, Le Blanc K, Remberger M, Gertow J, Uzunel M, Svenberg P, Winiarski J, Ljungman P, Ringdén O, Uhlin M, Mattsson J. Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation.Transplantation 94:1066-1074, 2012.Times cited: 5.
  821. Ringdén O, Erkers T, Nava S, Uzunel M, Iwarsson E, Conrad R, Westgren M, Mattsson J, Kaipe H. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 31:592-601, 2013.Times cited: 13.
  822. Ringdén O, Erkers T, Aschan J, Garming-Legert K, Le Blanc K, Hägglund H, Omazic B, Svenberg P, Dahllöf G, Mattsson J, Ljungman P, Remberger M. A prospective randomized toxicity study comparing reduced-intensity and myeloablative conditioning in patients with myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Journal of Internal Medicine 274:153-162, 2013. Times cited: 5.
  823. Potácová Z, Dalianis T, Le Blanc K, Ringdén O. Hemorrhagic cystitis. In: Wingard JR, Gastineau DA, Leather HL, Snyder EL, SzczepiorkowskiZM (Eds.). Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians, 2nd Edition, Bethesda, MD: AABB, 2015, chapter 34, pp. 529-538
  824. Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplantation 48:825-831, 2013.Times cited: 4.
  825. Sadeghi B, Ringdén O. Mesenchymal stem cells for graft-versus-host disease in experimental animal models. In: G. Gross and Thomas Häupl (Eds.). Stem Cell-Dependent Therapies: Mesenchymal stem cells in chronic inflammatory disorders. Berlin: De Gruyter; 2013, pp. 125-141.
  826. Ringdén O, Sadeghi B. Mesenchymal stem cells for clinical/therapeutic interventions of graft-versus-host disease. In: G. Gross and Thomas Häupl (Eds.). Stem Cell-Dependent Therapies: Mesenchymal stem cells in chronic inflammatory disorders. Berlin: De Gruyter; 2013, pp. 101-124.
  827. Mårtensson T, Priftakis P, Casswall T, Ringdén O, Mattsson J, Remberger M, Hassan M, Gustafsson B. Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning. Pediatric Transplantation 17:285-293, 2013. Times cited: 3.
  828. Jitschin R, Mougiakakos D, von Bahr L, Völkl S, Moll G, Ringdén O, Kiessling R, Linder S, Le Blanc K. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation. Stem Cells 31:1715-1725, 2013.Times Cited: 9.
  829. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J,  Sureda A, Wiktor-Jedrzejczak W, Madrigal A, and Niederwieser D; a working group of the European Group for Blood and Marrow Transplantation (EBMT) and the European LeukemiaNet (ELN). Prophylaxis and treatment of graft-versus-host disease: EBMT – ELN working grouprecommendations for a standardized practice. Bone Marrow Transplantation 49:168-173,  2014. Times cited: 13.
  830. Erkers T, Nava S, Yosef J, Ringdén O, Kaipe H. Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner. Stem Cells and Development22:2596-605, 2013.Times cited: 5.
  831. Åhlin A, Fugeläng J, de Boer M, Ringdén O, Fasth A, Winiarski J. Chronic granulomatous disease – haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatrica 102:1087-1094, 2013.
  832. Pidala J, Wang T, Haagenson MD, Spellman S, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Vina MA, Gandhi M, Jakubowski A, Maiers M, Marino SR, Marsh SGE, Oudshoorn M, Palmer JM, Prasad V, Reddy V, Ringden O, Saber W, Santarone S, Schultz K, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood 122:3651-3658, 2013. Times cited: 19.
  833. Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringdén O, Winiarski J, Ljungman P, Remberger M, Mattsson J. Risk factors for Epstein-Barr virus related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99:346-352, 2014. Times cited: 7.
  834. Remberger M, Ringdén O, Hägglund H, Svahn BM, Ljungman P, Uhlin M, Mattsson J. A high antithymocyte globuline dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clinical Transplantation 27:E368-E374, 2013. Times cited: 7.
  835. Watz E, Remberger M, Ringdén O, Lundahl J, Ljungman P, Mattsson J, Wikman A, Uhlin M. Analysis of donor and recipient AB0-incompatibility and antibody associated complications after allogeneic stem cell transplantation with reduced intensity conditioning. Biol Blood Marrow Transpl 20:264-271, 2014.
  836. Warlick E, Paulson K, Brazauskas R, Zhong X, Miller A, Camitta B, George B, Savani B, Ustin C, Marks D, Waller E, Baron F, Freytes C, Socié G, Akpek G, Schouten H, Lazarus H, Horwitz E, Koreth J, Cahn J-Y, Bornhauser M, Seftel M, Cairo M, Laughlin M, Sabloff M, Ringdén O, Gale RP, Kamble R, Vij R, Gergis U, Mathews V, Saber W, Chen Y-B, Liesveld J, Cutler C, Ghobadi A, Uy G, Eapen M, Weisdorf D, Litzow M. Effect of post remission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biology of Blood and Marrow Transplantation 20;202-208, 2014.
  837. Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, Nihtinen A, Hägglund H, Ringdén O. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study of the Nordic Bone Marrow Transplantation Group. Biology of Blood and Marrow Transplantation 20:135-138, 2014.
  838. Kaipe H, Erkers, T, Sadeghi B, Ringdén O. Stromal cells – are they really useful for GVHD? Bone Marrow Transplantation 49: 737-743, 2014.
  839. Ringdén O, Labopin M, Solders M, Beelen D, Arnold R, Ehninger G, Milpied N, Niederwieser D, Hamladi R-M, Kyrcz-Krzemien S, Ganser A, Socié G, Stelljes M, Volin L, Craddock C, Brown P, Mohty M, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Who is the best haematopoietic stem cell donor for a male patient with acute leukaemia? Transplantation 98:569-577, 2014.
  840. Solders M, Martin DA, Andersson C, Remberger M, Andersson T, Ringdén O*, Solders G*. Hematopoieticstem cell transplantation: A useful treatment for late metachromatic leukodystrophy. Bone Marrow Transplantation 49:1046-1051, 2014.*Shared senior authorship.
  841. Garming-Legert K, Remberger M, Ringdén O, Heimdahl A, Dahllöf G. Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Supportive Care in Cancer 22:2133-2140, 2014.
  842. Ringdén O, Remberger M, Törlén J, Engström M, Fjaertoft G, Mattsson J, Svahn BM. Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be advantageous than isolation in the hospital. Pediatric Transplantation 18:398-404,  2014.
  843. Poiret T, Rane L, Remberger M, Omazic B, Gustafsson-Jernberg Å, Vudattu NK, Ahmed R, Ernberg I, Winiarski J, Magalhaes I, Ringdén O, Maeurer M. Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. BMC Immunology 15 (June 19): article no. 25,2014.
  844. Ahmed R, Poiret T, Ambati A, Rane L, Remberger M, Omazic B, Vudattu NK, Winiarski J, Ernberg I, Axelsson-Robertson J, Magalhaes I,Castelli C , Ringden O, and Maeurer M.TCR+ CD4-CD8- T-cells in antigen specific MHC class I – restricted T-cell responses after allogeneic hematopoietic stem cell transplantation. Journal of Immunotherapy 37:416-425, 2014.
  845. Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Ho V, Kebriaei P, Keever-Taylor C, Kindwell-Keller T, Lazarus H, Laughlin M, Lill M, O’Brien T, Perales M, Rocha V, Savani B, Szwajcer D, Valcarcel D, Eapen M. Low CD34 cell dose is associated with poor survival after reduced intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biology of Blood and Marrow Transplantation 20:1418-1425, 2014.
  846. Hägglund H, Remberger M, Ringdén O. Twenty-year follow-up of a randomized trial comparing intraosseous and intravenous bone marrow transplantation. Bone Marrow Transplantation 49:1541-1542,2014.
  847. Ringdén O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, Burns LJ, Cahn JY, Duncan C, Hale GA, Halter J, Hayashi RJ, Hsu JW, Jacobsohn DA, Kamble RT, Kamani NR, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Myers KC, Ramanathan M, Saber W, Savani BN, Schouten HC, Socie G, Sorror ML, Steinberg A, Popat U, Wingard JR, Mattsson J, Majhail NS. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced intensity conditioning. Biology of Blood and Marrow Transplantation 20:1777-1784, 2014.
  848. Blennow O, Eliasson E, Pettersson T, Pohanka A, Szakos A, El-Serafi I, Hassan M,Ringdén O, Mattsson J. Posaconazole concentrations in human tissue after allogeneic stem cell transplantation.Antimicrobial Agents and Chemotherapy 58:4941-4943, 2014.
  849. Erkers T, Kaipe H, Nava S, Molldén P, Gustafsson B, Axelsson R and Ringdén O. Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with 111Indium radiolabeling. Stem Cells and Development 24: 253-263, 2014.
  850. Arnberg F, Lundberg J, Kenne E, Jaff N, Müller P, Nava S, Kaipe H, Ringdén O, Holmin S. Superselective intra-arterial umbilical cord blood administration to BM in experimental animals. Bone Marrow Transplantation 49: 1486-1491, 2014.
  851. Ericzon BG, Lundgren G, Tibell A, Tydén G, Ringdén O. In Memoriam – Carl-Gustav Groth 1933-2014. Transplantation 98:122-123, 2014.
  852. Petersdorf  EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A, Du Toit E, Ehninger G, Egeland T, Fischer GF, Gervais T, Haagenson MD, Horowitz MM, Hsu K, Jindra P, Madrigal A, Oudshoorn M, Ringdén O, Schroeder ML, Spellman SR, Tiercy J-M, Velardi A, Witt CS, O’Huigin C, Apps R, and Carrington M, for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation. HLA-C Expression Levels Define Permissible Mismatches in Hematopoietic CellTransplantation. Blood 124:3996-4003, 2014.
  853. Ringdén O. Graft-versus-host disease, a major complication after stem cell transplantation – home care for prevention and stromal cells for therapy. Hamdan Medical Journal 7(3):375-388, 2014.
  854. Ringdén O. GVHD prophylaxis made safe, easy and inexpensive. Blood 124:3672-3673, 2014.
  855. Ringdén O, Uzunel M, Sadeghi B, Solders M, Uhlin M, Mattsson J, Remberger M. Decreased Risk of Acute Graft-versus-Host Disease Using Reduced Intensity Conditioning Compared to Myeloablative Conditioning is Independent of Donor-Recipient T-cell Chimerism. Journal of Transplantation Technologies & Research 4(2): 1000142, 2014 (Biomedical Journals).
  856. Ringdén O.In Memoriam – Carl-Gustav Groth 1933-2014. Obituary for Plarr’s Lives.http://livesonline.rcseng.ac.uk/biogs/E005811b.htm
  857. Ringdén O, Solders M, Erkers T, Nava S, Molldén P, Hultcrantz M, Kaipe H, Mattsson J.  Successful reversal of acute lung injury using placenta-derived decidual stromal cells. Journal of Stem Cell Research and Therapy 4: 244, 2014.doi:10.4172/2157-7633.1000244
  858. Maeurer M, Magalhaes I, Andersson J, Ljungman P, Sandholm E, Uhlin M, Mattsson J, and Ringdén O.Allogeneic hematopoietic cell transplantation for GATA2 deficiency in a patient with disseminated human papilloma virus disease. Transplantation 98: E95-E96, 2014.
  859. Garming-Legert K, Tsilingaridis G, Remberger M, Ringdén O, Heimdahl A, Yucel-Lindberg T, Dahllöf G. The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and gingival crevicular fluid in allogeneic stem cell recipients. Support Care Cancer 23:1749-1757, 2015.
  860. Ringdén O. Placenta-derived decidual stromal cells – a novel therapy for graft-versus-host disease, haemorrhages and toxicity after allogeneic haematopoietic stem cell transplantation.  Hamdan Medical Journal 7(3, suppl 1):19-20, 2014.
  861. Kaipe H, Carlson L-M, Erkers T, Nava S, Molldén P, Gustafsson B, Qian H, Li X, Hashimoto T, Sadeghi B, Alheim M, Ringdén O. Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.Stem Cells and Development, 24:1471-1482, 2015.
  862. Remberger M, Törlén J, Ringdén O, Engström M, Watz E, Uhlin M, Mattsson J. The effect of total nucleated and CD34+ cell dose on outcome after allogeneic hematopoietic stem cell transplantation.Biology of Blood and Marrow Transplantation 21:889-893, 2015.
  863. Ringdén O. Side-effects of allogeneic mesenchymal stem (stromal) cells for acute respiratory distress syndrome. The Lancet Respiratory Medicine 3:e12, 2015.
  864. Veys PA, Nanduri V, Baker KS, He W, Bandini G, Biondi A, Dalissier A, Davis JH, Eames GM, Egeler RM, Filipovich AH, Fischer A, Jurgens H, Krance R, Lanino E, Leung WH, Matthes S, Michel, Orchard PJ, Pieczonka A, Ringdén O, Schlegel PG, Sirvent A, Vettenranta K, Eapen M. Hematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: Outcome by intensity of conditioning. British Journal of Haematology 169:711-718, 2015.
  865. Remberger M, Ringdén O, Mattsson J. Bone marrow aspiration techniques has deteriorated in recent years. Bone Marrow Transplantation 50:1007-1009, 2015.
  866. Olsson R, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ, Bredeson CN, Dvorak CC, Gupta V, Ho VT, Lazarus HM, Marks DI, Ringdén O, Pasquini MC, Schriber JR, Cooke KR. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation  for hematologic malignancies. Leukemia, e-pub ahead of print Mar 16, 2015.
  867. Moll G, Ignatowicz L, Catar R, Luecht C, Sadeghi B, Hamad O, Jungebluth P, Dragun D, Schmidtchen A, Ringdén O. Different procoagulant activity of therapeutic mesenchymal stromal cells derived fron bone marrow and placental decidua. Stem Cells& Development, July 2015, E-pub ahead of print.
  868. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hus JW, Hematti P, Verdonck LF, Sohl MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ; Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation 21:266-274, 2015.
  869. Watz E, Remberger M, Ringdén O, Ljungman P, Sundin M, Mattsson J, Uhlin M. Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation. Transfusion, in press 2015.
  870. Remberger M, Törlén J, Ringdén O, Engström M, Watz E, Uhlin M, Mattsson J. Effect of total nucleated and CD34+ cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 21:889-893, 2015.
  871. Arnberg F, Lundberg J, Olsson A, Samén E, Jaff N, Jussing E, Dahlén U, Nava S, Axelsson R, Ringdén O, Kaipe H, Holmin S. Intra-arterial administration of placenta-derived decidual stromal cells to the superior mesenteric artery in the rabbit: distribution of cells, feasibility and safety. Cell Transplant. 2015 May 13 (E-pub ahead of print.
  872. Ciurea SO, Zhang M-J, Bacigalupo A, Bashey A, Appelbaum FR, Antin JH, Chen J, Devine SM, Fowler DH, Nakamura R, Perales M-A, Pingali SR, Porter DL, Ringdén O, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Fuchs EJ, Eapen M. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia.Blood, in press 2015.
  873. Ringdén O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, Ghavamzadeh A, Hamladji RM, Schmid C, Nagler N, Mohty M, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors than with HLA-identical siblings? Leukemia, in press 2015. E-pub ahead of print August 21, 2015.
  874. Olsson R, Hagelberg S, Schiller B, Ringdén O, Truedsson L, Åhlin A. Allogeneic hematopoietic stem cell transplantation in the treatment for human C1q deficiency – The Karolinska Experience. Transplantation 2015, in press.
  875. Sadeghi B, Heshmati Y, Kaipe H, Walfridsson J, Ringdén O. Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity, in vitro and in vivo. Cytotherapy 2015, in press.
  876. Sobecks RM, Wang T, Askar M, Gallagher MM, Haagenson M, Spellman S, Fernandez-Vina M, Malmberg K-J, Müller C, Battiwalla M, Gajewski J, Verneris MR, Ringdén O, Marino S, Davies S, Dehn J, Bornhäuser M, Inamoto Y, Woolfrey A, Shaw P, Pollack M, Weisdorf D, Miller J, Hurley C, Lee SJ, Hsu K. Impact of KIR and HLA genotypes on outcomes after reduced-intensity conditioning hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 21:1589-1596, 2015.

Autoimmune Journal Flyer